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Summary 
Radiopharmaceuticals based on regulatory peptides have become an indispensable tool in nuclear 
medicine for the diagnosis (molecular imaging) and radionuclide therapy of cancer. The specificity of 
these radiopeptides towards G-protein-coupled receptors (GPCR), which are overexpressed by various 
cancer cells and their favorable pharmacological properties make them ideal vectors for the targeted 
delivery of radioactivity to tumors and metastases. However, there are still challenges to be met in 
order to develop peptide-based radiopharmaceuticals with ideal properties in terms of imaging quality 
and therapeutic efficacy where therapeutic radionuclides are employed.  
A potential drawback of several radiolabeled peptides under investigation is represented by a rapid 
washout of radioactivity after receptor-mediated internalization into tumor cells. In certain cases, the 
washout of radioactivity from cells occurs at a rate comparable to that required for accumulation in 
cancerous tissues. This not only renders the initial efforts of targeted delivery in part futile but also 
results in an imaging quality and therapeutic efficiency lower than achievable. To address this issue, 
novel strategies are needed to improve the cellular retention of the radioactivity. A possible approach 
may include the employment of multi-targeting radioconjugates made of different moieties specific for 
extra- and intracellular targets. Towards this goal, we investigated the combination of tumor targeting 
peptides with an additional moiety specific for an intracellular target and radiolabeled the conjugate 
with the 99mTc-tricarbonyl core as a reporter probe for single-photon emission computed tomography 
(SPECT). We envisioned that enabling interactions of radioconjugates with intracellular targets after 
receptor-mediated uptake by endocytosis would result in the trapping of radioactivity in tumors. 
Specifically, we combined a modified binding sequence of the peptide bombesin, [Nle14]BBS(7-14), 
for extracellular targeting of the tumor-associated gastrin releasing peptide receptor (GRP-r) with a 
triphenylphosphonium group for intracellular targeting of the organelle mitochondria or with the 
peptide shepherdin, an inhibitor of the cytosolic chaperon heat-shock protein 90 (Hsp90). The 
conjugates were assembled by the "Click-to-Chelate" approach, an efficient synthetic strategy for the 
preparation of bifunctional 99mTc-labeled radiopharmaceuticals. The radioconjugates were evaluated in 
vitro using GRP-r-overexpressing PC-3 cells. Our investigations revealed that the additional moiety 
for intracellular targeting did not impact the tumor-targeting capability of the bombesin-derived 
conjugates but neither did it result in an improved cellular retention of the radioactivity. Drawing from 
our experience and considering recent literature data, we conclude that endosomal entrapment or 
lysosomal degradation of the bifunctional radiopeptide conjugates is likely to impede with intracellular 
interactions and thus, responsible for the observed unaltered cellular efflux of radioactivity. Future 
studies will be directed towards the combination of bifunctional radiopeptide conjugates with drug 
delivery systems designed to facilitate endosomal escape. 
A different approach for the optimization of peptidic radiotracers includes the improvement of their 
metabolic stability since most of them exhibit a very short biological half-life due to rapid degradation 
by endogenous peptidases. Enhancement of the stability of radiopeptides results in a prolonged 
circulation time in the blood and, as a consequence, an improved tumor uptake in vivo. A number of 
different strategies have been reported for the stabilization of regulatory peptides, however, with 
varying degree of success in providing peptidomimetics with retained affinity to the corresponding 
GPCR. In an effort to probe a novel peptide backbone modification methodology, the use of 1,4-
disubstituted 1,2,3-triazoles as metabolically stable trans amide bond isosters was investigated. The 
systematic replacement of amide bonds within the binding sequence of the tumor-affine peptide 
bombesin, [Nle14]BBS(7-14), by triazoles provided a series of 177Lu-labeled peptidomimetics with 
both retained affinity towards GRP-r and an increased stability in blood serum. In vivo evaluation of a 
VII 
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lead compound in xenografted mice showed that the enhanced stability of the radiopeptidomimetic 
resulted in a doubling of the uptake of radioactivity in tumors. The described amide-to-triazole 
substitution methodology is currently being applied to other tumor targeting peptides of medicinal 
interest. 
The specificity and affinity of radiopeptides towards different receptor subtypes is another aspect to 
consider for optimizations. Inhomogeneous expression of receptor subtypes by tumors may influence 
the efficiency of a radiotracer. For example, intratumoral administration of radiolabeled substance P 
(SP) led to significant differences in the clinical response of patients suffering from gliomas despite 
proven expression of its target, the neurokinin-1 receptor (NK1R). In an effort to identify factors that 
may be responsible for the varying therapeutic outcome observed, several SP conjugates were 
evaluated in vitro using four established glioma cell lines differing in their level of RNA expression of 
the full length and truncated receptor isoforms. Cell binding and internalization of SP-conjugates were 
only observed with cell lines exhibiting high expression of RNA of the full-length NK1R. Pre-
therapeutic screening for NK1R isoforms may therefore be advisable for the selection of glioma 
patients for NK1R-targeted radionuclide therapy.  
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hydroxy-6-methylheptanoic acid) 
T  absolute temperature 
t  time; triplet 
t1/2  half-life 
tacnR:  1,4,7-triazacyclononan derivatives 
TAMS  triamide-thiols 
TBTA Tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine 
TBTU 2-(1H-Benzotriazole-1-yl)-1, 
1,3,3-tetramethylaminium 
tetrafluoroborate 
tBu  tert-butyl 
TETA 1,4,8,11-tetraazacyclotetradecane-
1,4,8,11-tetraacetic acid 
tetrofosmin 1,2-bis[bis(2-
ethoxyethyl)phosphino]ethan 
TFA  trifluoroacetic acid 
Thi  thienylalanine 
Thr (T)  threonine 
TK  tachykinin 
TLC  thin-layer chromatography 
TMS  trimethylsilyl  
TOF  time of flight 
TPP  triphenylphosphonium 
TPPTS trisodium triphenylphospine-
3,3',3''-trisulfonate 
TRAP 1,4,7-triazacyclononane-1,4,7-
tris[methyl(2-carboxyethyl)-
phosphinic acid)] 
Trp (W)  tryptophane 
Trt  trityl 
Tyr (Y)  tyrosine 
UV  ultraviolet 
Val (V)  valine 
VIP  vasoactive intestinal peptide 
VIS  visible 
WHO  world health organization 
wt  weight 
α  alpha 
α-MSH α-melanocyte-stimulating 
hormone 
β  beta 
β3hGlu  β3-homoglutamic acid 
β3hLys  β3-homolysine 
β3hSer  β3-homoserine 
γ  gamma 
δ chemical shift in parts per million 
ψ[Tz] 1,4-disubstituted [1,2,3]-triazole 
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I. Introduction 
  
1. Radiopharmaceutical chemistry and nuclear medicine 
Radiopharmaceutical chemistry deals with the development and evaluation of pharmaceuticals labeled 
with radioactive probes for applications in nuclear medicine. The development of 
radiopharmaceuticals dates back to the Hungarian chemist and Nobel laureate (1943) George de 
Hevesy’s work studying the biochemical processes of animals with radioactive tracers (“tracer 
principle”).1 Most radiopharmaceuticals or radiotracers consist of a radioactive nuclide and a 
biological ligand or pharmaceutical. They are classified according to their medical application into 
diagnostic or therapeutic radiopharmaceuticals. They can be categorized into two classes, compounds 
that accumulate exclusively by their chemical and physical properties and those whose distribution is 
targeted, through specific receptor binding or other biological interactions (target-specific 
radiopharmaceuticals).1-2 Depending on the nature of the disease-relevant target, the targeting vector 
can be a macromolecule, for example, an antibody, or a small biomolecule, such as a peptide, 
peptidomimetic, or non-peptide receptor ligand (Figure 1).1-2  
 
Figure 1. Schematic overview 
of radiopharmaceuticals. 
 
 
A diagnostic radiopharmaceutical is labeled with a gamma-emitting (γ) radioisotope for single-photon 
emission computed tomography (SPECT, section 1.1.1) or a positron-emitting radioisotope (β+) for 
positron emission tomography (PET, section 1.1.2 and 1.2.2.4).3 The principle of diagnostic 
radiopharmaceuticals is to enable visualization of molecular or functional information through 
accumulation in different organs and tissues.2 Molecular imaging using radiopharmaceuticals may 
provide the means for characterization, visualization, and measurement of biological mechanisms at 
the cellular and molecular level in humans.2,4 With this non-invasive method, diseases and their status 
can be assessed. Diagnostic radiopharmaceuticals can also be used to monitor the efficacy of specific 
therapeutic applications (section 2.3.2).2 
Therapeutic radiopharmaceuticals are administered in nanomolar, subpharmacological concentrations 
and are not intended to have any pharmacological effect.2,5 Instead, radiopharmaceuticals deliver 
therapeutic doses of ionizing radiation to disease sites that are mainly tumor tissues (section 1.2.2.1).2,5 
Important characteristics of radionuclide therapy are the time of exposure, dose rate, distribution of the 
Radiopharmaceutical 
(Radionuclide + biological ligand) 
Target specific  
radiopharmaceutical 
Accumulation  
by chemical & physical properties 
Macromolecule 
(AB, AB fragment) 
Small biomolecule 
•  Peptide 
•  Peptidomimetic 
•  Small ligand 
Diagnostic 
•  γ (SPECT) 
•  β+ (PET) 
Therapeutic 
•  α 
•  β- 
•  Auger electrons 
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radioactivity, and as a result of those, the absorbed dose of radiation in both the diseased and healthy 
tissue.2,6 Thus, the type of radiation, half-life, and energy deposited of the emitting radionuclides are 
crucial. Radionuclide therapy can be applied using three different administration routes; either via 
external beam radiation (photons), implants (brachytherapy), or systemic application.2 Brachytherapy, 
or internal radiotherapy, uses sealed sources of radiation (seeds) that are implanted inside or next to 
the disease tissue. It is used for treatment of easily accessible tumors and most often in the treatment 
of prostate cancer patients.2 Disseminated metastatic tumors can be treated with systemically 
administrated radiopharmaceuticals that deliver therapeutic radionuclides specifically to tumor sites 
without damaging the surrounding healthy tissue (e.g., peptide-receptor radionuclide therapy, PRRT, 
section 2.4.1).2 Appropriate radionuclides for radionuclide therapy are alpha (α ), beta (β-), and Auger 
electron emitters (section 1.2.2.3).2-3 This thesis focuses on targeted molecular imaging and therapy, 
using peptide-based radiopharmaceuticals. The principles and general considerations thereof are 
described in subchapter 2. 
 
1.1 Different imaging modalities in nuclear medicine 
SPECT and PET are important modalities in nuclear medicine for non-invasive molecular imaging of 
(patho)physiological processes in vivo.3 Compared to other imaging modalities, such as computed 
tomography (CT) and magnetic resonance imaging (MRI), which provide morphological information 
of tissues and organs with high spatial resolution, the strength of PET and SPECT lies in their ability 
to visualize biochemical processes on a cellular level.7 Compared to CT or MRI, the high sensitivity of 
PET and SPECT allow the administration of imaging compounds in very low concentration (Table 
1).7-8 
 
Table 1. Comparison of different imaging modalities.7-8 
Modality Spatial resolution 
[mm] 
Concentration of 
imaging agent [M] 
Radiation Information 
SPECT 8-20 10-6 yes functional 
PET 3-10 10-8-10-10 yes functional 
CT 1 10-4 yes morphological 
MRI <1 10-5 no morphological 
 
1.1.1 SPECT imaging 
SPECT imaging requires a gamma (scintillation) camera with a detector head that rotates around the 
long axis of the patient from multiple angles. A three-dimensional dataset can be acquired through a 
computer-based tomographic reconstruction algorithm. Usually, a full 360-degree rotation is applied 
to obtain an optimal reconstruction. The acquisition time can be accelerated by using multiple-headed 
gamma cameras (2-4 detector heads) rotating around the patient. Such a camera head is made up of a 
collimator, scintillation crystal (usually sodium iodide), photomultiplier, and an amplifier (Figure 2).3 
The collimator is a device used to narrow radiation beams that allows only vertical radiation beams to 
pass, which results in the high spatial resolution of the detector.3 Different collimator types can be 
applied, including parallel hole, pinhole, converging, and diverging collimators.3 Pinhole collimators 
are used to image small organs (e.g., thyroid glands). Diverging collimators are used to image organs 
that are larger than the size of the detector, whereas converging collimators are used to target organs 
that are smaller than the detector. The most commonly used collimators in nuclear medicine 
applications are parallel-hole collimators with varying diameter of the holes.3 Each gamma photon that 
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reaches the connected scintillation detector results in a light flash, or scintillation. A photo-multiplier 
is needed to multiply the signal, which is subsequently converted by an amplifier to an electric signal 
that can be reported.3 For SPECT imaging, γ-emitting radionuclides (section 1.2.2.4), which have an 
ideal γ-energy of 70-250 keV are used, such as 99mTc, 111In, and 67Ga (Table 2 and Figure 6).1,3,8  
 
Figure 2. Schematic illustration 
showing the composition of a 
scintillation detector and illustration of 
a SPECT-camera with three detector-
heads.9 
 
1.1.2 PET imaging  
PET is based on the coincidence-measurement of two 511 keV γ photons that are emitted in opposite 
directions (180 ° apart) after annihilation of a positron (obtained from position-emitting radionuclides, 
section 1.2.2.4 and Figure 7) and an electron. Two oppositely located detectors detect these two 
photons in coincidence (Figure 3).3,8 To construct an image of the distribution of radioactivity, data is 
collected over many angles around the body axis of the patient. Such coincidence measurement 
obviates the need for a collimator to focus the field of view. The PET-camera consists of circularly 
arranged γ-detectors (detector ring) where each detector is connected to the opposite detector by a 
coincidence circuit.3 Manufacturers use different scintillation detector crystals, such as bismuth 
germanate, sodium iodide, lutetium oxyorthosilicate, gadolinium oxyorthosilicate, or lutetium yttrium 
oxyorthosilicate.3 By measuring coincidence, images can be generated that have less scattered 
background radiation. Compared to SPECT imaging, better spatial resolution and higher sensitivity 
can be achieved with PET.7-8 A selection of some of the relevant β+-emitting radionuclides is listed in 
Table 2.1,3  
 Figure 3. Pictures of a PET-scanner.9  
 
1.1.3 Multimodality imaging 
In the past, single modality instruments were used for SPECT and PET imaging, but nowadays 
multimodality SPECT/CT and PET/CT instruments are state of the art. This means morphologically 
imaging of high resolution (CT) is combined with functional information (SPECT, PET) in a fused 
image that is resulting in higher diagnostic accuracy and localization.3 A very recent development is 
using MRI instead of CT for morphological imaging. SPECT/MRI and PET/MRI hybrid imaging 
reduce the radiation burden on the patient and higher special resolution may be obtained (Table 1).7,10 
1.2 Radionuclides for medical application 
Radionuclides are atoms with an unstable nucleus that transform randomly to a more stable or stable 
nuclides by undergoing radioactive decay.3 Radioactive decay may result in either electromagnetic or 
Parallel hole collimator  
Scintillation NaI-crystal  
Photomultiplier 
Amplifier (electronics) 
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particle radiation.3 Electromagnetic radiation, resulting from emission of gamma- (γ) or x-rays, is 
applied for diagnostic purposes. Subatomic particle emitting radionuclides (e.g., α, β-) are clinically 
used for therapeutic applications.1-3 Radionuclides either occur naturally or can be artificially 
produced.3 They can be classified further by their decay characteristics or their physico-chemical 
character (non-metallic: e.g., 11C, 13N, 15O, 18F, 32P, 131I, or metallic: e.g., lanthanides and transition 
elements).3  
1.2.1 Production of radionuclides 
Most radionuclides used in nuclear medicine are artificially produced. Nowadays, more than 2700 
radionuclides can be primarily generated in a cyclotron, reactor, or linear accelerator, depending on the 
target nuclei, the irradiating particle, and its energy.3 
1.2.1.1 Cyclotron 
In a cyclotron, charged particles (e.g., protons, deuterons, or α-particles) are accelerated under vacuum 
in a circular path by an electromagnetic field.3 Depending on the design and type of the cyclotron, 
these accelerated particles can obtain very high energies. If targets of stable elements are irradiated by 
locating them in the beam of the accelerated particles in a cyclotron, the target nuclei get irradiated 
and a nuclear reaction occurs.3 Depending on the energy of the beam, a certain number of nucleons 
(protons, neutrons) are randomly emitted from the irradiated target nucleus, which leads to the 
formation of the desired radionuclide (Table 2).3  
1.2.1.2 Nuclear reactor 
A nuclear reactor is built of fuel rods of fissile materials, such as enriched uranium-235 or plutonium-
239 that undergo spontaneous fissions.3 Nuclear fission is the disruption of a heavy nucleus into two 
fragments, accompanied by the emission of neutrons.3 The emitted neutrons cause further fission of 
other nuclei, initiating a chain reaction. If a target element is introduced into the reactor core, a neutron 
will interact by fission or reaction of neutron capture with this target nucleus and another 
(radio)nuclide is produced (Table 2).3  
Due to their high equipment cost, only few facilities possess cyclotrons or reactors and thus, 
radionuclides are supplied to distant facilities that are lacking this production equipment.3 However, 
very short-lived radionuclides cannot be distributed over long distances and thus, they can only be 
applied by medical facilities possessing a cyclotron or a reactor.3  
1.2.1.3 Radionuclide generator 
A radionuclide generator is based on the principle of the decay-growth relationship of a long-lived 
parent radionuclide and its short-lived daughter radionuclide. An important requirement is different 
chemical characteristics of both radionuclides. If this is the case, the parent radionuclide decays 
constantly and forms the daughter radionuclide that can be easily separated.3 Radionuclide generators 
can be easily transported and facilitate the use of short-lived radionuclides in medical institutions that 
are lacking a cyclotron or reactor for the production of radionuclides.3 A radionuclide generator is 
composed of a glass or plastic column that is filled with adsorbent material (e.g., cation-, anion-
exchange resin, alumina, or zirconia) on which the mother radionuclide is fixed.3 Due to the chemical 
differences, the mother nuclide stays adsorbed and the daughter radionuclide that is produced can be 
eluted from the generator column with an appropriate solvent (e.g., physiological sodium chloride 
solution for 99Mo/99mTc generator).11 After elution, the amount of daughter nuclide starts to grow again 
by radioactive decay of the remaining mother nuclide and can repeatedly be obtained by elution 
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(“milking” of the generator).3 The eluted daughter nuclide should decay to a very long-lived or non-
radioactive “grandchild” nuclide to minimize the radiation burden on the patient.3 A schematic 
illustration of a radionuclide generator is given in Figure 4. A vial containing the solution of the eluent 
(A) has to be connected to the generator. Applying vacuum by connecting another evacuated empty 
vial (B), the daughter nuclide is selectively eluted, while leaving the parent nuclide on the column.3 
Since this radionuclide-eluate is used further for the production of radiopharmaceuticals for parenteral 
administration, it has to be sterile and pyrogen-free and elution of the generator has to be performed 
under aseptic conditions.2-3,11 An ideal radionuclide generator should be convenient to use, give 
reproducible and repeatedly high yield of the daughter nuclide, is supposed to be free from the parent 
nuclide (minimal breakthrough) and adsorbent material, and has to be adequately shielded to minimize 
radiation exposure of the personnel.3 One of the first and most commonly used radionuclide generator 
systems is the 99Mo/99mTc-generator, developed by Tucker and Richards in the late 1950s for the 
production of technetium-99m.12 Other commonly used radionuclide generator systems for 
applications in nuclear medicine are e.g., 68Ge/68Ga, 82Sr/82Rb, and 188W/188Re generators.1,3
Figure 4. Schematic illustration of the 
elution of a produced daughter radio-
nuclide in a radionuclide generator.3,9 
 
1.2.2 Medical applications of radionuclides 
1.2.2.1 Radiobiology  
Applying radionuclide therapy, the target of ionizing radiation is the DNA of the cells. Several 
different lesions are caused by direct ionization of DNA, including single-strand breaks (SSB), 
double-strand breaks (DSB), damage of base, multiple damaged sites, and cross-links of DNA-bases.13 
These lesions are the result of direct effects (ionization of DNA) or of indirect interaction of free 
radicals (mainly hydroxyl radicals) with DNA that can be altered by radical scavengers. Distribution 
of ionizations and the type of lesions depends strongly on the type of radiation and energy.13 DSB 
induced by highly specific ionization (α-particles and Auger electrons) are more severe than those 
caused by more diffuse irradiation.13 The ability for indefinite cell division declines in mammalian 
cells as a function of radiation dose and their survival depends on the density of ionization.13 After 
irradiation, a delay in progression of cell division in their cell cycle occurs, which is reversible and 
dose-dependent. This delay depends on the cell cycle phase, whereas cells in pre-mitotic G2 phase 
exhibit maximum delay, which is altering the mitotic index.13 After cell irradiation and DNA damage, 
harm is sensed, several genes are activated, and cells are either awaiting repair of DNA and proceed in 
the cell cycle, or damages are irreparable and the cells undergo programmed cell death or apoptosis.13 
It has been reported that cells that are adjacent to irradiated cells but have not been irradiated 
themselves also show increased mutation rates and decreased survival rates. This phenomenon is 
called “bystander effect”.13 
Mother nuclide 
(adsorbed on column) 
Shielding 
Vial A 
(eluent solution)  
Air vent 
Evacuated vial B 
with eluted  
daughter nuclide 
Filter 
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1.2.2.2 Radiation dosimetry 
Radiopharmaceuticals are applied in subpharmacological concentrations.2,5 However, radiation can 
cause deleterious effects in living organisms.13 Therefore, it is essential to assess the biological effects 
in humans for an administered radiopharmaceutical by dosimetric calculations. Dosimetry is the 
computation of the absorbed dose to different tissues of the body in relation to the total administered 
radioactivity.1 Damaging effects caused by irradiation of tissues depend on the administered 
radioactivity, biological and physical half-lives of the radiopharmaceutical, distribution and 
metabolism of the radiotracer in the body, individual variations of physiological functions, shape, size, 
density, relative location, and radiosensitivity of different organs and tissues.3,13 
1.2.2.3 Therapeutic applications 
Alpha-decay, the emission of a helium nucleus (α-particle) is common for heavy nuclei (e.g., 211At, 
212/213Bi, 225Ac, Table 2) and is characterized by a high degree of ionization along a linear track with 
energies of several MeV (5-9 MeV) within a very short range (10-100 µm) and low depth of 
penetration.13 Their high linear energy transfer (LET; density of ionization along the path) and 
micromolar range result in an extremely high-localized dose of radiation and effective killing of single 
small cells and their clusters, without damaging the surrounding tissue (Figure 5).3,13 This high-energy 
radiation is exploited for radionuclide therapy, especially for treatment of small tumors and metastases 
(section 2.4.1).1,3,10,13  
Beta-minus (β-) radiation occurs by the decay of a neutron into a proton, an electron, and electron 
capture, leading to electron emission.3 β-particle ionization is infrequent along a linear track and has a 
short range (0.5-10 mm) with low to medium energy (0.3-2.3 MeV).13 This radiation can be used for 
therapeutic applications of small to large size cell clusters (Table 2, Figure 5). A unique advantage of 
β-particle radiation is their “crossfire effect” (irradiation by decays in distant or neighboring cells, 
Figure 5).13 If a sufficient amount of emission occurs in a tissue volume, the probability of lethal hits 
increases, predominantly from sources bound to other cells.13 This crossfire killing obviates the 
necessity for targeting each cancer cell and improves homogeneity of the tumor dose in ensuring 
sufficient radiation to each cell.1,3,10,13  
Figure 5. Schematic illustration of crossfire 
effect, the range of α, β, and Auger electron-
emitting radionuclides (length of arrows), and 
their LET (thickness of arrows).  
Auger electrons, first described in the 1920s by Pierre Auger, are concomitantly emitted by 
radionuclides that are decaying by electron capture or internal convention (almost 50% of the known 
radioisotopes).14 Related with these decay processes, inner atomic shell vacancies are formed. To fill 
these vacancies, cascades of transitions of inner shell electrons take place that result in concomitant 
emission of several low-energy electrons (Auger, Coster-Kronig, and super-Coster-Kronig 
transitions).14 Biological damages caused by this radiation are highly dependent on the location of the 
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decaying radionuclide within the cell.13-14 Compared to other particle-emitting radionuclides, the range 
(nanometer) and also the emitted energy of Auger electrons are extremely low (Figure 5).13 However, 
if Auger electrons are in close proximity to the cell nucleus, or even intercalated into DNA of tumor 
cells, their potential of highly radiotoxic fragmentation and DBS of DNA can be exploited for 
radionuclide therapy of cancers.13 Examples of radionuclides that are emitting Auger electrons for 
potential clinical applications are 67Ga, 99mTc, 111In, 123I, 125I, and 201Tl (Table 2).1,3,13-14  
1.2.2.4 Gamma radiation for molecular imaging 
Gamma rays are emitted alongside other radioactive decay. After radioactive particle decay (α, β), the 
daughter nucleus is usually left in an excited state.3 By moving to a lower energy state, residual energy 
can be emitted by the nucleus in the form of electromagnetic radiation (γ-radiation, Figure 6).3 
Radionuclides emitting γ-radiation (Table 2) are used for SPECT-imaging (section 1.1.1).1,3,8  
Figure 6. Schematic illustration of gamma decay for SPECT 
imaging. 
Unstable, proton-rich radionuclides decay by positron emission (β+; proton decay). This is a subtype of 
beta decay, in which a proton of the nucleus is converted into a neutron, a positron (β+), and a 
neutrino.3 The positron collates with an electron and the resulting energy is released as annihilation 
radiation of two diametrically opposed γ-lines of each 511 keV (Figure 7).1,3,8 This pair of emitted 
gamma rays is appropriate for detection by PET-cameras (section 1.1.2).1,3,8 
Figure 7. Schematic illustration of proton decay and 
annihilation radiation for PET imaging. 
Relevant radionuclides used in nuclear medicine, for both therapeutic (α, β-, Auger electrons), and 
diagnostic (γ, β+) applications are summarized in Table 2.  
The tracers described in this thesis are radiolabeled with technetium-99m and lutetium-177. Thus, 
these radiometals will be discussed further in the following sections. 
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Table 2. Selected radionuclides, their decay properties, and applications in nuclear medicine.1-2,8,10,15 
Type Isotope t1/2 
[h] 
Decay mode (%), 
max E, range 
Medical 
application 
source 
γ -emitter 67Ga 78.3 EC (100), γ, Auger SPECT cyclotron 
99mTc 6.02 IT (100), γ, Auger SPECT generator 
111In 67.9 EC (100), γ, Auger SPECT cyclotron 
123I 13.3 EC (100), γ, Auger SPECT cyclotron
β+-emitter 11C 0.34 EC, β+ (100) PET cyclotron 
18F 1.83 EC, β+ (97) PET cyclotron 
64Cu 12.9 EC (41), β+ (19), β- (40), γ PET, therapy cyclotron 
68Ga 1.13 EC (11), β+ (89), γ PET generator 
89Zr 78.5 EC (77), β+ (23) PET cyclotron 
β--emitter 90Y 64.1 β- (2.28 MeV, 12.0 mm) therapy reactor, 
generator 
131I 193 β- (0.61 MeV, 0.31 mm) therapy reactor
177Lu 161 β- (0.5 MeV, 2.0 mm), γ therapy reactor 
186Re 90.5 β- (1.07 MeV, 5.0 mm), γ therapy accelerator, 
reactor 
188Re 16.9
8 
β- (2.12 MeV, 11.0 mm), γ therapy reactor, 
generator 
α -emitter 211At 7.2 α (6.79 MeV), 0.06 mm), EC, 
γ 
therapy cyclotron 
213Bi 0.76 α (8.38 MeV, 0.08 mm), β-, γ therapy generator 
EC: electron capture, IT: isomeric transition 
1.2.3 Technetium-99m 
Technetium-99m (99mTc, m= metastable) is of particular interest for SPECT imaging, due to its ideal 
nuclear properties. 99mTc is the most widely used (> 80%) diagnostic radionuclide in nuclear medicine 
because of its easy and cost efficient on-site production with a readily available commercial 
99Mo/99mTc-generator system.2-3,8,11,16 The energy of gamma radiation emitted by 99mTc (140 keV) is 
sufficient to penetrate human tissue and enables external detection by SPECT scanners.3,11,17 The 
comparatively long half-life (6.02 h, Table 2) conveniently allows for the production of 
radiopharmaceuticals, administration to the patient, in vivo accumulation in the target tissue, and 
subsequent scintigraphic imaging.3 In addition, 99mTc-radiopharmaceuticals could also be administered 
for radiation therapy, exploiting their concomitant emitted Auger electrons.14 The decay scheme of 
99Mo via 99mTc to stable 99Ru is summarized in Figure 8.3,11,17  
Figure 8. Decay scheme of 99Mo to 
99Ru.3,11,17 
Ready to use pertechnetate (99mTcO4-) can be obtained by eluting the generator column with sterile 
saline. The specific activity (amount of radioactivity per amount of radionuclide)3 of the 99mTc-eluate 
99mTc 
99Ru (stable) 
γ (140 keV) 
 t½=6.02 h 
ß-, γ, (87%) 
t½=66 h 
ß-, γ, (13%) 
t½=66 h 
99Mo 
99Tc 
ß- 
t½=2.1x105 a  
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depends on the time interval between the performed elutions.11,16-17 99mTc-radiopharmaceuticals are 
intravenously administered and hence, radiosynthesis has to be accomplished under sterile and 
pyrogen-free conditions.2,11 Synthesis of established 99mTc-radiopharmaceuticals can be simply 
performed by adding pertechnetate to a kit formulation.2,11,15c,16 Kit formulations are used for the sake 
of convenience, consistency, and reproducibility of the radiochemical purity during radiolabeling. Kits 
are sterile, pyrogen-free, and lyophilized mixtures of all the required ingredients, including a reducing 
agent.1-2,11,16 The most commonly used reducing agent in commercial kits is stannous chloride. But 
many other reducing agents are also used, such as borohydride, dithionate, dithionite, and 
phosphines.2,16 To improve the radiolabeling yield and stability of 99mTc-radiopharmaceutical, different 
components can be included, such as solubilizing agents, antioxidants, or weak transferring ligands.2,16 
Many ready-to-use kit-formulations for a huge variety of 99mTc-radiopharmaceuticals are 
commercially available for imaging of different organ functions, bone scanning, imaging of 
myocardial perfusion, and immunoscintigraphy.11,16-18 The majority of 99mTc-based 
radiopharmaceuticals currently used in the clinic are complexes with low molecular weight, whose 
biological distribution is determined by blood flow and accumulation in organs and tissues due to their 
chemical and physical properties (Figure 1).11 Nowadays, efforts in the development of radiotracers 
are focused on the design of specific (receptor-)targeting radiopharmaceuticals.2,11,15a,16-17,18b,19  
Based on their periodic relationship, the coordination chemistry of technetium is similar to that of its 
group VII transition metal congener rhenium (“matched pair”).2,18b,19a Thus, the strategies developed 
for technetium labeling of molecular imaging agents can also be adapted to the β--emitting 
radionuclides 186/188Re for the development of therapeutic radiopharmaceuticals, using the same 
biomolecule (“theranostics”, section 2.3.2).2,8,18b,19a However, there are also significant differences 
between 99mTc and 186/188Re. For instance, they show different redox potential, the reduction of 
perrhenate ([Re(VII)O4]-) is slower, and a stronger reducing agent is required. Furthermore, it can be 
challenging to achieve high in vivo stability because of oxidation reactions occurring in vivo.1-2,11,15a,16  
[99mTcO4]- cannot be used for direct attachment to biomolecules because it does not form stable 
complexes. Thus, 99mTc(VII) of pertechnetate has to be reduced to a lower oxidation state. Technetium 
exhibits diverse redox chemistry with various oxidation states (-I to +VII).2,11,16-17,18b,20 The resulting 
oxidation state depends on the reducing agent, reaction condition, and the chelating system used. The 
rich redox chemistry offers the possibility of modifying structures and characteristics of technetium 
complexes developed, by the choice of chelators that possess high affinity for a certain oxidation 
state.2,11,16,18b It goes far beyond the scope of this thesis to discuss the diverse coordination chemistry 
of technetium, various chelating agents, 99mTc cores, labeling strategies, and the enormous amount of 
developed 99mTc-radiopharmaceuticals. All of this is described in many excellent reviews, for 
example, those by Liu and others.2,10-11,16-17,18b,19-20 In the context of this thesis, some selected 
technetium cores, including Tc(V)-oxo, Tc(V)-dioxo, Tc(V)-nitrido, Tc(III)-hydrazino, and Tc(I)-
tricarbonyl (Figure 9) that are used for 99mTc-labelings of biomolecules will be discussed in the 
following sections.  
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Figure 9. Common 99mTc cores and schematic complexes thereof with chelating agents used for the radiolabeling 
of targeted biomolecules; A) Tc(V)-oxo, B) Tc(V)-nitrido, C) Tc(III)-hydrazino and D) Tc(I)-tricarbonyl core 
(spheres represent coordinating ligands).16 
 
1.2.3.1 [99mTc=O]3+ and [O=Tc=O]+ cores 
The Tc(V)-oxo core, [99mTc=O]3+, is one of the most frequently used cores for 99mTc-labeling of 
biomolecules. It forms square pyramidal complexes, in which the π-bonding oxo-group occupies the 
apical position and stabilizing σ- or π-donating amino, amido, or thiolate ligands form the basal 
plane.2,10,16,18b,19a A wide range of ligand systems for the chelation of the [99mTc=O]3+ core are reported 
with tetradentate chelators, such as N4 tetraamine type propylene amine oxime (PnAO), N3S 
triamidethiols (TAMS), N3S diamide-monoamine-thiols (DAMA), N2S2 diaminedithiols (DADT), 
N2S2 diamidedithiols (DADS), N2S2 monoamide-monoamine-dithiols (MAMA), or N2S4 
diaminetetrathiol (for examples thereof, Figure 10 A).2,16 Tripeptide sequences (e.g., Gly-Ser-Cys) are 
mimicking an N2S2 or N3S type chelating systems and also form stable Tc(V)-oxo complexes.2,16 The 
most prominent example of N3S type chelators for conjugation to biomolecules is 
mercaptoacetyltriglycine (MAG3).2,16,18b The MAG3 chelator itself, radiolabeled with 99mTc (99mTc-
MAG3) is also commonly administered in nuclear medicine as radiopharmaceutical for imaging of 
renal perfusion.2,10,16,18b,19a 
The Tc(V)-dioxo core forms octahedral Tc(V)-complexes with macrocyclic (e.g., cyclam) or acyclic 
tetraamines that have been used for radiolabeling of antibodies or peptides (Figure 10 B).16,19a,21 
Bidentate phosphines can also form stable complexes with the Tc(V)-dioxo core.16 An example of a 
Tc(V)-dioxo-radiopharmaceutical, chelated to bidentate phosphines is [99mTcO2(tetrofosmin)2]+ 
(tetrofosmin: 1,2-bis[bis(2-ethoxyethyl)phosphino]ethan) that is commonly administered in nuclear 
medicine for myocardial imaging.11,16-17,18b  
 
Figure 10. Examples 
of A) technetium(V)-
oxo and B) 
technetium(V)-dioxo 
complexes with NxS4-x 
type chelators.16 
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1.2.3.2 [99mTc≡N]2+ core 
The technetium-nitrido core, [99mTc≡N]2+ is isoelectronic with the technetium-oxo core and forms 
stable Tc(V)-complexes (square pyramidal, nitrido-group in apical position) with various chelators 
(e.g., thiolate-S, amine-N, and carboxylic-O donors) for radiolabeling of small molecules with 
99mTc.2,18b Compared to the technetium-oxo core, the strong π-electron donating nitrido ligand enables 
the high stabilization of the Tc(V) oxidation state.2,16,18b Among other ligand systems, cysteine and 
dithiocarbamates in combination with co-ligands (e.g., biphosphines) have been shown to be 
particularly suitable chelating systems for the radiolabeling of targeted (bio)molecules with the 
[99mTcN]2+ core (Figure 11).2,11,16,18b  
 
Figure 11. Examples of 
cysteine- and dithiocarbamato-
based chelating ligands for the 
nitrido core [99mTcN]2+; R: alkyl 
or aromatic residues.2 
 
 
1.2.3.3 [99mTc]HYNIC core 
Hydrazine groups of organic molecules react with metal-oxo species by a condensation reaction to 
form chemically robust metal-organohydrazine entities, offering an alternative method for the 
synthesis of 99mTc-radiopharmaceuticals.18b Using the HYNIC (6-hydrazinonicotinamide) core, 
coligands, such as ethylenediamine-N,N'-diacetic acid (EDDA), tricine, or glucoheptonate are required 
to complete the square pyramidal or octahedral complexes, because HYNIC occupies only one or two 
coordination sites of the metal, the pyridyl and/or hydrazine nitrogen (Figure 12).2,10,16,18b,22 High 
labeling efficacies can be achieved with the [99mTc]HYNIC core and the use of coligands also enables 
pharmacokinetic or hydrophilic modifications.2,10,16,18b,22 There are also ternary ligand systems with 
water-soluble phosphines described for 99mTc labeling of different biomolecules in very high yield and 
specific activity, e.g., [99mTc(HYNIC-biomolecule)(tricine)(phosphine)].2,16,22 However, formations of 
product mixtures are possible, depending on the coligands and reaction conditions that are 
used.2,10,16,18b,22 The HYNIC core has been reported for 99mTc-labeling of various biomolecules, such as 
peptides, antibody fragments, antisense oligonucleotides, and liposomes.2,16 However, the lack of 
identity of species present on the tracer level has impeded the general utility of the HYNIC core for 
the development of 99mTc-radiotracers.2,10,16,18b,22  
 
Figure 12. Two possible isomers of 
[99mTc(tricineH2)HYNIC] complexes as 
the result of mono- or bidentate 
coordination modes of the HYNIC ligand. 
TPPTS = trisodium triphenylphospine-
3,3',3''-trisulfonate.22 
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1.2.3.4 [99mTc(CO)3]+ core  
The stable and water-soluble organometallic fac-tricarbonyl core, [M(CO)3(H2O)3]+ (M=99mTc(I), 
186/188Re(I)) was introduced by Alberto, Schibli, and coworkers in 1998.23 The complex was first 
formed by direct reduction of pertechnetate or perrhenate with sodium borohydride in the presence of 
carbon monoxide.23 In pioneering work by the Schubiger group, the breakthrough for a convenient kit 
utilization of the tricarbonyl core was the application of solid, stable, and non-toxic potassium 
boranocarbonate, K2[H3BCO2].24 Boranocarbonate provides CO release upon hydrolysis, and 
reduction of Tc/Re(VII) to Tc/Re(I) in a ready to use kit-formulation (IsoLinkTM kit, “CRS IsoLink kit 
for tricarbonyl”) for the synthesis of 99mTc and 186/188Re-tricarbonyl complexes.19b,24 To use the 99mTc-
tricarbonyl core for the radiolabeling of biomolecules, several bifunctional chelating agents were 
developed. The three labile water molecules are easily substituted with S, O, or N atoms of various 
chelating ligands (Figure 13).17,18b,19,25 Numerous mono-, bi-, or tridentate ligand systems, of e.g., 
amines, amides, carboxylic acids, imidazoles, pyrazoles, pyridines, thioethers, thiols, phosphines, and 
combinations thereof lead to stable complexes of 99mTc and 186/188Re-tricarbonyl.17,18b,19,25 Among the 
possible ligand systems, aromatic amines provide fast complexation, high thermodynamic stability, 
and kinetic inertness. Combining an aromatic amine with aliphatic amines and/or carboxylates has 
proven to be advantageous in aqueous solutions.18b,19b,25a The amino acid histidine (His) has ideal 
characteristics for facile and stable complexation of the tricarbonyl core in low ligand concentration 
(10-6 M).19b,25a In addition, histidine as a chelating system (e.g., Nα-Ac-His-chelator) can be easily 
coupled to the N-terminus of peptides for the preparation of targeting radiopharmaceuticals with very 
high specific activity.18b,19b,25a Furthermore, the octahedral fac-[99mTc(CO)3(H2O)3]+ core is generally 
smaller than octahedral or square-pyramidal complexes of technetium in higher oxidation states and 
thus, the organometallic tricarbonyl core is the preferred metal core for labeling small biomolecules 
with technetium or rhenium.18b,19b,25a  Technetium and rhenium tricarbonyl cores have been widely 
used for the development of radiolabeled biomolecules, such as peptides (e.g., somatostatin, bombesin, 
neurotensin, and neuropeptide Y analogs),25d,26 proteins, and small molecules (e.g., tropane, serotonin, 
and steroid derivatives).19b,25b,d 99mTc-tricarbonyl complexes with mono- and bidentate chelators suffer 
from low stability and adverse biodistribution profiles. They display high aggregation of plasma 
proteins and are retained in the blood pool and the excreting organs (liver, kidneys).19b,27 Tridentate 
chelating systems form more stable 99mTc-tricarbonyl complexes with superior pharmacokinetics in 
vivo.19b,25b-d,27 Another example of a tridentate ligand is bis(pyridine-2-ylmethyl)amine (dpa), which 
rapidly forms very stable complexes with 99mTc-tricarbonyl.18b,25b The dpa ligand provides the 
structural basis for a bifunctional chelate in the single amino acid chelates (SAAC).18b,28 In this 
approach, natural or synthetic amino acids are modified by incorporation of a tridentate chelate 
terminus and a terminus for attachment to small biomolecules.28 Functionalized η5 cyclopentadienes 
(Cp, Figure 13) and carboranes have been used for stable complexation of the fac-[99mTc(CO)3(H2O)3]+ 
core as well.18b,19b,25b,d The tricarbonyl core also enables the production of isostructural 186/188Re-
radiopharmaceuticals as therapeutic analogues, which cannot always be achieved for Tc(V)/Re(V)-
complexes.18b,19,25a For applications in radiopharmacy, the rather lipophilic character of the fac-
[99mTc(CO)3(H2O)3]+ core can be a limiting factor, causing an unfavorable alteration of the 
hydrophilicity of the radiometal (peptide)conjugate.18b,19,25b  
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Figure 13. Representative 
examples of structurally 
diverse chelating systems for 
complexation of fac-
[99mTc(CO)3(H2O)3]+.2,18b,19b,25
b,d  
 
 
An elegant synthetic approach for the formation of chelating systems for the fac-[99mTc(CO)3(H2O)3]+ 
core and simultaneous conjugation to a biomolecule was reported by Mindt et al. in 2006.29 This 
approach employs the versatile Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC, click 
chemistry)30 and was termed “Click-to-Chelate”.29 The strategy is shown in Figure 14. 
Figure 14. The “Click-to-Chelate” approach enables the labeling with 99mTc-tricarbonyl and simultaneous 
assembly with azide-functionalized biomolecules by efficient and convenient one-pot procedures. 
The final radioconjugate can be obtained directly by a convenient and efficient one-pot procedure. The 
“Click-to-Chelate” methodology has proven useful for the assembly and radiolabeling of a broad 
variety of biomolecules, such as peptides, vitamins, nucleosides, carbohydrates, and phospholipids.29,31 
This promising strategy for the development of 99mTc-based radiotracers will be discussed in more 
detail in chapter II of this thesis, since the bifunctional radioconjugates (chapter III and IV) are 
assembled using an “extended Click-to-Chelate” methodology.31c 
 
1.2.3.5 [99mTcO3]+ core 
 
A Tc metal core recently developed is the fac-[TcO3]+ core, which is stabilized by tripodal ligands to 
form a core of approximately the size of an iodide ion.32 Two synthetic approaches are possible for the 
formation of [TcO3]+ cores; direct activation of pertechnetate or oxidation of stable Tc complexes 
containing the metal atom in a lower oxidation state.32 In contrast to synthetic strategies for 
bifunctional 99mTc-complexes based on ligand replacement reactions at the metal core, bifunctional 
fac-[TcO3]+ complexes can be formed conveniently using a ligand-based strategy.32 Tc-trioxo 
complexes react with alkenes via a metal-mediated vicinal cis-dihydroxylation reaction ((3+2)-
cycloaddition).33 This approach enables the preparation of novel molecular imaging agents and may 
overcome some of the limitations previously experienced with the coordination chemistry of 
technetium.32 In 2009 the group of Alberto reported the synthesis of stable [99mTcO3(tacnR)]+ (tacnR: 
1,4,7-triazacyclononan derivatives) complexes from pertechnetate, using phosphines as reagents and 
called this approach “clack chemistry” (an analogy to established “click chemistry”).34 This 
methodology was applied to synthesize conveniently bifunctional bioconjugates containing either a 
hypoxia targeting pharmacophore, a glucose derivative, or an artificial amino acid to demonstrate the 
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suitability and flexibility of this new labeling approach.35 Compared to the 99mTc-tricarbonyl core, 
advantageous hydrophilicity was confirmed for the [99mTcO3(tacnR)]+ core and further in vivo studies 
are currently ongoing.35-36 However, more detailed kinetic investigations are needed and the 
stereochemistry of the (3+2) cycloaddition has to be controlled to optimize this labeling strategy for 
routine radiolabeling of biomolecules.35 
 
1.2.3.6 General considerations 
Due to the central role of technetium-99m in nuclear medicine, a large number of 
radiopharmaceuticals, based on the various, previously described technetium cores have been 
developed and evaluated in (pre)clinical studies and some are routinely administered in the 
clinic.2,11,16,19a,25b Examples range from radiolabeled large proteins to medium-size peptides19a,37 and 
small compounds, including vitamins (biotin, vitamin B12, and folic acid),19a steroid hormones, and 
neurotransmitters (dopamine and serotonin).2,11,16,25b 
Because of its ideal nuclear characteristics, 99mTc remains the most widely used radionuclide in nuclear 
medicine and radiopharmaceutical sciences. Thus, 99mTc will continue to be important for the future 
development of novel targeting radiotracers for diagnosis, assessment of diseases, and monitoring of 
therapy outcomes.18b,19a,25b  
However, it has to be critically acknowledged that the continuing global shortage of 99mTc is a 
challenge.19a Aging nuclear reactors that are important for the world’s supply require frequent 
maintenance and repair.19a Less than ten reactors worldwide supply radionuclides for medical 
applications.38 Half of the world’s supply of radionuclide raw material is produced in the National 
Research Universal (NRU) reactor at Chalk River (Canada).38 Unforeseen maintenance at the NRU 
reactor and coincidental shutdowns of other international reactors led to a global shortage of medical 
radionuclides (especially 99mTc) in 2009.38-39 The NRU reactor is several decades old and although it 
has since restarted its production, it is planned to cease the production of isotopes in 2016.39 Thus, 
consistent and reliable methods for the production of 99Mo or direct production routes of 99mTc have to 
be established in order to fulfil the world’s demand of 99mTc.38 Possible production routes for 99Mo 
include production from less security-critical low-enriched uranium (LEU) rather than high-enriched 
uranium (HEU) targets, reactor production by neutron activation (98Mo(n,γ)99Mo reaction), or 
production by accelerators.38 However, all of these methods result in 99Mo with lower specific activity, 
requiring, for example, adapted kit formulations and 99Mo/99mTc separation techniques.38 Another 
potential approach is using cyclotron bombarding of enriched 100Mo targets as an alternative for the 
direct production of 99mTc (100Mo(p,2n)99mTc reaction).38,40 The Canadian government’s “Non-reactor 
Based Isotope Supply Contribution Program” (NISP) is evaluating the use of linear electron 
accelerators (LINAC) for the production of 99Mo via the 100Mo(γ,n) reaction.39 LINAC-produced 99mTc 
appear to be clinically equivalent to the current fission-produced 99mTc. In addition, this “green” 
production route reduces radioactive waste and 100Mo left after processing can be reused and 
recycled.39  
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1.2.4 Lutetium-177 
The radiometal lutetium-177 (177Lu) belongs to the lanthanide group. Its common occurring oxidation 
state is +3.1,15c 177Lu can be produced in a cyclotron, but most commonly this radiometal is produced 
by neutron bombardment of purified target materials in medium flux nuclear reactors via direct or 
indirect methods.1-2 Direct neutron activation of enriched 176Lu (176Lu(n,γ)177Lu reaction) in a medium 
flux reactor leads to production yields of 20-30%.1,8 Higher specific activities can be reached in higher 
flux reactors. Disadvantages of this direct production technique are high costs and impurities of long-
lived 177mLu (half-life of 160 d).1 The indirect production route is realized via neutron capture and 
subsequent β- decay of the parent radioisotope to the desired 177Lu.1 Neutron activation of enriched 
176Yb leads to the production of 177Yb, which decays (half-life of 1.9 h) by β- decay to 177Lu 
(176Yb(n,γ)177Yb(β-)177Lu reaction).1 This indirect production route circumvents the formation of the 
177mLu impurity, since β- decay of 177Yb has no branching through the metastable radioactive 177mLu 
isotope.1 Compared to the direct production route, the indirect method provides carrier-free 177Lu at 
very high specific activity.1 177Lu has a physical half-life of 6.7 days.1-2,15c The half-life is long enough 
to allow distribution to hospitals in remote regions and is best suited for radiolabeling of biomolecules 
with medium to long biological half-lives.1,8 177Lu has three low energy β--emissions (0.498 MeV 
(79%), 0.385 MeV (9%), 0.177 MeV (12%)) with a relatively short range of 1.5 mm (Figure 15).1-2,8,15c 
Owing to its weak energy and short range of β--emission, 177Lu is considered a promising radionuclide 
for targeted radiotherapy of small tumors and metastases while sparing normal tissue.1,8,10,41 177Lu also 
emits two low energetic γ-rays (0.208 MeV (11%) and 0.113 MeV (6%)), enabling simultaneous 
imaging with a gamma camera, to determine the extent of disease, calculation and prediction of 
dosimetry, as well as monitoring of therapeutic efficacy.1-2,8,15c The chemistry of 177Lu is similar to 
other lanthanide radiometals. 177Lu mainly forms highly stable octadentate chelates with cyclic or 
acyclic polyaminopolycarboxylates.1-2,8,11,15c A variety of bifunctional chelating systems suitable for 
radiolabeling with 177Lu and other lanthanides will be discussed in section 2.3.3.  
Figure 15. Simplified decay scheme of 177Lu to 177Hf.42 
177Lu has gained interest for targeted radionuclide therapy and many 177Lu-radiolabeled antibodies or 
small peptides have been (pre)clinically evaluated.1,15c,43 177Lu-radiolabeled peptides were developed in 
particular for targeted radionuclide therapy of neuroendocrine tumors, using somatostatin analogs, 
e.g., DOTA-TOC and DOTA-TATE (section 2.5.2).1,15c,43 Administration of these targeting 
radiopharmaceuticals results in an average survival benefit of several years and markedly improves the 
quality of life of patients suffering from neuroendocrine tumors.43 In addition, analogs of the bombesin 
peptide (section 2.6.1) were radiolabeled with 177Lu.1,15c 177Lu-AMBA was clinically evaluated for 
therapy of prostate cancer. However, severe side effects were reported.1,44  
Another medical application of 177Lu is the treatment of lymphoma. Malignant lymphoma cells often 
diffusely infiltrate normal tissue. Because of the advantageous short range of tissue penetration, 177Lu-
DOTA-rituximab, a chimeric anti-CD20 antibody was evaluated in a clinical phase I/II study for 
treatment of patients with indolent lymphomas.45 High rate of tumor response in all dose levels and in 
ß- (177, 385, 498 keV) 
γ, (113, 208 keV) 
t½=6.647 d 
177Lu 
177Hf 
16                Introduction 
all entities of lymphoma were reported and hematologic toxicity was only temporary and 
controllable.45  
177Lu was also clinically evaluated as a palliative therapy for bone metastases, which occur in 60-75% 
of patients as a corollary of breast and prostate cancer.1 Its emission of low β--energy is ideal to 
minimize unwanted ablation of bone marrow.1 177Lu was conjugated to both 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonate (DOTMP) and ethylene diamine 
tetramethylene phosphonate (EDTMP) and administered for palliation of bone metastases.1 Compared 
to similar 153Sm-EDTMP, 177Lu-DOTMP was revealed to be superior and may result in longer 
intervals of remission.1 Clinical trials evaluating 177Lu-EDTMP are ongoing.1  
177Lu was also conjugated to J591, an antibody targeting the antiprostate membrane antigen (PSMA) 
and evaluated as treatment in androgen-independent prostate cancer (Phase II clinical trials).1 177Lu-
J591 showed very promising results and phase III clinical trials are planned.1 Another clinical trial is 
underway to evaluate 177Lu-J591 in combination with the chemotherapeutic drug ketoconazole.1   
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2. Peptide-based, targeting radiopharmaceuticals for cancer 
applications 
2.1 Regulatory peptides 
Peptides typically contain between two to fifty amino acids (AA) linked by amide bonds.5 An 
enormous number of peptides occur physiologically. This thesis focuses on regulatory peptides, such 
as neuropeptides, gut peptide hormones, vasoactive peptides, and endocrine peptides. Regulatory 
peptides occur in many different organs and their targets may be present in the gastrointestinal (GI) 
tract, brain, kidneys, lungs, or in the lymphatic, endocrine, immune, vascular, and peripheral systems.5 
The biological function and metabolic processes of almost all organs are modulated and controlled by 
regulatory peptides through interaction with specific membrane-bound receptors, most commonly G-
protein-coupled receptors (GPCR).5 Regulatory peptides and their receptors are important for not only 
physiological processes, but also pathological conditions, such as inflammation and cancer.5,26,46  
 
2.2 GPCRs as targets for tumor diagnosis and treatment 
2.2.1 GPCR, signal transduction, and signaling pathways  
GPCRs belong to the largest and most diverse family of signaling receptors. Nearly half of the drugs 
currently applied target this receptor family and show enormous success in the development of 
treatments for a wide range of human diseases.47 GPCRs are integral membrane proteins that are 
comprised of a single polypeptide chain with seven transmembrane domains, an intracellular domain 
that is linked to G-proteins and arrestin for activation of secondary messengers, and an extracellular 
domain for ligand binding. GPCRs recognize ligands outside of the cell to activate intracellular signal 
transduction pathways and cellular responses.47-48 Usually, GPCRs conjugate to heterotrimeric (α, β, γ 
subunits) guanosine 5’-triphosphate (GTP)-hydrolyzing proteins (G-proteins) at the plasma membrane. 
In the inactivated state, guanosine 5’-diphosphate (GDP) is bound to G-proteins.48 Upon ligand 
binding, GPCRs undergo conformational changes leading to the interaction with G-proteins.48 
Activation of GPCRs promotes the exchange of GDP to GTP on the α-subunit. This leads to 
dissociation into the Gα-GTP and the Gβ,γ-subunits that independently signal several membrane bound 
effectors, for example, phospholipases, ion channels, mitogen-activated protein kinases, guanine 
nucleotide exchange factors, and many other enzymes.47-48 They also activate a second intracellular 
signal and the synthesis of secondary messengers, including 3’-5’-cyclic adenosine monophosphate 
(cAMP), 3',5'-cyclic guanosine monophosphate (cGMP), diacetylglycerol (DG), inositol-1,4,5-
triphosphate (IP3).48 GTPase activity of the Gα-subunits hydrolyzes GTP to GDP and the Gβ,γ-subunit 
reassociates with the Ga-GDP subunit, to inactivate the signal transduction.48 Depending on the type of 
the Gα-subunit (e.g., Gαt, Gαolf, Gαi, Gαs, Gαq), different intracellular signaling proteins are affected.48 
Gαs stimulates adenylate cyclase (AC), leading to increased cAMP concentration and activation of 
various ion channels as well as cAMP dependent ser/thr-specific protein kinases A; whereas Gαi 
inhibits AC.48 The Gαq pathway activates phospholipase C-β (PLC), catalyzing cleavage of membrane-
bound phosphatidylinositol 4,5-diphosphate (PIP2) into the secondary messengers DG and IP3. IP3 
binds to IP3 receptors in the membrane of the endoplasmatic reticulum (ER) to trigger calcium release 
from the ER.48 Gβ,γ subunit effects several ion channels, including K+(Ach)-channels, and Ca2+-channels, 
and activates PLC-β-isoenzymes, which lead to the IP3 and DG pathways mentioned above.47-48 
Endogenous ligands that cause physiological changes after binding to the receptor and internalize are 
called agonists. Ligands that lead to inhibition of the binding of the agonist and do not activate 
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physiological changes are described as antagonists.5,10,16,37,41 Binding of agonistic peptide ligands to 
their corresponding membrane-bound GPCR leads to activation of different effectors and signaling 
pathways described above that are regulated by temporal membrane trafficking of GPCRs from the 
cell membrane surface. Excess ligand binding induces acute signal termination or receptor 
desensitization of G-protein signaling by rapid internalization of the receptor-ligand complex by 
clathrin-mediated endocytosis.47-48  
All radiopeptides described in this thesis are agonists and they internalize into tumor cells via clathrin-
mediated endocytosis.49 Especially in the case of dual-targeting bombesin derivatives, internalization 
is a crucial requirement to facilitate intracellular targeting of organelles or cytosolic enzymes. Thus, 
the mechanism of clathrin-mediated endocytosis will be described in the following section.  
 
2.2.2 Internalization of the receptor-ligand complex via clathrin-mediated endocytosis 
The steps leading to GPCR endocytotic internalization are the functional uncoupling of the G-proteins 
from the receptor and the subsequent receptor phosphorylation (PP) by G-protein-coupled receptor 
kinases (GRKs), which lead to binding of β-arrestin (βarr) to the receptor.48,50 β-arrestin stabilizes the 
association with clathrin-coated pits (CCPs) that progressively invaginate the formed pits. 49,52 Finally, 
through GTPase activity of dynamin (d), the pits are pinched off from the plasma membrane and free 
clathrin-coated vesicles (CCV) of the receptor-ligand complex are released into the cytosol. 49,52 The 
CCV fuses with an early endosome, where the receptor-ligand complex dissociates. Either the receptor 
is directed to recycling endosomes, resensitized and recycled back to the surface of the cell membrane, 
or the receptor is directed to late endosomes and lysosomes for its terminal degradation (Figure 
16).49,52 The agonistic ligand is either released to the cytosol or degraded within lysosomes, and is 
finally externalized via exocytosis.48-51  
 
Figure 16. Steps of receptor-ligand internalization by clathrin-mediated endocytosis. Agonist (A) binding, 
receptor phosphorylation through GRK, and receptor desensitization (1); binding to β-arrestin (βarr) (2) targets 
the receptor-arrestin-complex to CCP (3) that are pinched-off by the GTPase dynamin (d) (3) to CCV (4) that 
internalize the receptor-agonist complex into endosomes (5); finally, receptor resensitization and recycling to the 
cell membrane (6) or downregulation and degradation of the receptor in lysosomes (7) take place.50b 
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2.2.3 Medical application of GPCR-targeting peptides 
Due to their internalization, ligands of agonistic peptides can be exploited for specific delivery of 
cargo (e.g., radioactivity) into cells of interest.5,52 To identify potentially interesting receptor targets 
for medical applications, several in vitro techniques are available that are based on biochemical 
(radioligand binding and quantitative receptor autoradiography), immunological (immunoblotting, 
immunoprecipitation, and immunohistochemistry), and molecular biological methods (northern 
blotting, reverse transcription/polymerase chain reaction, and RT-PCR).5,46,53 Amongst them, 
quantitative receptor autoradiography is most advantageous for the identification of regulatory peptide 
receptors in pathologic tissue.5,46,53 For more detailed information concerning the different in vitro 
receptor identification techniques, it is referred to some excellent reviews of Reubi and coworkers, 
who contributed enormously in this field.5,46,53 Based on these techniques, the group of Reubi 
identified several GPCRs of different regulatory peptides to be overexpressed and specifically located 
in various cancer tissues but not in healthy tissues. They also identified several receptor subtypes of 
each GPCRs and discovered differences in the receptor binding affinities towards the various 
ligands.5,46,52-53 Because of these findings, regulatory peptides are interesting vectors for specific 
delivery of cargo and can be utilized for targeted imaging and therapy of different cancers (section 2.6, 
Table 4).5,37,41,46,53-54 Compared to the relatively low density of peptide receptors in physiological 
organs, the overexpression of GPCRs of regulatory peptides in numerous cancers is the molecular 
basis and most important requirement for imaging and targeted therapy with radiopeptides.15c If this 
requirement if fulfilled, regulatory peptides can be used in general in two different ways; either for 
targeting the mediated functional response of the overexpressed receptors, or to utilize them as binding 
sites for cytotoxic ligands.5 In the first case, unlabeled, non-toxic peptide analogs can be used for long-
term treatment of cancers to induce a particular biological response, such as growth regulation of 
cancer cells.5 Successful clinical utilization of the second application type are targeted molecular 
imaging or therapy with cytotoxic peptides, carrying cytotoxic drugs or radionuclides.5  
 
This thesis is focused on tumor targeting, radiometal-labeled peptides for molecular imaging and 
peptide-receptor radionuclide therapy of different cancers. The composition, principles of their 
administration, pharmacodynamics, pharmacokinetics, steps towards their optimization, and selected 
examples of radiolabeled, tumor targeting conjugates based on regulatory peptides are discussed in the 
following sections.  
 
2.3 Composition of target-specific, radiometal-labeled peptides 
Target-specific, radiometal-labeled peptides are schematically composed of four parts; a targeting 
peptide, a linker moiety, a bifunctional chelating agent (BFCA), and a radionuclide for imaging and/or 
therapy (Figure 17).2,8,15c,16 The targeting peptide serves as a vehicle for specific delivery of the 
radionuclide to receptors that are overexpressed by the tumor tissue. The BFCA provides both stable 
complexation of the radiometal and covalent conjugation of it to the targeting peptide. A linker/spacer 
entity is often incorporated between the peptide and the BFCA. This keeps the chelated radiometal at a 
reasonable distance from the receptor binding sequence of the peptide and minimizes possible 
interferences to maintain high binding affinity towards the targeted receptor. A pharmacokinetic 
modifier may also be built into the linker. The in vivo metabolism, binding to the receptor, the 
biodistribution profile, and the tumor uptake of radiopharmaceuticals can be affected by all four 
components.2,8,15c,16 All building blocks will be discussed in more detail in the following sections.  
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Figure 17. Schematic composition of a targeting radiometal conjugate and targeted GPCRs overexpressed on the 
plasma membrane of tumor cells. 
 
2.3.1 Peptides as targeting vectors 
There are several advantages of using regulatory peptides as targeting vectors. The sequences of 
regulatory peptides can be easily synthesized by solid-phase peptide synthesis (SPPS).5,26,41 This well 
established synthetic technique allows easy scale-up, reproducible preparation of chemically well-
defined peptides, and facilitates modifications of the peptide sequence in order to optimize their 
pharmacodynamics (e.g., target affinity and specificity, agonistic or antagonistic effect) and 
pharmacokinetics (e.g., metabolic stability or clearance pathways).5,26,41 Chemical modifications, such 
as incorporation of chelating agents, prosthetic groups, or spacer moieties can be easily realized by 
SPPS and other bioconjugation techniques.26 In addition, peptides have high chemical stability, 
withstanding the harsh conditions that may occur during synthesis or radiolabeling processes.5,26,41 
Compared to other targeting vehicles, such as antibodies, peptides are relatively small in size. Peptides 
diffuse readily, permitting easy and rapid accessibility to the tumor site after systemic applications and 
they are usually rapidly cleared from the body, which minimizes the radiation burden on the 
patient.5,26,41,55 The favored elimination route is renal clearance but hepatobiliary excretion may also 
occur, depending on the receptor expression and physicochemical characteristics of the peptide.5,26,41 
In comparison to cytostatic drugs, regulatory peptides are physiologically-occurring and hence, are 
usually non-toxic.5 Potential side effects due to their physiological action would only be expected after 
application of pharmacological doses, as e.g., administration of high doses of non-radioactive 
compounds for long-term cancer treatments.5 Radiolabeled peptides for tumor imaging or therapy are 
administered in very low, subpharmacological concentrations (tracer principle) and thus, 
pharmacological side effects are usually negligible.2,5 In contrast to other targeting vectors, such as 
antibodies, small-sized peptides do usually not lead to antigenicity.5,41,53,55  
However, there are also limitations. For example, regulatory peptides suffer from poor metabolic 
stability in vivo. They can be rapidly degraded in biological systems by several peptidases present in 
the serum and most tissues.5,26,41,55 Increased metabolic stability is important to extend the blood 
circulation time and enables higher tumor uptake. Thus, metabolic stabilization of the radiopeptide 
against proteolytic degradation is critical for enhanced accumulation in the targeted tissue.  
Internalization and thereby active accumulation and retention of the radioligand in tumor cells have 
always been considered prerequisites for successful molecular imaging and therapy.5,52 Interestingly, 
compared to peptide agonists that internalize, high-affinity peptide antagonists that poorly internalize 
into tumor cells have recently shown superior tumor binding, tumor uptake, and higher retention rates 
in preclinical studies.56 These findings led to a change of paradigm and antagonistic derivatives of 
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regulatory peptides are now justified as equal or even preferable as potential target-specific 
radiopharmaceuticals.19a,37,41,52,57  
The development of targeting peptides can be achieved by rational design and the use of screening 
libraries.58 Peptides as targeting vectors can be identified and selected by modifying established 
endogenous peptides, screening combinatorial peptide libraries, or molecular modeling of peptide-
receptor structures.58d Established approaches to identify novel targeting peptides include phage 
display peptide library methods, synthetic library methods requiring deconvolution, the one-bead one-
compound combinatorial library methods, and affinity selection methods.58d The application of phage 
display libraries is an especially widely used technique.58a This method allows convenient screening of 
an enormously high number of different phages for the isolation of novel targeting peptides.58a,d 
Detailed information on rational approaches for the discovery of targeting peptides is reviewed in the 
literature.58 Examples of different targeting peptides that are applied in nuclear medicine for molecular 
imaging and therapy of various cancers will be discussed in section 2.6.  
 
2.3.2 Radiometals as imaging probe or therapeutics 
The choice of the radiometal depends on the medical application of interest, nuclear emission 
properties, decay mode, radiation type and its energy, physical half-life, stability of any daughter 
nuclides formed, likely in vivo pharmacokinetics of the radio-conjugate, radionuclide production route, 
cost, and availability. Radiolabeling efficacy, radiochemical yield (RCY), as well as the radiochemical 
purity (RCP) of the chosen radionuclide and its achievable specific activity are also important 
considerations when choosing a radiometal for clinical applications.1-3,6,8,10-11,13,15c  
For imaging, the physical half–life of the radionuclide should complement the pharmacokinetics and 
be comparable to the biological half-life of the targeting peptide. If the targeting ligand exhibits fast 
uptake and rapid clearance from the body, a radionuclide with short half-life is ideal. However, the 
half-life of the radiometal must be long enough to allow convenient preparation of the targeting 
radiopharmaceutical and application to the patient.2,6,10-11 The half-life of gamma-emitting 
radionuclides for imaging applications should allow convenient measurement, dosimetric calculations, 
and scintigraphy. The radiation burden on the patient is also an important selection criterion for the 
choice of the radionuclide for molecular imaging.2,6,10-11 
For radionuclide therapy, most effective tumor cell destruction is achieved by radionuclides that emit 
high LET radiation in close proximity to the targeted tumor tissue. A physical half-life between 10 
hours to 10 days of longer lived radionuclides is appropriate to increase the radiation dose deposited.6 
Additionally, radiometals with stable or very long-lived daughter nuclides should be utilized for 
radionuclide therapy. This is to prevent uncontrollable irradiation of non-targeted tissue by unstable 
daughter nuclides should the radiometal become dissociated from the targeting peptide.2,6,10-11  
Molecular targeting vectors that can be used for both diagnosis and therapy are described as 
“theranostics”.59 Theranostic agents have recently become of interest in the field of nuclear medicine 
as they have the potential to be used in patient-individualized treatments, which improve efficacy and 
cost effectiveness.60 The theranostic approach is realized by using an identical strategy to radiolabel a 
targeting vector (e.g., regulatory peptide) with either a diagnostic or therapeutic radiometal.59 The 
diagnostic agent enables detection of primary and metastatic diseases by determining the specific 
phenotype on the molecular level, and assessing the heterogeneity of the tumor tissue. Initial low-dose 
imaging allows the biodistribution, dosimetry, maximum tolerated dose (MTD, not causing undesired 
side effects), receptor expression, and clearance to be evaluated.59 This is then followed by 
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personalized treatment using the analogous targeting vector labeled with a therapeutic radiometal.1 In 
principle, the theranostic approach can predict toxicity and guarantee optimal balance between 
therapeutic risk and benefit for each individual patient.60a Successful clinical examples of the 
theranostic approach include PET/CT imaging with 68Ga-DOTA-TOC/DOTA-TATE and targeted 
radionuclide therapy with 177Lu/90Y-DOTA-TOC/DOTA-TATE for the treatments of neuroendocrine 
tumors (section 2.5.2).60b Theranostic bombesin analogs (e.g., AMBA), radiolabeled with 68Ga and 
177Lu have been evaluated in humans for the imaging and therapy of metastatic breast, lung, and 
prostate cancers (section 2.6.1).44b,60b Another example is the application of the bisphosphonate-based 
agent ((4-{[(bis-(phosphonomethyl))-carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-
tetraazacyclododec-1-yl) acetic acid (BPAMD)61 radiolabeled with 177Lu for treatment of skeletal 
metastases and monitored follow-up care of the patients using 68Ga-BPAMD for PET/CT imaging.60b 
 
2.3.3 Bifunctional chelating agents 
Appropriate bifunctional chelating agents (BFCAs) depend on the metallic radionuclide and its 
oxidation state. The BFCA should provide both functionalities for convenient coupling with the 
regulatory targeting peptide and ensure stable complexation of the radiometal (high thermodynamic 
stability and kinetic inertness). Different radiometals require different coordination chemistries, thus 
various BFCAs exist with varying donor atoms and ligand frameworks.1-2,8,11,15a,c,26,41,62 Kinetic 
inertness of the radiometal-chelate complex in vivo is an important factor, since there are many 
endogenous metal binding proteins in the plasma that may compete with the chelating system for 
radiometal binding.1-2,8,11,15a,c,62a Sufficiently tight binding is crucial to inhibit transchelation of the 
radiometal to proteins in vivo. The release of the radiometal in vivo can lead to radiation damage to 
normal tissue and bone marrow toxicity. Especially 89Zr, 90Y, and 177Lu are recognized “bone 
seekers”.2,8,15c Examples of metal-binding serum proteins are superoxide dismutase and transferrin that 
reveal high affinity for copper and for gallium(III), indium(III), and other metals, respectively.1-
2,8,11,15a,c,62a,63 Kinetic inertness of the radiometal-chelate complex can be estimated in vitro by 
challenging or competition assays against proteins or blood serum during radiopharmaceutical 
development. However, in vitro stability data cannot always predict in vivo stability of the radiometal 
conjugate.8 Equally important as thermodynamic stability and kinetic inertness of the radiometal-
chelate complex are appropriate complexation kinetics under radiochemical labeling conditions, such 
as low concentrations, limited time, and, in the case of temperature-sensitive biomolecule, labeling at 
mild temperature.8,62a With the exception of brain tracers, the BFCA should also have a high 
hydrophilicity to enhance the blood-clearance and renal elimination of the radioconjugate.1-
2,8,11,15a,c,26,41,62a  
Each radiometal is unique and characterized by its coordination number, oxidation state, redox 
stability, hard-soft Lewis acid characteristics, and kinetic inertness. D-block transition metals (e.g., 
99mTc and 186/188Re) form mainly octahedral complexes and therefore tetradentate to hexadentate 
chelating systems are often used for complexation of these radiometals.1-2,8,11,15a,c,62 Lanthanides have a 
tendency to form eight or nine coordination sites in complexes with ionic character.1-2,8,15a,62b 
Octadentate carboxylate-containing chelates are often used for the hard metal center lanthanides (e.g., 
177Lu) to build kinetically inert complexes.1-2,15a,c,62a BFCAs for the different 99mTc cores have already 
been discussed in section 1.2.3. The most extensively evaluated BFCAs for stable complexation of 
other radiometals are acyclic or cyclic polyaminopolycarboxylic acid ligands.1-2,8,11,15a,62,64  
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2.3.3.1 Acyclic chelating systems 
Radiometal complexation reactions with open-chain polyaminopolycarboxylates can usually be 
achieved under mild conditions and show fast metal-binding kinetics, which are advantageous when 
using temperature-sensitive biomolecules and short-lived radiometals, respectively. However, 
compared to macrocyclic chelators, acyclic chelating systems are usually less kinetically inert.1-
2,8,11,15a,c,62 The most common examples of acyclic chelators in radiopharmaceutical chemistry are 
ethylene diamine tetraacetic acid (EDTA) and diethylene triamine pentaacetic acid (DTPA) (Figure 
18). The hard oxygen donor set and large binding spheres of DTPA are appropriate for stable 
complexation of large, hard-acid radiometals. DTPA has been widely used for complexation of the 
radiometals Cu2+, In3+, Y3+, and Ga3+.1-2,8,15a,c,26,58d,62,64 Three radiopharmaceuticals that are approved by 
the Food-and-Drug-Administration (FDA) are chelated by DTPA or DTPA analogs, including 111In-
DTPA-octreotide (OctreoScan®; for imaging of neuroendocrine tumor), 111In-capromab pendetide 
(ProstaScint®; for imaging of prostate cancer ), and 90Y-ibritumomab tiuxetan (Zevalin®, for 
treatment of non-Hodgkin’s lymphoma).2,8 To improve kinetic inertness of acyclic BFCA, pre-
organized, backbone-rigidified DTPA analogs, such as the MX-DTPA analog tiuxetan or CHX-A”-
DTPA (Figure 18) are also described.1-2,8,15a,c,62 Desferrioxamine B (DFO, Figure 18) is an acyclic 
chelator widely used for iron chelation therapy.8 DFO is a useful BFCA as it has three hydroxamate 
groups for radiometal complexation and a terminal primary amine for bioconjugation. DFO 
coordinates Ga3+ to form radiometal-complexes with high thermodynamic stability that can be 
conjugated to peptides and small molecules.8,64 DFO complexes with Zr4+ have also been evaluated.8,64-
65 Bifunctional versions of acyclic chelators with isothiocyanate, maleimide derivatives, or activated 
tetrafluorophenolic ester are commercially available for bioconjugation (Figure 18).64-65  
 
Figure 18. Selected acyclic, bifunctional chelators for radiometal labeling (e.g., 68Ga, 89Zr, 90Y, 111In); R 
represents a conjugated biomolecule (e.g., peptide).8,15c,62b,64 
 
2.3.3.2 Macrocyclic chelating systems 
In general, macrocyclic chelators provide thermodynamically more stable and kinetically more inert 
metal complexes than acyclic chelating agents but often require harsher radiolabeling conditions.1-
2,8,11,15a,c,62 Examples of macrocyclic chelating agents are either cyclen-type or cyclam-type tetraaza or 
triaza chelators. A ubiquitous chelator for +3-charged radiometals is the cyclen-type 1,4,7,10,-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA, Figure 19). Several M3+ radiometals, such as 
68Ga, 90Y, 111In, and 177Lu form stable complexes with DOTA derivatives.1-2,8,15a,c,26,62,64 An example of 
a cyclam-based macrocyclic chelator is 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid 
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(TETA, Figure 19). TETA has been widely used for complexation of Cu2+ in radiopharmaceuticals. 
[Cu(TETA)]2- complexes are more kinetically inert than [Cu(DOTA)]2- complexes, but still reveal 
demetallation in vivo.1-2,8,15a,c,58d,62b,64 The cross-bridged TETA analog 1,4,8,11-tetraazabicyclo[6.6.2]-
hexadecane-4,11-diyldiacetic acid (CB-TE2A) forms Cu2+ radiometal complexes with superior in vivo 
characteristics, but harsh reaction conditions (>90 °C, ~1 h) are needed for radiolabeling.1-
2,8,15a,c,58d,62b,64 The comparably slow formation kinetics of macrocyclic chelators can be overcome by 
heating or microwave technology.15c However, the triaza macrocyclic chelator 1,4,7-
triazacyclononane-1,4,7-triacetic acid (NOTA, Figure 19) rapidly forms very stable radiometal-
complexes even under mild conditions and is commonly used to form hexadentate complexes with 
Ga3+ and Cu2+ radioisotopes.1-2,8,15a,c,26,58d,62b,64 In DOTA and NOTA, if one of the pendant carboxylic 
acid arms is used for covalent bioconjugation to a targeting vector, the donor-ability and native 
binding sphere of the chelator is altered. To overcome this alteration, an extra carboxylic pendant arm 
is attached, forming 1,4,7,10-tetraazacyclododecane-4,7,10-triacetic acid-1-[2-glutaric acid] 
(DOTAGA) and NODAGA, respectively (Figure 19).2,8,15a,c,62b,64 NOTA derived chelator 1,4,7-
triazacyclononane-1,4,7-tris[methyl(2-carboxyethyl)phosphinic acid)] (TRAP, Figure 19) also rapidly 
forms very highly thermodynamically stable complexes with 68Ga in high radiochemical yield.8  
 
Figure 19. Selected commonly used macrocyclic bifunctional chelators to label peptides (R) with M2+/3+ 
radiometals (e.g., 64Cu,68Ga, 90Y, 111In, 177Lu, and 213Bi).1-2,8,15a,c,58d,62b  
 
The triazole substituted bombesin analogs and the stabilized substance P derivative that are described 
in chapter V and VI of this thesis, respectively were prepared using the commercial 2-(4,7,10-tris(2-
tert-butoxy)-2-oxoethyl)-DOTA (DOTA-tris(tBu) ester, Figure 19) via amide bond formation.66  
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2.3.3.3 Bioconjugation 
BFCAs contain a conjugation group for covalent attachment of the targeting biomolecule. The BFCA 
can be conjugated to peptide sequences via the primary N-terminal amine or via functionalities in the 
side chain of the amino acids. Examples include ε-amine side chain functionality in lysine, phenol 
moiety in tyrosine, carboxylate group in glutamic or aspartic acid, and thiol group in cysteine.8,16 
Alternatively, reactive groups can be incorporated into the peptide sequence by chemical modification. 
Covalent conjugation of BFCAs occurs most often using one of four common conjugation strategies, 
which make use of N-hydroxysuccinimide (NHS) esters, maleimides, isothiocyanates, or 
azides/alkynes for click chemistry.2,8,15a,c,16,62,64,67  
Activated NHS esters form an amide bond with a primary amine of, for example, lysine or the amine 
group at the N-terminus of the peptide sequence (Figure 20 A). NHS esters show intermediate 
reactivity but high selectivity for aliphatic amines. A basic pH (pH 8-9) is required for amide bond 
formation in aqueous media. Advantages of this approach are the stability of the amide bond formed 
and the versatility of this method, since nearly any molecule containing a carboxylic acid group can be 
activated to its NHS ester. Activated NHS esters are the most commonly used conjugation group for 
small biomolecules and proteins.2,8,15c,16,62,64  
Maleimide as a strong electrophile reacts selectively with thiol-groups from cysteine side chains of 
biomolecules (peptide, or antibody) by forming a thioether bond (Figure 20 B). Under basic conditions 
(pH >8) maleimides may hydrolyze to non-reactive maleamic acids. The optimum pH for this 
conjugation reaction is neutral (pH 7).2,8,15c,16,62,64  
Isothiocyanates react with primary amines of peptides or proteins to form thiourea bonds (Figure 20 
C). To deprotonate the primary amine, more basic reaction conditions (pH 8-9.5) are needed therefore 
this strategy may not be suitable for conjugation of biomolecules that are alkaline-sensitive. Aromatic 
isothiocyanates are commonly applied in bioconjugation with DOTA and DTPA analogs.2,8,15c,16,62,64  
The Cu(I)-catalyzed 1,3-dipolar Huisgen cycloaddition reaction of terminal azides and alkynes, 
leading to 1,2,3-triazoles (“click reaction”)30 is another commonly used bioconjugation method 
(Figure 20 D).8,62b,64,67 This reaction will be discussed in more detail in the context of the “Click-to-
Chelate” approach in chapter II, since the dual-targeting radioconjugates described in this thesis 
(chapter III and IV) are based on this bioconjugation strategy. Application of bioorthogonal copper-
free click cycloaddition reactions68 has also become increasingly popular for the development of 
radiotracers.67 
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Figure 20. Common conjugation reactions for covalent attachment of a BFCA to a targeting biomolecule;       
(A) amide, (B) thioether, (C) thiourea, (D) triazole bond.2,8,15c,16,62,64  
 
Other examples of conjugation strategies for covalent attachment of BFCAs to the targeting peptides 
are acid halogenides reacting with primary amines to form amides, haloacetyl groups with thiols to 
form sulfides (thiother), and thiol groups that couple to thiol functionalities in the peptide under 
oxidizing conditions by forming disulfide bonds.2,16 Enzymes, such as e.g., transglutaminases have 
also been described for site-specific conjugation of chelators to proteins.69  
Targeting radiopeptides are usually radiolabeled in a “post-labeling” approach; the BFCA is 
conjugated to the targeting peptide (e.g., by SPPS) before radiolabeling is performed. This sequence is 
compatible with ready-to-use kit formulations for routine applications in the clinic.2,15c,16,26  
 
2.3.4 Linkers  
A linker provides two orthogonal conjugation sites to connect both the radiometal-chelate complex 
and the targeting peptide. The linker can serve as a spacer between the targeting peptide and the 
radiometal to minimize possible binding interference caused by the radiometal-chelator complex and 
to maintain high binding affinity of the peptide towards the targeted receptor. In order to modify the 
pharmacokinetics of the conjugate, the linker can be lipophilic, hydrophilic, or carry charges.70 
Examples include hydrocarbon chains of different lengths, hydrophilic amino acid sequences to 
increase renal clearance (e.g., polyglycine, or polyaspartic acid),70-71 or polyethylene glycol (PEG) 
entities to reduce hepatobiliary excretion72 and potentially improve tumor uptake and tumor-to-
background ratios (also section 2.6.1.1).2,8,15a,c,16,58d A linker may also be introduced to provide an 
additional functionality leading to bifunctional radioconjugates. Employing this approach, additional 
intracellular targeting entities can be introduced into the radioconjugate.51b,73 Hydrophilic 
carbohydrates can also be covalently attached through an appropriate linker to increase the tumor-to-
liver ratio.74 Branched linkers with various functional groups can be used for the conjugation of 
multiple chelating agents75 leading to higher specific activity.2,8,15a,c,16,58d  
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Bombesin analogs described in chapter III and IV of this thesis are N-terminally conjugated with a 
linker composed of three β-Ala71 entities for pharmacokinetic improvements (also section 2.6.1.1). 
Following the β-Ala-spacer, a lysine precursor was N-terminally conjugated that serves both for 
conjugation of an entity for intracellular targeting and for chelation of 99mTc-tricarbonyl using the 
extended Click-to-Chelate strategy31c (chapter II). Bombesin triazole analogs (chapter V) were N-
terminally conjugated to a PEG4 linker that has proven useful in increasing tumor uptake.76 
 
2.4 Administration of tumor targeting, radiolabeled peptides in nuclear 
medicine 
The established treatment of primary tumors in oncology is surgery, adjuvant chemotherapy, and 
external radiation therapy.10,77 Disseminated tumors and metastases are usually treated with 
chemotherapy, which has particularly high success rates in lymphoma.10,77 However, chemotherapy is 
not always curative, but at most palliative and non-targeted chemotherapeutic drugs can cause severe 
side effects.10 On the account of this, peptide-based, targeting radiopharmaceuticals are accordingly 
interesting for providing alternative complementary diagnosis and potential treatments of cancer.10,77-78 
In principle, tumor targeting, peptide-based radiopharmaceuticals are systemically administered into 
the blood circulation of patients suffering from a GPCR-positive tumor (Figure 21 A). After 
distribution (Figure 21 B) of the targeting radiotracer in the body, it will selectively bind to the 
particular GPCR. After binding of the agonistic peptide, the receptor-ligand complex is subsequently 
internalized through endocytosis (section 2.2.2). Binding or internalization of the radiopeptide leads to 
selective accumulation of radioactivity in the tumor whereas excess radiotracer and/or its metabolites 
are rapidly cleared from the blood pool and non-targeted tissue (Figure 21 C). Because of predominant 
renal excretion, the kidney and bladder show also significant but not persistent uptake of 
radioactivity.5,15b,c,41,52-53,79 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Principle of 
specific tumor targeting with 
systematically administered 
radiopeptides.15b  
This principle can be diagnostically exploited for detection of tumors and their metastases, treatment 
planning, and dosimetric calculations of cancer patients, using SPECT or PET. Peptidic 
radiopharmaceuticals labeled with high energy, low range particle emitters (α, ß-), or Auger electron 
emitting radionuclides can be administered for targeted PRRT.52-53 The challenge for internal radiation 
therapy is to balance the delivery of the MTD to the tumor while protecting normal healthy tissue from 
radiation damage. The mean absorbed doses to tumors and normal organs has to be accurately 
estimated and individual variation in dose delivery, different metabolism, or diverse receptor density 
in organs and tissue have to be carefully considered. Individual patient dosimetry is essential for 
PRRT.5,15b,c,41,52-53,60a,79 
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2.4.1 General considerations for peptide-receptor radionuclide therapy  
Cancer patients with multiple inoperable metastases may benefit from PRRT. These patients are 
usually pretreated with chemotherapy or external radiotherapy.53 Cancer patients who may benefit 
from PRRT are selected based on several criteria that have to be fulfilled.5,53,80 As a basic prerequisite, 
overexpression of the targeted receptor in the cancerous tissue has to be proven. Ideally, the receptor 
should be homogeneously distributed at a high density and the occurring receptor subtypes have to be 
targeted with the administered radioligand.53 It is important to deliver sufficient radiation dose to the 
tumor to cause cell death.6,13 The minimal dose rate for sterilization of the tumor tissue (>0.4 Gy/h; 
accumulated tumor dose >50 Gy)6 should be achieved and the tumor cells should be irradiated during 
the most radiation-sensitive cell cycle phases (section 1.2.2.1).6 The choice of the radionuclide is 
based on the size and location of the tumor, type of emitted radiation, emission energies, range of 
radiation, and physical half-life (section 2.3.2).5,10,41 Combinations of radionuclides with different 
energies and particle ranges may result in higher success rates.41 Tumor response to radiotherapy 
depends on several factors, such as total absorbed radiation dose, dose rate, tumor radiosensitivity, and 
intracellular localization of short-range emitting radionuclides.6,13,14b,53 Targeted radionuclide therapy 
towards multiple receptors can also be advantageous. The application of, for example, two or more 
radiotracers at the same time, or multivalent/-specific radiopeptides, can increase the therapeutic dose 
delivered to the tumor and can also overcome limitations, such as receptor heterogeneity.5,10,41,53 For 
brain cancers, a loco-regional application or brachytherapy can be administered to overcome the 
blood-brain barrier.53 This method will be introduced later using substance P as a targeting peptide for 
glioma treatment (section 2.6.2.2). 
However, there are also limitations to targeted PRRT. Most importantly, radiation-induced destruction 
of the surrounding healthy tissue or distant receptor-positive healthy tissues has to be minimal. 
Radiosensitive tissues, such as bone marrow are limiting the MTD.6,41,60a Acute hematological toxicity 
can occur, especially after high energy 90Y-labeled PRTT.60a High bone marrow doses, especially in 
patients that were pretreated with alkylating chemotoxic agents, may lead to severe side effects, such 
as myelodysplastic syndrome or leukemia after PRRT.60a,81 The kidneys are also a dose-limiting organ, 
due to the excretion of radiopeptides and potential physiological receptor expression. Small-sized 
radiolabeled peptides are filtered through the glomerular capillaries, become subsequently reabsorbed, 
and are retained in the proximal tubular cells, leading to high uptake of radioactivity in the 
kidneys.37,41,60a,81-82 Thus, the scintigraphic sensitivity for small tumors in the perirenal region is 
decreased. To reduce the kidney uptake and the risk of potential nephrotoxicity, infusions of positive 
charged amino acids (L-lysine and L-arginine) are continuously administered before, during, and after 
radionuclide therapy to block transporter sites in the kidneys.37,60a,82 It has been shown that 
cytoprotective drugs, such as amifostine, and low doses of succinylated gelatin or gelatin-based 
gelofusine as a plasma expander can also decrease the renal uptake of radiopeptides.37,41,60a,82  
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2.5 Development of peptide-based radiopharmaceuticals – from bench to 
bedside and back to bench
2.5.1 General aspects to be considered 
First, molecular targets (e.g., GPCRs) with relevance in human diseases, overexpressed at high density 
and homogeneity at the target site have to be identified. Identification of their peptide ligands and 
subsequent development of analogs thereof can lead to new radiopharmaceuticals. The required 
peptide sequence can be synthesized by versatile SPPS. A chelating system or prosthetic group is 
covalently bound to the peptide sequence for radiolabeling. Radiolabeling has to be conducted with a 
specific activity and radiochemical yield and purity as high as possible. Biological evaluation of the 
radiolabeled peptide is followed in vitro using appropriate tumor cell lines that overexpress the 
targeted receptor. In vitro evaluation usually includes receptor binding affinity (competition or 
saturation binding assays), tumor cell uptake (internalization), and efflux (externalization) assays. In 
case of successful in vitro results, the biological behavior of the radiolabeled peptide conjugate is 
studied in vivo for its pharmacokinetics and tumor-targeting efficacy in animal models, mainly 
xenograft models in mice or rats. In vivo evaluation includes biodistribution experiments, molecular 
imaging, or therapy studies. Important factors for a successful approach are metabolic stability of the 
radiotracer, sufficient extent of accumulation in the targeted tissue versus non-specific uptake in non-
targeted, healthy tissue, radiation doses rates deposited, and excretion of radioactivity from the body. 
After successful preclinical assessment of the targeting radiopeptide, toxicological studies are 
conducted and an appropriate formulation protocol for clinic production under good manufacturing 
practice (GMP) conditions has to be established to enable first clinical studies in humans. Clinical 
trials with volunteers and patients are carried out (phase I-III) to evaluate safety, side effects, and 
optimal dosage of the targeting radiopeptide. After regulatory approval, the novel radiopharmaceutical 
is launched on the market and studies follow to assess long-term adverse side effects. As depicted in 
Figure 22, all these processes are iterative and failure of the radiopeptide in any of the developmental 
stages leads back to radiopharmaceutical chemistry research to identify and synthesize targeting 
radiopeptides with improved pharmacodynamics or pharmacokinetics.5,9-10,15c,19a,41,52-53 
           
Figure 22. Steps in development of a targeting 
radiopharmaceutical – from bench to bedside and back 
to bench.9-10,41 
Identification of molecular target (GPCR) 
Identification of targeting peptide vector 
SPPS and modification of peptide 
Radiolabeling 
In vitro evaluation  
In vivo evaluation 
Toxicity studies and dosimetry 
Clinical trails (phase I-III) 
Approval and market launch 
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This very short summary shows that there is a long way from the design of a targeting, peptidic 
radiopharmaceutical to its successful administration in the clinics and up to now only very few 
radiopeptides have succeeded.8,10,15c,19a,37,41,83 Several radiolabeled peptide derivatives (e.g., 
somatostatin, bombesin, neurotensin, exendin, gastrin, α-MSH, vasoactive intestinal, and RGD 
peptides, Table 4) are currently under clinical evaluation for molecular imaging and therapy of 
different cancers.5,10,15a,c,18a,19a,26,37,41,43b,52-53,57,58d,83 However, only a somatostatin analog (111In-DTPA-
octreotide, OctreoScan®) has so far been approved by the FDA for scintigraphy of neuroendocrine 
tumors (NET).8,10,37,41,83 Thanks mainly to the pioneering collaboration of the groups of Reubi, 
Krenning, Lamberts, Mäcke, and Müller-Brand, who developed and evaluated this and other 
compounds, radiolabeled somatostatin derivatives are now routinely used for molecular imaging and 
therapy of NET.5,15c,43,52-53  
 
2.5.2 Somatostatin  
The first and currently most extensively studied examples of radiopharmaceuticals based on regulatory 
peptides are somatostatin (SST) analogs that are used for targeted imaging and therapy of 
neuroendocrine tumors.5,15c,19a,26,37,41,43,52,58d,82-83 The derivatives SST-14 (Table 3) and SST-28 are 
naturally occurring cyclopeptides, which inhibit the secretion of growth and other hormones and are 
endogenous ligands of the five SST receptors (SST1-SST5).84 The SST receptor family (predominantly 
SST2 receptor subtype) is overexpressed on several tumors, such as NET (pituitary adenomas, islet cell 
carcinomas, paragangliomas, pheochromocytomas, medullary thyroid carcinomas (MTC), 
gastrinomas), tumors of the nervous system (astrocytomas, neuroblastomas, meningiomas), 
lymphomas, breast, and small-cell lung cancer (SCLC), which makes the SST receptors very 
interesting targets for cancer treatments.5,52-53,85 However, the endogenous SST derivatives are 
metabolically unstable (biological half-life <3 minutes) and therefore, their medical use is limited.15c 
To overcome this limitation, several SST analogs with improved metabolic stability and maintained 
biological activity were developed over the last decades.15c,42,44,54-55 Shortening of the bioactive peptide 
sequence and introduction of D-amino acids led to eight AA-containing analog octreotide (OC, Table 
3). OC served as a lead compound for the development of several other SST analogs, such as DTPA-
octreotide, DOTA-[Tyr3]-octreotide (DOTA-TOC), DOTA-[Tyr3, Thr8]-octreotide (DOTA-TATE) 
with improved SST2 receptor affinity, and DOTA-[NaI3]-octreotide (DOTA-NOC).15c These SST 
analogs can be labeled with either 68Ga, 64Cu, 111In for imaging or for therapy of NET, when labeled 
with 90Y, or 177Lu.15c,41,43,52-53 These and many other different SST analogs (e.g., 99mTc- and 18F-labeled 
SST-analogs, pan-somatostatin derivatives, and SST2-receptor antagonists) currently under 
(pre)clinical evaluation are nicely summarized in several reviews.5,15c,19a,26,37,41,43,52,58d,82-83 Also non-
radioactive SST derivatives, such as octreotide, lanreotide, and vapreotide are administrated for long-
term treatments of symptoms caused by NET to improve the quality of life of the patients.5,43b 
Table 3. Selected somatostatin analogs.15c Peptide structures of SST analogs, substitutions of the 
original OC peptide sequence are in bold; 1-NaI: 1-Naphthyl-alanin.  
Analogs Chemical structure 
SST-14 Ala-Gly-cyclo(Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys) 
OC D-Phe1-cyclo(Cys2-Phe3-D-Trp4-Lys5-Thr6-Cys7)Thr(ol)8 
TOC D-Phe1-cyclo(Cys2-Tyr3-D-Trp4-Lys5-Thr6-Cys7)Thr(ol)8 
TATE D-Phe1-cyclo(Cys2-Tyr3-D-Trp4-Lys5-Thr6-Cys7)Thr8 
NOC D-Phe1-cyclo(Cys2-1-NaI3-D-Trp4-Lys5-Thr6-Cys7)Thr(ol)8 
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2.6 Targeting peptides and their receptors for molecular imaging and 
therapy of different cancers 
The successful implementation of radiolabeled SST derivatives into the clinics for visualization and 
treatment of NET increased interest in the development of other radiolabeled regulatory peptides. In 
the last two decades, it has been shown that several other commonly occurring cancers overexpress 
receptors of peptidic hormones.5,52-53 Other extensively evaluated pairs of regulatory peptides and their 
receptors suitable for tumor targeting are summarized in Table 4. Further regulatory peptides as 
potential tumor targeting vectors for future developments are for example, atrial natural peptide, 
bradykinin, calcitonin, endothelin, luteinizing hormone-releasing hormone, opioid peptides, and 
oxytocin.10,15c,41 
Table 4. Peptides, their receptors, and expression pattern for tumor targeting; main receptor subtypes 
that are overexpressed in human tumors are depicted in bold.5,10,15a,c,19a,26,37,41,52-53,58d,83  
Targeting peptide Receptor subtypes Tumor expression 
Somatostatin (SST) 
 
 
SST1, SST2, SST3, 
SST4, SST5 
Neuroendocrine tumors, 
gastroenteropancreatic tumors, non-
Hodgkin's lymphoma, 
paragangliomas, melanoma, breast, 
brain, renal, SCLC, and MTC 
Bombesin (BBS, BBN) 
Gastrin-releasing peptide (GRP) 
BB1 (NMB-R), BB2 
(GRP-r), BB3, BB4 
Prostate, breast, gastric, colorectal, 
pancreas, and SCLC 
Substance P (SP) NK1, NK2, NK3 Glial tumors, MTC, pancreas, 
breast, SCLC, and intra- and 
peritumoral blood vessels 
Neurotensin (NT) NTR1, NTR2, NTR3 Colon, exocrine ductal pancreatic, 
SCLC, Ewing's sarcoma, 
astrocytoma, meningioma, prostate, 
and breast cancer 
Neuropeptide Y (NPY) Y1, Y2, Y3, Y4, Y5 Breast, ovarian, prostate cancer, 
neuroblastoma, and lymph node 
metastases 
Glucagon-like peptide (GLP) 
Exendin  
GLP-1-R Insulinomas, gastrinomas, 
paragangliomas, MTC, and 
pheochromocytomas 
Vasoactive intestinal peptide (VIP) VPAC1, VPAC2 Prostate, breast, colon, stomach, 
lung, and liver adenocarcinomas 
Cholecystokinin (CCK) 
Gastrin 
CCK1, CCK2 MTC, gastrointestinal stromal 
cancer, astrocytomas, ovarian, and 
SCLC 
α-melanocyte-stimulating hormone  
(α-MSH) 
MC1-5R Melanomas 
Arg-Gly-Asp (RGD) αvβ3-integrin R Breast, lung, ovarian, prostate 
cancer, melanoma, and glioma 
 
The radiopeptides described in this thesis are based on the regulatory peptides bombesin and substance 
P, which will be described in the following sections. 
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2.6.1 Bombesin 
The amphibian, amidated tetradecapeptide bombesin (BBS, Table 5) was originally isolated from the 
skin of the European frog bombina bombina in the early 1970s (Figure 23).86  
                        
Figure 23. European fire-bellied toad, bombina 
bombina.87 
 
 
Later, other related amphibian peptides were isolated and categorized, for example, ranatesin, and 
peptides of the phyllolitorin group. Three mammalian BBS-like endogenous peptides, gastrin-
releasing peptide (GRP)88, neuromedin B (NMB), and neuromedin C (GRP-10) were isolated from 
porcine organs. GRP is a 27 amino acid peptide, which shares the final seven C-terminal residues with 
bombesin (Table 5).5,18a,78,89 BBS(7-14) has been shown to be the minimum binding sequence required 
for receptor recognition, signal transduction, and biological activity.5,18a,78,89 GRP and NMB are widely 
expressed in the mammalian nervous and peripheral system. They are especially found in the 
gastrointestinal (GI) tract and mediate a broad variety of pharmacological and biological responses, 
such as stimulation of smooth muscle contraction (GI and urogenital tract), GI motility, and the release 
of several gastrointestinal hormones and neurotransmitters.5,18a,78,89 The secretion of GRP and NMB 
induces growth processes in normal human tissues and tumors. These hormones also control several 
processes of the CNS, such as regulation of circadian rhythm, thermoregulation, anxiety, and 
behavioral effects.5,18a,78,89 Binding studies identified four different bombesin receptor subtypes, 
namely NMB-receptor (BB1)90, GRP-receptor (GRP-r; BB2)91, BB392 (orphan receptor), and BB493 
(amphibian only).89 More detailed information on all bombesin receptor subtypes, their receptor 
expression, pharmacology, structural basis for receptor binding activation, receptor function, and their 
broad therapeutic implications is comprehensively described by Jensen et al. and others.5,18a,78,89 Both 
GRP and BBS have high affinities in the low nanomolar range and show specificity for the GRP-r.18a,89 
The GRP-r consists of 384 AA and belongs to the family of GPCRs (Gαq).89 GRP-r expression was 
studied in humans and mice. The receptor was found in the GI-tract, pancreas, stomach, brain, and 
adrenal gland in humans, as well as in the brain, pancreas, and the colon, but not in the stomach or 
small intestine of mice.89 In addition, the GRP-r is overexpressed in a number of most frequently 
occurring human tumors, such as prostate, small cell lung, and breast cancer. GRP-receptors are also 
overexpressed in a variety of other cancers, including head and neck squamous cell, colon, uterine, 
various CNS, ovarian, gastrointestinal, and renal cancers.5,18a,52-53,78,89,94 Also BB1 and BB3 receptor 
subtypes were identified to be overexpressed in different cancer tissues, including intestinal, bronchial, 
thymic, renal carcinoids, and SCLC (Table 4).94 Thus, bombesin receptors (especially the GRP-r) are 
very interesting targets for the management of different cancers.5,18a,26,52-53,57,78,89 Additionally, several 
of these cancers have poor prognosis in advanced states of the diseases and current treatments could be 
improved.78 The development of bombesin derivatives is a promising approach for imaging of tumors 
and for targeted delivery of cytotoxic agents for the treatment of cancers mentioned above.18a,78 This 
thesis is focused on the specific delivery of radioactivity, but also several non-radioactive approaches 
have been reported for the targeted delivery of cytotoxic agents using BBS analogs that are coupled to 
e.g., chemotherapeutic agents (camptothecin, paclitaxel, and doxorubicin), various cytotoxins, immune 
activating agents, mitochondria-disrupting peptides, photosensitizer for photodynamic therapy, mRNA 
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interfering agents, or gene-delivery enhancing agents.15c,18a,77-78,89 However, there are only very limited 
in vivo studies and the effectiveness of these cytotoxic bombesin analogs for the treatment of cancer is 
under evaluation.15c,18a,77-78,89  
 
2.6.1.1 Radiolabeled bombesin derivatives for targeted imaging or therapy of 
different cancers 
Utilizing the unique feature of GRP-r overexpression on the membranes of cancer cells, a large 
number of radiolabeled bombesin derivatives has been designed and preclinically evaluated. The most 
common cell line for in vitro assays has been the human prostate adenocarcinoma cell line PC-3, 
overexpressing GRP-r.95 Typically, PC-3 cells were subcutaneously injected into animals for the 
induction of xenografts of solid tumors for in vivo biodistribution, molecular imaging, and therapy 
studies.18a,78 Substantial efforts have been made in the last decades to develop compounds that would 
achieve high metabolic stability, high GRP-r affinity, high tumor uptake, and long tumor retention in 
order to enhance molecular imaging quality and therapy efficacy. Different approaches were applied, 
for example, alterations in the amino acid sequence, comparison of various linker moieties, different 
chelating/-radiometals systems, or organic radionuclides for utilization of either SPECT (e.g., 67Ga, 
99mTc, 111In) or PET-imaging (e.g., 18F, 64Cu, 68Ga) modalities, or PRRT (90Y, 177Lu, 186/188Re, 
213Bi).5,15a,c,18a,26,37,41,53,57,58d,89 There has been much progress in this field and it is far beyond the scope 
of this thesis to comprehensively cover all of the radiolabeled bombesin-based conjugates described in 
the literature. Some excellent reviews cover the huge variety of radiolabeled bombesin derivatives 
evaluated.5,15a,c,18a,26,37,41,53,57,58d,83,89 In the following section, only some selected highlights and 
examples relating to the bombesin derivatives described in this thesis will be emphasized.  
Radiolabeled BBS analogs are based either on the full-length BBS(1-14) sequence or the minimum 
binding sequence of the C-terminus (BBS(7-14) or BBS(6-14), Table 5).18a Van de Wiele et al. 
reported first proof of the GRP-r targeting concept in vivo in a clinical study by administration of 
99mTc-RP527 (Table 5) to ten patients suffering from metastatic prostate or breast cancer.96 Specific 
uptake was reported in breast (67%) and prostate (25%) carcinomas by SPECT and no short-term side 
effects were described.96  
Influences of different spacer moieties were evaluated in several 99mTcO-N3S-X-BBS(7-14) analogs 
(N3S: dimethylglycyl-L-seryl-L-cysteinglycinamide) with varying length of hydrocarbon linkers (X: 
no spacer, β-Ala, 5-aminovaleric acid, 8-aminoocatanoic acid, or 11-aminoundecanoic acid).97 Spacers 
with between three and eight carbon atoms do not adversely affect agonistic binding to GRP-receptors. 
β-Ala linker revealed highest uptake in the pancreas (GRP-r-positive organ in mice). Increasing the 
size of the linker resulted in decreased pancreas uptake.97 Natural BBS has a biological half-life of 
about 2-3 min in vivo.15c Therefore, more metabolic stable analogs have to be developed for potential 
clinic administration to cancer patients.15c In order to increase the metabolic stability in vivo and to 
reduce the formation of unwanted side products, e.g., oxidation of the oxidation-sensitive C-terminal 
methionine (Met) to sulfoxide during radiolabeling, García-Garayoa et al. reported the replacement of 
Leu13 by cyclohexylalanine (Cha) and Met14 by norleucine (Nle), respectively.71 They also introduced 
a linker of two ß-Ala moieties, conjugated to the (NαHis)Ac chelator for stable complexation of 
[99mTc(CO)3(H2O)]+ (BBS-38, Table 5).71 The substitution of Leu13 by Cha increased the metabolic 
stability and improved tumor uptake, while maintaining high receptor affinity to the GRP-r. 
Introduction of the polar (ß-Ala)2-linker led to improved pharmacokinetics (increased tumor-to-
blood/kidney/liver ratios) by compensating for the high lipophilicity of the 99mTc-tricarbonly-His 
complex.71 To decrease further the lipophilicity of the tricarbonyl core, Schweinsberg et al. introduced 
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hydrophilic carbohydrate moieties (shikimic acid, glucose derivatives) to lysine or the 
propargylglycine linker.74a Glycation of radiolabeled [Cha13,Nle14]BBS(7-14) analogs resulted in 
reduced abdominal accumulation, increased tumor uptake, and improved tumor-to-background ratios 
in vivo.74a García-Garayoa et al. also evaluated the influence of molecular charge on the 
biodistribution of 99mTc-tricarbonyl labeled [13Cha,14Nle]BBS(7-14) analogs.70 They introduced 
different polar spacers containing β-amino acids with either positively charged β3-homolysine 
(β3hLys), neutral β3-homoserine (β3hSer), or negatively charged β3-homoglutamic acid (β3hGlu) 
between the BBS-analogs and the (NαHis)Ac chelator.70 They concluded that both the polarity and 
charge influence the biodistribution profile. Positive charge (β3hLys) resulted in increased kidney 
uptake and unfavorable biodistribution, whereas uncharged β3hSer-analogs revealed significantly 
improved tumor-to-tissue ratio. One negative charge of the β3hGlu-BBS analog significantly increased 
both the tumor uptake and the tumor-to-tissue ratios.70 Mindt et al. reported the use of CuAAC for the 
assembly of bombesin conjugates and simultaneous synthesis of a tridentate chelating system for 
stable complexation of the 99mTc-tricarbonyl core.29,31c,98 This elegant and versatile “Click-to-
Chelate”29 methodology will be described in more detail in chapter II. 
BBS-analogs with macrocyclic chelating systems have also been evaluated. The first radiolabeled 
BBS analog for therapeutic cancer treatment was 177Lu-AMBA, based on BBS(7-14) conjugated to 
DOTA by a glycine-4-aminobenzoyl spacer (Table 5) that showed high affinity to both GRP- and BB1 
receptor.44a Because of its favorable affinity, internalization, and retention profile in vivo, a small 
phase I clinical study was conducted in seven patients for treatment of prostate cancer.44b However, 
uptake was not detected in all lesions of the patients and adverse side effects (diarrhea, nausea, 
abdominal convulsions) was observed.44b Zhang et al. incorporated a PEG4 spacer between BBS(7-14) 
and DOTA (DOTA-PESIN, Table 5).76 67Ga/177Lu-DOTA-PESIN showed a favorable biodistribution 
profile in tumor-bearing mice.76 Wild et al. compared α-emitting 213Bi-DOTA-PESIN with 213Bi-
AMBA and 177Lu-DOTA-PESIN in PC-3 tumor-bearing mice.99 At the MTD, both 213Bi-radiolabeled 
BBS-analogs were superior to 177Lu-DOTA-PESIN for prostate cancer treatment, and 213Bi-DOTA-
PESIN showed a better safety profile in terms of kidney toxicity than 213Bi-AMBA.99 The authors 
conclude that administration of 213Bi-DOTA-PESIN could be an important strategy for PRRT of 
recurring prostate cancer.99 Recently, multimers of PESIN, radiolabeled with 68Ga-NODAGA were 
reported with substantially improved binding avidities to the GRP-r in vitro and increased tumor 
uptake and higher tumor-to-background ratios than monomeric DOTA-PESIN radioconjugate in PC-3 
tumor-bearing mice.100 
Since BB1 and BB3 receptor subtypes are also overexpressed in several cancers,94 Zhang et al. reported 
111In, 90Y, and 177Lu radiolabeled pan-bombesin conjugates101 derivatives, which bind to all three 
mammalian bombesin receptor subtypes.102 Analogs BZH1 and BZH2 (Table 5) revealed high binding 
affinity to all bombesin receptor subtypes in the low nanomolar range and specific and high uptake in 
AR4-2J tumor-bearing rats.102 Schuhmacher et al. incorporated a PEG2 linker into BZH3, radiolabeled 
with 68Ga (Table 5).103 High uptake and improved tumor-to-tissue ratio were reported in 
biodistribution and PET imaging experiments with AR42J tumor-bearing mice.103 68Ga-BZH3 was 
compared to 2’-[18F]fluoro-2’-deoxyglucose (18F-FDG) for PET imaging of patients with 
gastrointestinal stromal tumors (GIST).104 Since one recurrent tumor of the stomach could only be 
detected with 68Ga-BZH3, the authors conclude that 68Ga-BZH3 may be helpful for tumor diagnosis in 
a subgroup of GIST patients where PET imaging with 18F-FDG gives false negative results.104 
In addition, radiolabeled bombesin antagonists were developed and preclinically evaluated. In 2003 
Nock et al. reported [99mTcO2]+-demobesin 1 (Table 5), a very potent BBS-antagonist that showed 
high affinity to the GRP-r and high binding to PC-3 cells in vitro.56a Compared to agonists, such as 
99mTc-demobesin 4, 111In-DOTA-PESIN, and 111In-AMBA, 99mTc-demobesin 1 displayed substantially 
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improved and prolonged uptake in PC-3 tumor-bearing mice, which lead to a change of paradigm in 
terms of necessity for tumor cell internalization of radioconjugates.105 Meanwhile, there is rapid 
progress in the field and several other BBS-antagonists were preclinically evaluated.15c Abiraj et al. 
reported another potent bombesin antagonist, AR (Table 5) conjugated to DOTA, 6-carboxy-1,4,7,11-
tetraazaundecane (N4), NODAGA, and CB-TE2A for radiolabeling of 111In, 99mTc, 68Ga, and 64Cu, 
respectively.106 The antagonists were evaluated in biodistribution experiments in PC-3 tumor-bearing 
mice and imaging with SPECT and PET were performed.106 The different chelators employed 
influenced receptor affinity towards GRP-r, uptake to the tumor, and pharmacokinetics of the 
conjugates. All four radiolabeled bombesin analogs showed promising in vitro and in vivo results.106 
64Cu-CB-TE2A-AR06 was most promising and evaluated further in a clinical study for PET-imaging 
of four patients suffering from prostate cancer.107 Also 18F-labeled analogs of BBS-antagonist were 
reported,15c of which 18F-BAY86-4367 (Table 5) showed most favorable preclinical results and first 
clinical studies are underway.108 Recently, a first clinical study was reported using the analog 68Ga-
BAY86-7548 (Table 5).109 PET-imaging of prostate cancer with 68Ga-BAY86-7548 was very 
promising, resulting in high specificity, sensitivity, and accuracy for the detection of primary prostate 
cancers and metastatic lymph nodes.109 Combining bombesin agonists and antagonists, structurally 
defined radiolabeled hybrid conjugates based on oligoproline scaffolds were recently designed.110 
Amongst those, a hybrid-analog revealed the highest reported total cellular uptake for BBS derivatives 
in PC-3 cells.110 The hybrid constructs combined the advantageously high internalization of agonists 
with the high tumor binding of antagonists, leading to superior tumor uptake and long retention in 
vivo.110 
Table 5. Selected bombesin analogs; peptide structures based on the BBS(7-14) binding sequence, 
substitutions in the bombesin analogs are in bold.15c,18a,41,83 
Analogs Chemical structure 
GRP88 Ala1-Pro-Val-Ser-Val-Gly-Gly-Gly-Thr-Val-Leu-Ala-Lys-Met-Try-Pro-Arg-Gly-
Asn-His-Trp21-Ala-Val-Gly-His-Leu-Met27-NH2 
BBS, BN pGlu1-Gln2-Arg3-Leu4-Gly5-Asn6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Leu13-Met14-
NH2 
BBS(7-14) Gln7-Trp8-Ala9-Val10-Gly11-His12-Leu13-Met14-NH2 
RP527 N3S-Gly-5-Ava-[Gln7-Trp8-Ala9-Val10-Gly11-His12-Leu13-Met14-NH2] 
BBS-38 (NαHis)Ac-β-Ala-β-Ala-[Gln7-Trp8-Ala9-Val10-Gly11-His12-Cha13-Nle14-NH2] 
AMBA DOTA-Gly-4-aminobenzoyl-[Gln7-Trp8-Ala9-Val10-Gly11-His12-Leu13-Met14-NH2] 
DOTA-PESIN DOTA-PEG4-[Gln7-Trp8-Ala9-Val10-Gly11-His12-Leu13-Met14-NH2] 
BZH1/BZH2 DTPA/DOTA-GABA-[D-Tyr6-Gln7-Trp8-Ala9-Val10-β-Ala11-His12-Thi13-Nle14-
NH2] 
BZH3 DOTA-PEG2-[D-Tyr6-Gln7-Trp8-Ala9-Val10-β-Ala11-His12-Thi13-Nle14-NH2] 
Demobesin 1 N40-1-bzlg0-[D-Phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Leu-NHEt13] 
Demobesin 4 N4-[Pro1-Gln2-Arg3-Tyr4-Gly5-Asn6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Leu13-Nle14-
NH2] 
AR PEG4-[D-Phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2] 
BAY86-4367 3-cyano-4-18F-fluorobenzoyl-Ala(SO3H)-Ala(SO3H)-Ava-[Gln7-Trp8-Ala9-Val10-
NMeGly11-His12-Sta13-Leu14-NH2] 
BAY86-7548 DOTA-4-amino-1-carboxymethyl-piperidine-[D-Phe6-Gln7-Trp8-Ala9-Val10-Gly11-
His12-Sta13-Leu14-NH2] 
N3S: N,N-dimethyl-Gly-L-Ser-L-Cys(acm), Ava: 5-aminovaleric acid, PEG4: 15-amino-4,7,10,13-
tetraoxapentadecanoic acid, GABA: γ-aminobutyric acid, N4: 6-carboxy-1,4,8,11-tetraazaundecanetetramine, 
bzlg: benzylaminodiglycolic acid, Sta: statin ((3S,4S)-4-amino-3-hydroxy-6-methylheptanoic acid), Ala(SO3H): 
L-cysteic acid. 
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Despite the enormous quantity of reported radiolabeled bombesin derivatives that were preclinically 
evaluated, only a very limited number of clinical trials has been reported. Most of them included 
imaging studies (12 studies; 83% based on 99mTc and 17% based on 68Ga analogs)18a and so far, only 
one bombesin derivative, 177Lu-AMBA, was evaluated in a phase I study with a small number of 
prostate cancer patients for targeted therapy.44b  
Due to the discussed findings, bombesin derivatives described in this thesis are based on the oxidation-
insensitive [Nle14]BBS(7-14) sequence. Compounds reported in chapter III and IV (dual-targeting 
analogs) are N-terminally conjugated with a polar linker of three ß-Ala units and assembled by “Click-
to-Chelate”29 strategy for radiolabeling with 99mTc-tricarbonyl. Triazole-BBS derivatives, described in 
chapter V (triazole-scan) are modified with a polar PEG4-spacer and conjugated to macrocyclic DOTA 
for the stable complexation of 177Lu.  
 
2.6.2 Substance P 
The neuropeptide substance P (SP; Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) is a 
member of the tachykinin (TK) peptide family sharing the C-terminal sequence Phe-X-Gly-Leu-Met-
NH2.111 Substance P was already discovered in the early 1930s, followed by the exploration of the 
mammalian tachykinins neurokinin A (NKA) and neurokinin B (NKB) in the mid-1980s.111 
Tachykinins are found in neuronal and glial cells of the human central and peripheral nervous 
system.111 SP, NKA, and NKB are all ligands of the tachykinin receptor family, consisting of three 
mammalian GPCRs, named NK1, NK2, and NK3.111 Their receptor affinities are varying, as the NK1 
receptor (NK1R) has the highest affinity and preference for substance P, NK2R for neurokinin A, and 
NK3R for neurokinin B.111 The NK receptors are involved in multiple intracellular signaling pathways, 
such as IP3 and cAMP-signaling mechanism (section 2.2.1). Several (patho)physiological effects are 
mediated through TKs, including regulation of synaptic transmission, nociception, and 
neuroimmunomodulation. TKs effect as well smooth muscle contraction, cardiovascular function, 
respiration control, and emesis.111 The NK1 receptors are broadly distributed in the central and 
peripheral nervous system in human and in several other species. It has been shown that two different 
isoform of the NK1R exist that are varying in the length of their C-terminus. A full-length form, 
containing 407 amino acids and a truncated isoform, containing only 311 AA have been isolated that 
reveal differences in biological function.111-112 Compared to the full-length isoform, SP shows less 
binding affinity to the truncated NK1R isoform, which is less effective in stimulation of an 
electrophysiological response.111-112 SP acts as a immune cells activator, neurotransmitter, 
neuromodulator, and is especially involved in the transmission of peripheral pain stimuli.111b SP 
reveals intrinsic neuroprotective and neurodegenerative characteristics and thus, acts as non-specific 
growth factor for tissues of the peripheral and central nervous system. SP derivatives play an 
important role for neurodegenerative disorders, such as Alzheimer’s disease, Parkinson, and 
Amyotrophic Lateral Sclerosis.111b Substance P is also associated in control of emesis, inflammatory 
conditions, regulation of mood, affective behavior, anxiety, and depression.111b,113 Thus, SP-
antagonists might be potential antiemetic, antiinflammative, analgetic, anxiolytic, and antidepressive 
agents.111b,113 NK1R-antagonist aprepitant is FDA approved and clinically administered for cytostatic 
induced nausea.111b SP and its preferred NK1-receptor are also involved in development and 
progression of cancer cells.111b,114 It has been shown that NK1R is overexpressed in malignant gliomas, 
but not in healthy neighboring brain tissue or benign neoplasms.53,115 Hennig et al. proved NK1R 
expression in glioblastoma multiforme, astrocytoma, medullary thyroid carcinoma, 
ganglioneuroblastoma, and breast carcinoma.115 Thus, targeting of NK1R with radiolabeled SP 
derivatives is interesting for diagnosis and therapy of cancers, especially of gliomas.53,83,115 In 1996, 
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van Hagen et al. reported radiolabeled SP analog 111In-DTPA-[Arg1]-SP for visualization of the 
thymus in 12 patients suffering from immune-mediated diseases.116 The radiolabeled SP analog 
revealed rapid washout, a short biological half-life, and uptake of radioactivity was found in all 
patients in the mammae, spleen, in the excretory organs.116 A high uptake in the thymus was reported 
and the authors concluded 111In-DTPA-[Arg1]-SP as useful for imaging of the thymus in immune-
mediated diseases.116 Uptake in non-targeted tissue, a short biological half-life, and rapid clearance 
may be acceptable for molecular imaging.117 However, these characteristics may impede systemic 
treatments of cancer with radiolabeled SP-derivatives where efficient radiation dose in the targeted 
tissue has to be achieved, while protecting non-targeted healthy tissues.66 Circumventing these 
obstacles, loco-regional administration of radiolabeled SP analogs was clinically evaluated for glioma 
therapy,83,118 which will be discussed in the following sections.  
 
2.6.2.1 Gliomas  
High grade gliomas (glioblastoma multiforme, GBM, WHO IV °)119 are the most common, aggressive, 
proliferative, and rapidly growing type of intrinsic brain tumors, leading to poor prognosis for the 
patient. There is currently no cure and only little progress has been achieved in the control of the 
disease.114a,119-120 GBM shows very high cell density and sometimes widespread infiltration of 
surrounding tissues.119,120b,c The current therapeutic standard for GBM is surgical resection and 
combined radio- and chemotherapy. 119,120b,c  A high extent of surgical resection is positively correlated 
with prolonged periods until tumor recurrence.118a,b,119,120b However, certain obstacles have to be 
overcome for the successful treatment of gliomas, for example, incapability of complete tumor 
resection in order to preserve functionally important brain areas.118a,b Another hindrance is poor 
penetration of the blood-brain barrier of most cytostatic drugs and accordingly only insufficient 
concentration of the drug in the desired tumor location can be achieved.114a,120b Therefore, new 
delivery techniques have to be established that allow glioma therapy beyond the blood-brain barrier 
and target glioma cells without affecting normal healthy surrounding tissue.114a,120a,b 
 
2.6.2.2 Loco-regional tumor targeting of gliomas using radiolabeled peptides 
Most glioblastomas occur as unifocal lesions (90%) that recur at the primary site and therefore, 
therapy of the surrounding infiltration zone is equally important.83,118c,121 To overcome insufficient 
local distribution through the blood-brain barrier, loco-regional drug administration of therapeutic, 
targeting radiopeptides has been evaluated.53,83,118d,e Low-grade gliomas are known to express the SST2 
receptor (Table 4). Therefore, 90Y-DOTA-TOC was locally administered as novel therapeutic 
application of diffusible brachytherapy through an implanted catheter system (port-a-cath device, 
Figure 24) into the tumor or resection cavity of glioma patients in a clinical pilot study.118d,e 
            
Figure 24. Intratumoral catheter system (port 
capsule and connected intraventricular 
catheter).118b 
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Compared to systemic application, this technique resulted in enormous improved tumor uptake and 
rapid intratumoral distribution.118d,e 90Y-DOTA-TOC was well tolerated and no severe adverse side 
effects occurred.118d,e However, glioblastomas cannot be efficiently targeted with radiolabeled DOTA-
TOC, since the levels of SST2 receptor expression is gradually lost with malignancy 
progression.85,118d,e Primary malignant gliomas and glioblastomas overexpress NK1 receptors and thus, 
can be targeted with radiolabeled SP derivatives.5,53,83,115 Kneifel and Cordier et al. reported the use of 
radiolabeled DOTA- and DOTAGA-SP derivatives that showed high affinity in the low nanomolar 
range to the NK1R.118c The radioconjugates were rapidly internalized into tumor cells and showed 
good metabolic stability.118c 90Y, 177Lu, or 213Bi labeled DOTAGA-SP radioconjugates were locally 
applied into the tumor or resection cavity of 20 patients (glioma WHO°II-IV) in a clinical pilot 
study.118c Extensive radiation necrosis of the tumor tissue could be observed, which enabled and 
considerably facilitated subsequent surgical resection due to improved demarcation of tumor margins 
and reduced intraoperative bleeding, caused by radiation effects on tumor vasculature.118c Local 
radionuclide therapy of NK1 receptors with SP derivatives was superior than targeting of SST 
receptors with 90Y-DOTA-TOC.118c To improve the metabolic stability of radiolabeled SP derivatives, 
while maintaining high affinity to the NK1R, several radiolabeled SP derivatives have been developed 
and preclinically evaluated.66 Compared to 111In-DOTA-SP, 111In-DOTA-[Thi8,Met(O2)11]-SP and 
111In-DOTAGA-[Thi8,Met(O2)11]-SP displayed increased metabolic stability and binding affinity to the 
NK1 receptor.66 To spare surrounding healthy brain tissue, short range 213Bi-DOTA-[Thi8,Met(O2)11]-
SP was locally administrated to five glioma patients (WHO II°-IV°).118a The groups of Merlo, Müller-
Brand, and Mäcke also evaluated 90Y-DOTAGA-SP as neoadjuvant treatment to assess feasibility, 
extent of possible tumor resection, functional clinical outcome, and toxicity.118b It was possible to 
achieve a high extent of tumor resection (in average 96%) and the authors conclude this therapeutic 
approach as potentially beneficial to prolong recurrence time, improve overall time of survival, and 
quality of life of glioma patients.118b  
 
2.7 Ideal peptide-based radiopharmaceuticals for targeted imaging and 
therapy of cancer 
Radiopeptides are very promising for targeted diagnosis and therapy of various cancers, 
overexpressing their corresponding GPCRs.5,8,10,15a,c,19a,26,37,41,52-53,58d,83 Despite the enormous effort that 
has been made in radiopharmaceutical chemistry for the development of targeting radiopeptides in the 
last decades, only somatostatin derivatives are now routinely administered for diagnosis and therapy of 
NET and only one SST analog got approved by the FDA so far.8,10,37,41,83 There is still a need for the 
improvement of targeting radiopeptides for successful routine treatments of cancers in nuclear 
medicine.8,10,19a,37,41,83 Several crucial requirements needed to obtain ideal targeting radiopeptides to 
enhance the quality of molecular imaging and the efficacy of radionuclide therapy of cancers are 
summarized in Table 6.  
In regard to pharmacodynamics, the radiopeptide should display specific and very high affinity in the 
low nanomolar range towards its targeted GPCR. High affinity to the receptor decreases background 
and non-specific binding and allows administration of the radiopharmaceutical in very low 
concentrations. Since some regulatory peptides are pharmacologically very potent (e.g., VIP, 
exendin),41 the applied dose of the radiopharmaceuticals should be in the subpharmacological level to 
reduce any risk of pharmacological side effects. High specific activity and high radiochemical purity 
of the radiopeptide are essential to deliver sufficient amounts of radioactivity in subpharmacological 
peptide concentrations. Ideal pharmacokinetic and biodistribution profiles include rapid clearance 
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from the blood and non-targeted tissue, fast distribution, efficient penetration of the tumor, high 
accumulation and retention in the tumor, and fast renal clearance of excess of the radiopharmaceutical 
or metabolites thereof. Therefore, sufficient metabolic stability of the radiopeptides in vivo and 
suitable radio-physical properties of the radionuclides are crucial. Ensuring these requirements, high 
tumor-to-background ratios can be obtained, leading to improved quality of molecular imaging and 
enhanced radionuclide therapy, while reducing the radiation burden on surrounding healthy 
tissues.1,5,8,10,15a,19a,26,37,41,52-53,57,58d,82-83 
Table 6. General requirements for radiolabeled peptides as targeting vectors.1,5,8,10,15a,19a,26,37,41,52-
53,57,58d,82-83 
Specific targeting of a relevant biological structure (e.g., GPCRs) 
Homogenous overexpression of the biological target in diseased but not in normal tissues 
Small in size (leading to rapid blood clearance, good tissue penetration, and renal elimination) 
Easy synthesis by SPPS and amenable to chemical modifications (e.g., for pharmacokinetic 
modifications and conjugation of the BFCA) 
Convenient radiolabeling with high specific activity, RCY, and RCP (favored in a kit formulation in 
aqueous solutions) 
Thermodynamically stable and kinetically inert complexation of the radiometal by an appropriate 
BFCA  
Favorable pharmacokinetics (rapid clearance from the blood and non-targeted tissues, fast, high, and 
prolonged tumor uptake, low non-specific accumulation in the background, and fast renal clearance) 
High metabolic stability to allow distribution and sufficient tumor accumulation 
Specificity and high binding affinity to the targeted GPCR (nM) 
Minimum adverse side effects (e.g., no pharmacologic effects, no immunogenicity, reduced 
nephrotoxicity, and minimum radiation burden on healthy tissues) 
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3. Rationales, hypotheses, and goals of the projects 
 
Targeting radiopeptides have high potential for employment in molecular imaging and treatment of 
cancers in nuclear oncology. However, only a limited number of radiopeptides has been successfully 
introduced to the clinic so far.8,10,37,41,57,83 There are still several challenges to be met in order to 
develop radiopeptides, which provide enhanced imaging quality and therapeutic efficacy.8,10,19a,37,41,83 
Current obstacles of targeting radiopeptides will be described and different approaches introduced and 
discussed in this Ph.D. thesis to optimize radiolabeled, targeting peptides for molecular imaging and 
therapy of different cancers.  
 
3.1 Dual-targeting conjugates designed to improve the efficacy of 
radiolabeled peptides 
Radiolabeled agonists of regulatory peptides can be used for the specific delivery of radionuclides into 
cancer cells via receptor-mediated internalization for molecular imaging or targeted therapy of 
different cancers. However, after uptake of many radiopeptides into tumors, a rapid efflux of a 
significant fraction of the internalized radiotracers is often observed in vitro and in vivo.51b,70,122 This 
phenomenon impedes the initial efforts of targeted delivery of radioactivity to cancers. It also impairs 
imaging quality and efficacy of PRRT, since it is generally assumed that these features correlate with a 
high rate of internalization into tumor cells and a low rate of externalization from tumor 
tissues.5,10,19a,37,41,52 In some cases, the externalization of radioactivity occurs at rates comparable to the 
internalization (Figure 25).51b,122a-c 
 
Figure 25. Example of in vitro internalization (blue) and 
subsequent externalization (red) profiles of a 
radiolabeled, agonistic bombesin analog in PC-3 cells 
(chapter III/IV).  
 
To overcome the rapid washout of radioactivity from cancer cells, new strategies are needed to 
enhance the retention of radioactivity inside tumor cells. A possible approach to increase cellular 
retention of radioactivity is the application of dual-targeting radioconjugates that bind not only to the 
respective extracellular GPCR, but also to intracellular targets. We envisioned that after endocytotic 
cellular uptake, additional intracellular targeting with bifunctional radioconjugates (Figure 26) could 
improve the cellular retention of radioactivity. 
Figure 26. Schematic composition of 
bifunctional radioconjugate for dual-
targeting purposes. 
 
Additional functionality for 
intracellular targeting 
Tumor-specific vector 
for extracellular targeting 
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A bifunctional radioconjugate is first recognized by an extracellular target (e.g., a GPCR), triggering 
cell internalization by endocytosis. Once inside the cell, the additional second functionality of the 
radioconjugate interacts with its intracellular target (e.g., a cell organelle or cytosolic protein), which 
could lead to entrapment of the radioactive cargo inside the cell (Figure 27). An increased retention 
time of the radioactivity within the tumor holds the promise to improve the signal-to-background ratio, 
which is important for molecular imaging. Furthermore, it may enhance the efficacy of therapeutic 
radionuclides because of increased radiation energy deposited in cancerous tissues over time. The 
dual-targeting approach bears a particularly high potential for targeted PRRT in nuclear medicine. 
While increasing the efficacy of targeting peptides for PRRT, the radioactive dose administered to the 
patient to cause sterilization of the tumor could be decreased and, consequently, the overall radiation 
burden of the patient could be reduced.  
Only a few bifunctional radioconjugates, each specific for an extra- and intracellular target, 
respectively, have been reported. Ginj et al. reported the combination of radiolabeled somatostatin 
derivatives with a nuclear localization signal (NLS) sequence to transport the Auger electron emitter 
111In to the cell nucleus for PRRT.51b The reported conjugates targeted specifically the cell nucleus and 
displayed a decreased externalization rate in vitro; however, no according in vivo data is reported.51b 
With the same goal of targeting the cell nucleus, the groups of Alberto and Santos combined a 99mTc-
labeled BBS derivative with the DNA intercalator acridine orange, which also serves as a fluorescent 
probe for optical imaging.73 The in vitro results reported on the ability of the conjugates to target the 
cell nucleus are inconsistent and no data on the externalization of radioactivity from cells is given.73 
The group of Garrison investigated the combination of a radiolabeled BBS derivative with 2-
nitroimidazoles, a hypoxia-specific prodrug, which is covalently conjugated to intracellular proteins 
upon enzymatic reduction.123 While an enhancement of the retention of radioactivity in PC-3 cells, as a 
result of 2-nitroimidazole moieties, was demonstrated for the conjugates under hypoxic conditions in 
vitro, the effect was less pronounced in an in vivo mouse model.123  
To achieve the goal of intracellular trapping of radioactivity, we envisioned the application of 
bifunctional radiopeptides, bearing a tumor-targeting vector for extracellular targeting of GPCRs and 
an additional entity for intracellular targeting towards a cell organelle or a cytosolic protein (Figure 
27).  
 
Figure 27. Concept of dual-targeting radioconjugates to reduce cellular washout of radioactivity from cancer 
cells.124 
The application of bifunctional radioconjugates to exploit the individual properties of the single 
components is intriguing. However, the synthesis of bifunctional radioconjugates can be challenging. 
We chose the modular synthetic “extended Click-to-Chelate” approach31c (chapter II) for the efficient 
1. Extracellular  
Targeting 2. Intracellular  
Targeting  
 
Washout 
Tumor cell 
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preparation of the dual-targeting conjugates. In this approach, N(α)-propargyl lysine represents the key 
point of the final radioconjugate by providing the possibility for the orthogonal conjugation of two 
different functionalities (regulatory peptide analog for extracellular targeting and an entity for 
intracellular targeting) by selective amide bond formation (primary amine in ε-position) and by 
Copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC). In the course of the CuAAC, a 1,2,3-
triazole is formed and the prochelator N(α)-propargyl lysine transforms into a tridentate ligand system 
for the stable complexation of the fac-[M(CO)3(H2O)3]+ (M= 99mTc, 186/188Re) tricarbonyl core (Figure 
28 and section 1.2.3.4).31c  
Figure 28. Assembly of bifunctional radioconjugates by selective amide bond formation, CuAAC, and 
radiometal complexation;31c residues R1 and R2 represent any ligand for extra- and intracellular targeting, 
respectively.  
The first generation of dual-targeting, 99mTc-tricarbonyl-labeled conjugates is based on the stabilized 
minimum binding sequence of bombesin, [Nle14]BBS(7-14)71 for extracellular targeting of the GRP-r 
(section 2.6.1). The peptide is linked via a (β-Ala)3 spacer to the tridentate chelating system, which is 
equipped with a triphenylphosphonium (TPP) moiety125 for intracellular targeting of the organelle 
mitochondria to form the active conjugate [99mTc(CO)3(BBS-TPP)]+ (Figure 29 and chapter III). It has 
been shown that lipophilic, cationic TPP derivatives are driven through negatively charged 
transmembranes in an electrophoretic manner, resulting in an intracellular accumulation of the 
compounds in energized mitochondria.126 TPP derivatives have been used as drug delivery systems for 
the transport of therapeutic agents into mitochondria.126 Radiolabeled TPP derivatives have also been 
reported for imaging of tumors125,127 and myocardial perfusion.128 The utilization of TPP entities, 
combined with a receptor-specific peptide to enhance intracellular retention of radioactivity represents 
a novel and promising approach.  
 
Figure 29. Bifunctional [99mTc(CO)3(BBS-TPP)]+ conjugate for targeting both extracellular GRP-r and 
intracellular mitochondria, based on [Nle14]BBS(7-14), 3-tris(p-methoxyphenyl)-phosphonium moiety,125 and 
99mTc-tricarbonyl core. 
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The second generation of 99mTc-tricarbonyl-labeled, dual-targeting conjugates (Figure 30) is designed 
for intracellular targeting of the molecular, cytosolic chaperone heat-shock protein 90 (Hsp90). Hsp90 
represents an ubiquitous protein, which is essential for several biochemical processes, such as cell 
proliferation and survival.129 As such, it is found at high concentrations in normal cells and 
overexpressed by nearly all cancer cells.129-130 Hsp90 assists and controls the non-covalent 
folding/unfolding of many client proteins, for example, survivin.129b,131 The group of Altieri identified 
the peptide sequence of survivin (K79-L87), termed “shepherdin” as an inhibitor of both the survivin-
Hsp90 interaction and Hsp90 ATPase activity.132 The anticancer activity of conjugates consisting of 
cell penetrating peptides combined with shepherdin[79-87] (KHSSGCAFL) and its truncated form 
shepherdin[79-83] (KHSSG), respectively, have been demonstrated.132-133 Applications of radiolabeled 
derivatives of shepherdin or its combination with tumor targeting peptides for receptor-specific 
delivery have not been described yet.  
 
Figure 30. Bifunctional [99mTc(CO)3(BBS-shepherdin[79-87])] and [99mTc(CO)3(BBS-shepherdin[79-83])] 
radioconjugates for extracellular targeting of GRP-r and intracellular targeting of Hsp90. 
 
The novel, dual-targeting radioconjugates were evaluated for their hydrophilicity (logD), their cellular 
binding and uptake (internalization), their binding affinity towards the GRP-r (receptor saturation 
binding assays), and the cellular washout of radioactivity (externalization) in vitro, using PC-3 cells 
(chapter III and IV). 
 
3.2 1,2,3-Triazoles as amide bond mimics to yield protease-resistant 
peptidomimetics for tumor targeting 
Due to rapid degradation by various endogenous peptidases and proteases,55,134 a major obstacle for 
successful clinical use of radiolabeled derivatives of linear regulatory peptides is their very short 
biological half-life.10,15a,19a,26,37,41 Because of their poor metabolic stability, they may be degraded 
before reaching their target structures, which significantly restricts their use as targeting 
vectors.15c,19a,26,41 There are several synthetic strategies for the stabilization of peptides. Examples 
include the insertion of non-natural amino acids (e.g., D-amino acids or amino acids with modified 
side-chains), peptide backbone modifications (e.g., N-methylation, carbonyl reduction, or the use of 
amide bonds isosteres), and pegylation.10,19a,26,37,41,55 Considerable efforts have been made to develop 
stabilized targeting peptides, while maintaining favorable biological properties, for example, good 
tissue penetration and high affinity towards the corresponding GPCRs, however, with varying degree 
of success.10,19a,26,37,41,55 The replacement of α-AA residues by β-amino acids and their derivatives is 
known to result in significantly improved stability.10,135 For example, 14C-radiolabeled β-nonapeptide 
H(β-HAla-β-HLys-β-HPhe)3-OH revealed outstanding metabolic stability in animal models.136 
However, such prolonged residence time in the body may bear the risk of increased radiation dose at 
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non-targeted tissues and unwanted side effects of radiation.10 Thus, a fine-tuned balance between 
stability and biological half-life of radiopeptides is required. A very promising approach is the 
substitution of peptidase-sensitive amide bonds by enzyme-resistant entities.10,15a,41,137 For example, it 
is known that 1,4-disubstituted 1,2,3-triazoles can effectively mimic trans-amide bonds because of 
their similar size, planarity, H-bonding capabilities, and dipole moment (Figure 31).30c,137-138  
Figure 31. 1,4-disubstituted 1,2,3-
triazoles as amide bond mimics. 
 
 
It has also been suggested that the replacement of an amide bond by a 1,2,3-triazole isostere could 
afford protease-resistant peptidomimetics.30c,137-138 However, the influence of such backbone 
modifications on the stability of radiopeptides has not been reported yet. We replaced systematically 
amide bonds of linear peptides with 1,4-disubstituted 1,2,3-triazoles by CuAAC, with the goal to 
develop tumor targeting vectors with increased metabolic stability and maintained high affinity 
towards the receptor. To prove the concept of this new approach (termed “triazole scan”), we chose 
the bombesin analog ([Nle14]BBS(7-14),71 which was N-terminally conjugated to a short PEG4 spacer 
and the macrocyclic chelator DOTA for stable complexation of 177Lu (Figure 32). 
 
Figure 32. Example of novel triazole-peptidomimetic of DOTA-PEG4-[Nle14]BBS(7-14).  
 
Radiolabeled triazole-peptidomimetics of bombesin were evaluated for metabolic stability, 
hydrophilicity, internalization, and affinity towards the GRP-r, using PC-3 cells. The best candidate 
was evaluated in vivo by biodistribution experiments using tumor-bearing mice (chapter V).  
 
3.3 Expression of different neurokinin-1 receptor (NK1R) isoforms in 
glioblastoma multiforme: potential implications for targeted 
therapy 
Radiolabeled 90Y and 213Bi-substance P derivatives have previously been evaluated in clinical trials for 
the treatment of gliomas (subchapter 2.6.2.2).83 Before treatment, the overexpression of NK1 receptors 
was confirmed in every patient by local injection of 111In-labeled SP derivatives.118a-c The majority of 
patients within the study showed clinical response to locally administered SP radionuclide therapy.118a-
c However, despite proven NK1R overexpression, the response of several patients was not as 
pronounced as expected.118a,c Since sufficient intratumoral distribution was proven by pre-therapeutic 
test injections, there might be specific features leading to variable responses of patients to NK1R-
targeted therapy with radiolabeled SP derivatives.  
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Two isoforms of the NK1R exist, a full-length (NK1R-Fl) and a truncated isoform (NK1R-Tr; 
subchapter 2.6.2).111-112 They consist of identical domains for ligand binding, but show differences in 
the C-terminal region, which is important for phosphorylation by kinases of GPCRs. The C-terminus 
of NK1R-Tr lacks 96 amino acids (Figure 33) and thus, shows reduced capacity to undergo SP-induced 
internalization and desensitization.111-112  
 
Figure 33. Schematic illustration of full-length and truncated isoforms of human NK1Rs.111b 
 
Towards the goal of identifying factors that may be responsible for the varying therapeutic response of 
patients suffering from glioma, four different, commonly used glioma cell lines (LN71, LN229, 
LN319, and LN405) were analyzed for their RNA levels of NK1R-Fl and NK1R-Tr isoforms. Using 
these cell lines, NK1R-mediated binding and internalization of three different analogs of SP (Table 7) 
were evaluated. Potential therapeutic effect of saporin-SP analog for toxin-based, targeted therapy of 
gliomas was analyzed as well (chapter VI).  
 
Table 7. Structures of analyzed SP analogs. 
SP Arg1-Pro2-Lys3-Pro4-Gln5-Gln6-Phe7-Phe8-Gly9-Leu10-Met11-NH2  
radiolabeled 177Lu-DOTA-[Thi8,Met(O)211]-SP66 (Thi: thienylalanine) 
fluorescently-labeled FAM-SP (FAM: carboxyfluorescein), commercial  
toxin-based SP-SAP: [Sar9,Met(O)211]-SP-saporin (Sar: sarcosine), commercial 
 
 
D  S  D  V  P  L  V N  D M    NH2 L 
S 
P 
N N 
I  S  T  N  T  S E  H 
P  V A 
Q V  F  Q 
N 
P 
A 
W Q 
I  V  L W A A  A  Y T  V   I   V V  T  S  V 
V V  V M 
V G  N 
I   I   L W A 
H 
K 
R M  R 
T 
T 
V 
A  F  N 
S  M  A 
A  E  A 
L  A  F 
L  V  N 
N  Y  F 
T  V  V 
F 
N 
T 
Y 
E W  Y  Y G  L 
F 
Y 
C 
K 
F 
H 
N 
F  F 
P   I   A 
A  C  F 
A  S   I 
Y  S  M 
T  V  A 
V  A  F 
D      K 
R     T 
A M Y 
A 
I 
I 
H  P  L  Q  P R 
L 
T  A 
S 
P Q  G 
L  A  F 
A  L  L 
W  V   L 
C  V   I 
V  V   I 
Y  Y  S 
T 
T 
T  E 
P M 
S 
M 
C 
V 
V 
R 
E  I  
W P  E H 
P 
N 
K 
I 
Y 
E 
K 
V 
Y 
H 
I  C  V 
T  V  L 
I  Y  F L  P L L V  I 
G Y  A 
Y  T   I 
V G 
I 
T 
L 
W 
A 
S 
E 
I 
S  H 
P  G D 
D  R 
S  Y 
E  Q  V 
K 
A 
S 
          K  R 
V 
V 
K M M 
V  C  T 
I  V  V 
F  A I 
I   F  F  W  L  A 
P  F  H  M  S  
S C W  L 
L  L  P 
I 
P 
D 
N 
D 
L 
               II 
Y  L  K  K F 
Q 
Q 
V 
Y  L 
A  I  M 
T M  Y N P  I 
I  Y  C 
C  L  N 
D R 
S  I 
F R  L G  F K 
H 
C  R  F A 
G  P 
C 
A  F 
D 
Y 
E G  L      M K  S  T  R E 
Y 
L 
S  Q 
G Q  T 
V  K  Y  V 
S R 
L 
E 
T  T   I   S T  V V 
G A  H  E 
E 
E 
P  T  A  K  P  G  D  P  E  E  P 
S 
S 
C  L 
D 
S  T  L 
N 
S 
S 
S   D S  R 
K 
S  E  T 
M 
T 
F 
S 
F 
N  S  S 
S  
L  
V 
extracellular 
cytoplasm 
D  S  D  V  P  L  V N  D M    NH2 L 
S 
P 
N N 
I  S  T  N  T  S E  H 
P  V A 
Q V  F  Q 
N 
P 
A 
W Q 
I  V  L W A A  A  Y T  V   I   V V  T  S  V 
V V  V M 
V G  N 
I   I   L W A 
H 
K 
R M  R 
T 
T 
V 
A  F  N 
S  M  A 
A  E  A 
L  A  F 
L  V  N 
N  Y  F 
T  V  V 
F 
N 
T 
Y 
E W  Y  Y G  L 
F 
Y 
C 
K 
F 
H 
N 
F  F 
P   I   A 
A  C  F 
A  S   I 
Y  S  M 
T  V  A 
V  A  F 
D      K 
R     T 
A M Y 
A 
I 
I 
H  P  L  Q  P R 
L 
T  A 
S 
P Q  G 
L  A  F 
A  L  L 
W  V   L 
C  V   I 
V  V   I 
Y  Y  S 
T 
T 
T  E 
P M 
S 
M 
C 
V 
V 
R 
E  I  
W P  E H 
P 
N 
K 
I I      
Y 
E 
K 
V 
Y 
H 
I  C  V 
T  V  L 
I  Y  F L  P L L V  I 
G Y  A 
Y  T   I 
V G 
I 
L T W 
A 
S  
E  
I 
P 
G 
D S  S  D R  Y  H 
Q 
E 
V 
K 
A 
S 
V 
K R 
V 
K M M 
V  C  T 
I  V  V 
F  A I 
I   F  F  W  L  A 
P  F  H 
C W  L 
L  L  P 
I 
P 
D 
N 
D 
L 
          I 
Y  L  K  K 
F 
Q 
Q 
V 
Y  L 
A  I  M 
M  S  
S T M  Y N  P I 
I  Y  C 
C  L  N 
D 
R 
extracellular 
cytoplasm 
46         Click-to-Chelate: Development of Technetium and Rhenium-Tricarbonyl Labeled Radiopharmaceuticals 
II. Click-to-Chelate: Development of 
Technetium and Rhenium-Tricarbonyl 
Labeled Radiopharmaceuticals 
 
Christiane A. Kluba and Thomas L. Mindt* 
Division of Radiopharmaceutical Chemistry, Clinic of Radiology and Nuclear Medicine, University of 
Basel Hospital, Petersgraben 4, 4031 Basel; Switzerland 
(*corresponding author) 
 
Received: 20th February 2013; in revised form: 5th March 2013 / Accepted: 6th March 2013 /  
Published: 12th March 2013 
 
Kluba, C.A.; Mindt, T.L. Click-to-Chelate: Development of Technetium and Rhenium-
Tricarbonyl Labeled Radiopharmaceuticals. Molecules 2013, 18, 3206-3226. 
 
http://www.mdpi.com/1420-3049/18/3/3206 
 
(This article belongs to the Special Issue “Advances in Click Chemistry”;  
Guest Editor: Dr. Arnaud Gautier) 
 
  
Click-to-Chelate: Development of Technetium and Rhenium-Tricarbonyl Labeled Radiopharmaceuticals         47 
Abstract: The Click-to-Chelate approach is a highly efficient strategy for the radiolabeling of 
molecules of medicinal interest with technetium and rhenium-tricarbonyl cores. Reaction of 
azide-functionalized molecules with alkyne prochelators by the Cu(I)-catalyzed azide-alkyne 
cycloaddition (CuAAC; click reaction) enables the simultaneous synthesis and conjugation of 
tridentate chelating systems for the stable complexation of the radiometals. In many cases, the 
functionalization of (bio)molecules with the ligand system and radiolabeling can be achieved 
by convenient one-pot procedures. Since its first report in 2006, Click-to-Chelate has been 
applied to the development of numerous novel radiotracers with promising potential for 
translation into the clinic. This review summarizes the use of the Click-to-Chelate approach in 
radiopharmaceutical sciences and provides a perspective for future applications. 
 
 
Keywords: CuAAC; Click-to-Chelate; radiolabeling; radiopharmaceuticals; 99mTc-
tricarbonyl; 186/188Re-tricarbonyl 
 
Contributions: 
The review was written by Thomas L. Mindt and Christiane A. Fischer. 
 
 
48     Click-to-Chelate: Development of Technetium and Rhenium-Tricarbonyl Labeled Radiopharmaceuticals 
Molecules 2013, 18, 3206-3226; doi:10.3390/molecules18033206 
molecules 
ISSN 1420-3049 
www.mdpi.com/journal/molecules 
Review 
Click-to-Chelate: Development of Technetium and  
Rhenium-Tricarbonyl Labeled Radiopharmaceuticals 
Christiane A. Kluba and Thomas L. Mindt * 
Division of Radiopharmaceutical Chemistry, Department of Radiology and Nuclear Medicine, 
University of Basel Hospital, Petersgraben 4, 4031 Basel; Switzerland;  
E-Mail: Christiane.Kluba@usb.ch  
* Author to whom correspondence should be addressed; E-Mail: Thomas.Mindt@usb.ch;
Tel.: +41-(0)-61-556-5380; Fax: +41-(0)-61-265-5559.
Received: 20 February 2013; in revised form: 5 March 2013 / Accepted: 6 March 2013 / 
Published: 12 March 2013 
Abstract: The Click-to-Chelate approach is a highly efficient strategy for the 
radiolabeling of molecules of medicinal interest with technetium and rhenium-tricarbonyl 
cores. Reaction of azide-functionalized molecules with alkyne prochelators by the Cu(I)-
catalyzed azide-alkyne cycloaddition (CuAAC; click reaction) enables the simultaneous 
synthesis and conjugation of tridentate chelating systems for the stable complexation of 
the radiometals. In many cases, the functionalization of (bio)molecules with the ligand 
system and radiolabeling can be achieved by convenient one-pot procedures. Since its 
first report in 2006, Click-to-Chelate has been applied to the development of numerous 
novel radiotracers with promising potential for translation into the clinic. This review 
summarizes the use of the Click-to-Chelate approach in radiopharmaceutical sciences and 
provides a perspective for future applications. 
Keywords: CuAAC; Click-to-Chelate; radiolabeling; radiopharmaceuticals; 99mTc-
tricarbonyl; 186/188Re-tricarbonyl 
1. Introduction
Even though new generator-based radionuclides (e.g., 68Ga) are emerging [1], technetium 99m 
remains the workhorse of nuclear medicine due to its convenient availability via 99mMo/99mTc 
OPEN ACCESS 
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generators, reasonable cost, and ideal decay characteristics (t1/2 = 6.02 h, 140 keV, 89% abundance) for 
Single Photon Emission Computed Tomography (SPECT). Approximately 80% of all routine nuclear 
imaging applications are based on 99mTc, which translates into estimated 50 million doses of diagnostic 
radiopharmaceuticals annually worldwide, or more than 50,000 applications per day in the US alone 
[2,3]. In addition, the availability of β-particle-emitting rhenium 186/188 as group 7 transition metal 
congeners of 99mTc with similar chemical properties provides a “matched pair” constellation of 
radionuclides for both diagnostic and therapeutic applications. The possibility to radiolabel molecules 
of medicinal interest with diagnostic or therapeutic radionuclides by the same chemistry approach has 
recently received considerable interest in the field of nuclear medicine for the development of 
theranostic agents [4]. 
Because of the diverse redox chemistry of technetium and rhenium, a wealth of complexes 
differing in coordination numbers and geometries has been reported. Here, we focus on the technetium 
and rhenium-tricarbonyl cores ([M(H2O)3(CO)3]+, or short [M(CO)3]+; M = 99mTc(I), 186/188/natRe(I)). 
99mTc- and 186/188Re-tricarbonyl can be prepared by reduction of the corresponding permetallates 
([M(VII)O4]−) using K2[H3BCO2] (e.g., by the commercial IsoLinkTM kit; Scheme 1). [M(CO)3]+ 
contains three tightly coordinated CO ligands and three water molecules, the latter of which can be 
readily replaced by mono-, bi-, and tridentate ligand systems, or a combination thereof. Complexes of 
[M(CO)3]+ exhibit a low spin d6 configuration, which renders the metal inert and hence, provides 
complexes with high in vivo stability essential for medical applications [5]. In addition, octahedral 
complexes of [M(CO)3]+ are generally smaller than octahedral or square-pyramidal complexes of the 
corresponding metals in higher oxidation states (e.g., M(V)-oxo cores) and are therefore considered 
less likely to impact important characteristics of (bio)molecules to which they are conjugated to. 
Scheme 1. Synthesis of [M(CO)3]+ from permetallates and subsequent complexation with 
ligands (L). (a) For M = 99mTc: (i) IsoLinkTM kit (containing K2[H3BCO2]), saline, 100 °C, 
20 min; for M = 188Re: (i) SnCl2, gluconate, H3PO4; (ii) K2[H3BCO2]. 
Since the first report of the 99mTc-tricarbonyl core [99mTc(H2O)3(CO)3]+ in 1998 by Alberto and 
Schibli et al. [6] numerous ligand systems and their coordination with [M(CO)3]+ have been 
investigated. In particular, tridentate chelators containing N-, S-, or O-donors have been shown to 
provide well-defined and stable organometallic complexes, which are suitable for application in vivo 
(Figure 1) [7,8] Also, functionalized η5-ligand cyclopentadienide as well as carboranes [9] have been 
used for the stable complexation of the tricarbonyl core. A thorough discussion of the literature on 
ligand systems reported for the complexation of [M(CO)3]+ is beyond the scope of this article and instead, it 
is referred to some excellent reviews on the general topic of 99mTc chelation chemistry (see e.g., [10]). 
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Figure 1. Representative examples of bifunctional chelating agents (BFCAs) for the 
complexation of the [99mTc(CO)3]+ core and conjugation to (bio)molecules. 
Radiolabeling of molecules of medicinal interest with [M(CO)3]+ is usually achieved by a post-labeling 
approach using bifunctional chelating agents (BFCAs). As the name implies, BFCAs enable both the 
covalent linkage to a (bio)molecule and the coordination of the radiometal. For many of the ligand 
systems reported for [M(CO)3]+, appropriately functionalized derivatives for conjugation to (bio)molecules 
via different functional groups (e.g., amines, carboxylates, thiols) have been reported [10]. However, 
the multifunctional character of both the ligand system and (in most cases) the (bio)molecule of 
interest can make a selective conjugation in solution a difficult endeavor. To overcome these 
problems, protective group strategies are often employed; though, such approaches usually result in 
multi-step reaction sequences, which can significantly lower the overall efficiency of the labeling 
procedure. 
Despite the success of the metal tricarbonyl cores in the field of radiopharmaceutical sciences, there 
is still a need for novel and innovative strategies for (bio)conjugation techniques and radiolabeling 
procedures in order to expedite the development of radiotracers based on [M(CO)3]+. In the following, 
this review will focus on such a recently developed approach that utilizes click chemistry in this context. 
2. Click Chemistry in Radiopharmaceutical Sciences
Click chemistry, a term minted by Sharpless [11] et al. in 2001, is an attempt to define the 
characteristics of a perfect (or nearly perfect) chemical reaction that generates structurally diverse new 
substances by joining small building blocks in a quick, selective, efficient, and reliable manner. The 
prime example of a click reaction within the click chemistry concept is the copper (Cu(I))-catalyzed 
azide-alkyne cycloaddition (CuAAC), reported at the same time by the groups of Sharpless and Meldal 
in 2002 [12,13]. The CuAAC proceeds efficiently and selectively under mild reaction conditions (e.g., 
in water at room temperature) in the presence of other functional groups, and provides a stable 1,4-
disubstituted 1,2,3-triazole heterocyclic linkage between the reaction partners. Not surprisingly, the 
attractive features of this click reaction have inspired numerous applications across different scientific 
disciplines [14–16], including examples of the development of radiotracers. 
The first examples on the use of the CuAAC in radiopharmaceutical sciences were published in 
2006. Kolb et al. [17] and Marik et al. [18] described the click reaction of [18F]fluorinated alkyne 
derivatives with azide acceptors, such as azido thymidine (AZT) and azide-functionalized peptides. 
These applications employ a two-step prosthetic group approach, which enables the efficient and 
selective 18F radiolabeling of molecules in aqueous media. For an overview on the CuAAC-mediated 
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radiolabeling of molecules with 18F- (and 11C-) radionuclides, it is herein referred to some of the 
several recent review articles on the topic [19,20]. 
Also in 2006, Mindt and Schibli et al. reported the first example of an application of the CuAAC to 
metallic radionuclides [21]. In their approach, the click reaction is employed to the synthesis of 
tridentate ligand systems for the stable complexation of [99mTc(CO)3]+ while conjugating them 
simultaneously to (bio)molecules. Unlike subsequently published applications of the CuAAC for the 
labeling of molecules with radiometals, their approach utilizes the 1,2,3-triazole not only as a mere 
linker to connect a molecule with a radiometal chelate (conjugate design), but makes use of the 
excellent coordination properties of the heterocycle as part of a functional ligand system in an 
integrated approach [22]. The broad applicability and efficiency of this 99mTc-radiolabeling strategy, in 
particular those provided by convenient one-pot procedures developed in the course of the work, 
prompted the authors to term their approach “Click-to-Chelate” [21]. This review summarizes original 
articles on the Click-to-Chelate concept published since 2006. Examples of applications of the 
CuAAC in which the 1,2,3-triazole is not part of a chelating system but just tethers a radiometal complex to 
various molecules are not included. Particular attention has been paid to examples of “clicked” 99mTc-
radiotracers, which describe biological evaluations in vitro and in vivo, as this is an important aspect 
for potential translation of the compounds into the clinic. 
3. Click-to-Chelate
As discussed in the introduction, the preparation of tridentate chelating systems (and BFCAs 
thereof) for the complexation of [M(CO)3]+ generally requires multi-step synthesis and their 
incorporation into (bio)molecules often lacks efficiency and selectivity due to cross-reactivity with 
other functional groups present. The chemical orthogonality of the CuAAC together with the ease of the 
introduction of alkyne and azide moieties into molecules by synthetic or biochemical methods [23–27] 
provides a solution to these shortcomings. Thus, the reaction of azide-functionalized compounds with 
alkyne prochelators provides 1,4-disubstituted 1,2,3-triazole-containing tridentate ligand systems 
(termed “regular click ligands”; Scheme 2A) [21]. Similarly, cycloaddition of alkyne derivatives with 
azide prochelators yields isomeric triazolyl products (referred to as “inverse click ligands”; Scheme 2B), 
which are set up to coordinate to [M(CO)3]+ via the nitrogen in position 2 of the triazole heterocycle, 
rather than the nitrogen in position 3 of “regular click ligands” (see below). Noteworthy, all ligand 
systems can be prepared without the use of protective groups in a single step, high yields, and under 
mild reaction conditions suitable for the functionalization of delicate biomolecules. Reaction of the 
tridentate chelators with [M(CO)3]+ gives structurally diverse organometallic complexes that differ in 
size, lipophilicity, and overall charge (Table 1). All these characteristics are important for fine-tuning 
the physicochemical properties of a radiotracer for its application in vivo. 
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Scheme 2. Schematic representation of the synthesis of regular (A) and inverse (B) 1,2,3-
triazolyl ligand systems for the complexation of the [M(CO)3]+ core. A and B represents 
various functional groups for coordination of the tricarbonyl core. 
The radiolabeling of regular click ligands (L; Table 1, entries 1–5) with [99mTc(CO)3]+ proceeds 
smoothly under standard reactions conditions (PBS, pH 7.4, 100 °C, 20–30 min) [21]. Quantitative 
formation of [99mTc(CO)3(L)] can be achieved at a ligand concentration in the micromolar range (10–5–10–6 
M), which is comparable to that of histidine (or Nτ-substituted histidines), one of the most efficient 
chelators for complexation of the 99mTc tricarbonyl core [28]. Particularly for receptor targeting 
radiopharmaceuticals, it is important that high specific activities can be achieved (e.g., by employing 
low ligand concentrations) in order to avoid interfering receptor saturation. On the other hand, quantitative 
radiolabeling of the 99mTc-tricarbonyl core with inverse click ligands (e.g., Table 1, entry 6; for additional 
examples see ref. [21]) requires a ligand concentration orders of magnitudes higher (10–3–10–2 M) than 
that of regular click ligands. This indicates a decreased efficiency of the inverse click ligand systems 
likely due to the lower electron density at N2 compared to that of N3 of the triazole heterocycle as 
shown by density functional theory (DFT) calculations [21]. 
Brans et al. have conjugated both variations of click ligands to the N-terminus of a tumor targeting 
bombesin (BBS) derivative (Scheme 3; see below for the relevance of BBS in nuclear oncology) [29]. 
Radiolabeling of the two peptides with [99mTc(CO)3]+ under standard conditions revealed a 
significantly lower radiolabeling yield for the peptide with the inverse click ligand (<60%) in 
comparison to the compound with the regular click ligand (>95%). Moreover, the 99mTc adduct of the 
inverse ligand system was found to be unstable and thus, not suitable for in vivo evaluation. Anderson 
et al. have reported a similar instability of a natRe-tricarbonyl based luminescent probe in which the 
metal is coordinated by the N2 nitrogen of triazole ligands [30]. Even though different metal 
complexes of 1,4-disubstituted 1,2,3-triazoles with coordination can be synthesized via the N2 [31], 
the low chelation efficiency combined with the modest stability of the complexes in biological media 
makes them unlikely to find biological or medical applications. It is therefore important that 1,2,3-
triazole-based metallic bioprobes are designed in a way that ensures coordination via the N3 of the 
heterocycle. 
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Table 1. Examples of prochelators, formation of tridentate triazolyl ligands by CuAAC 
with benzyl azide (entry 1–5) or 3-phenyl-1-propyne (entry 6), and complexes with 
[M(CO)3]+ thereof. 
Entry Prochelator Tridentate ligand (L) 1 Metal complex 2 
1 3
2 4
3 
4 
5 
6 3, 5
(1) Coordinating nitrogen of the 1,2,3-triazole heterocycle is indicated; (2) M = 99mTc, natRe; 
(3) commercial compounds; (4) prochelators derived from amino acids (R = amino acid 
specific side chain); (5) example of an inverse click ligand. 
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Scheme 3. Regular and inverse click ligands conjugated to the N-terminus of a bombesin 
derivative. Peptide = (ßAla)1–2[Cha13, Nle14]BBS(7–14); the N-terminal ßAla units serve 
as a spacer between the peptide and the metal chelate. 
It is common practice to identify 99mTc-complexes prepared on a no carrier added (n.c.a.) level by 
comparison with the corresponding non-radioactive natRe analogues by HPLC (γ-trace versus 
UV-trace; Scheme 4). In addition, the corresponding natRe-tricarbonyl complexes allow structural 
analysis by spectrometric and spectroscopic methods including IR, MS, and NMR. natRe analogues of 
99mTc-tricarbonyl complexes can be synthesized conveniently on a macroscopic scale by the reaction 
of the ligand system of interests with [Et4N]2[Re(CO)3(Br)3] [32] in alcohol or water according to 
published procedures. In all cases discussed above (and more examples have been reported in the 
meantime), the corresponding natRe-tricarbonyl complexes were prepared and fully characterized. In 
addition, more than half a dozen reported X-ray structures confirm the formation of fac-M(CO)3 
complexes by tridentate coordination of the triazolyl ligands as depicted in, e.g., Figure 1, Table 1, or 
Scheme 5B [33–36]. 
Scheme 4. Labeling of a representative example of a regular click ligand with 99mTc- and 
natRe-tricarbonyl for identification and characterization of the organometallic products. 
	ϡ
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Scheme 5. Extension of the Click-to-Chelate approach provides efficiently trifunctional 
(A), or tetrafunctional (B) conjugates. TMS = trimethylsilyl group. 
As pointed out above, a large number of non-radioactive natRe-tricarbonyl complexes have been 
reported for structural elucidation and identification of the analogous 99mTc complexes. Only recently 
have Wang et al. reported the first example of a chelate in which the 188Re-tricarbonyl core is 
coordinated by a click ligand (Figure 2) [37]. In their work, the efficiency of the complexation of 
[188Re(CO)3(H2O)3]Br with bis(pyridine-2-ylmethyl)amine (dpa) was compared with that of a regular 
click ligand. Even though dpa was shown to be the more efficient chelator, respectable radiolabeling 
yields (>80%) were achieved with the regular click ligand system. 
Figure 2. Fac-188Re-tricarbonyl complexes of dpa and a regular click ligand. 
ϣ
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4. One-Pot Click-to-Chelate Procedures
While the ligands described above, in particularly the regular click ligands, represent a class of 
excellent chelators for the complexation of [M(CO)3]+, the individual azide and alkyne substrates as 
well as the various additives required for CuAAC are poor ligands and do not form stable or defined 
complexes with the organometallic tricarbonyl core [21]. Exploitation of this observation led to the 
development of efficient procedures by which the synthesis of the ligand system, its conjugation to a 
molecule of interest, and the radiolabeling with [M(CO)3]+ can be achieved in a single pot without 
isolation and purification of intermediates. Thus, heating of an aqueous solution of azide substrates 
and alkyne prochelators in the presence of catalytic amounts of Cu(I) for 20–30 min at 100 °C 
followed by addition of [99mTc(CO)3]+ and a second heating step (Scheme 6A) provided cleanly the 
same 99mTc tricarbonyl labeled compounds in identical radiochemical yields and purity as obtained by 
the reaction of pre-synthesized and isolated triazolyl ligands with [99mTc(CO)3]+ (Scheme 6C). 
Remarkably, the same 99mTc-tricarbonyl complexes can be obtained in some instances by simply 
mixing all substrates with the generator eluent containing pertechnetate ([99mTcO4]–) in the presence of 
the IsoLink™ kit (Scheme 6B). In the meantime, a number of examples of successful one-pot, two-
step- or single-step procedures have been reported for different click-ligand systems (see below). In 
some cases, the reaction time of individual steps can be accelerated by microwave heating 
(unpublished results). Simplification of radiolabeling procedures as illustrated by the one-pot 
examples shown are of fundamental importance for facilitating the translation of novel labeling 
strategies into routine practice for clinical applications in nuclear medicine. 
Scheme 6. Example of one-pot, two-step (A) and one-pot, single-step (B) Click-to-
Chelate procedures yielding the same radiolabeled compounds as obtained by multi-step 
synthesis with pre-synthesized and isolated triazolyl ligand systems (C).  
5. Comparison of Click Ligands with Established Chelators for [M(CO)3]+
As true for any new ligand system designed for the formation of radiometal complexes for use in 
nuclear medicine, its performance should be scrutinized and compared with established systems in 
order to evaluate its general utility. For regular click ligands, this was accomplished by a direct 
side-by-side comparison in vitro and in vivo with two gold standard chelators for [99mTc(CO)3]+, 
namely Nτ-derivatised histidine (His) and Nα-acetylated His (Figure 3). Towards this goal, 
Mindt et al. [38] Brans et al. [29], and Zhang et al. [39] have applied the click-to-chelate approach to 
tumor targeting vectors of relevance in nuclear oncology and studied the biological characteristics of 
the 99mTc-labeled conjugates. 
Radiolabeled folic acid derivatives functionalized at the γ-position with a radiometal chelate have 
been shown to be promising candidates for the development of radiotracers specific for folate 
receptors (FR), which are overexpressed by tumors of the ovary, cervix, endometrium, lung, kidney, 
breast, colon, and brain [40]. Bombesin (BBS) is a peptide, which targets the gastrin-releasing peptide 
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receptor (GRP-r). BBS and derivatives thereof are interesting vectors for the development of tumor 
targeting agents because of the overexpression of the GRP-r by different tumor cells including 
prostate, breast, colon, and small-cell lung carcinomas [41]. Finally, the peptide KCCYSL, identified 
by phage display, is a small peptide specific for the ErbB-2 receptor, a member of the epidermal 
growth factor receptor family, which is overexpressed by breast and prostate carcinoma cells [39]. 
The comparative studies of the 99mTc-tricarbonyl labeled folate (Figure 3A), BBS, and ErbB-2-
targeting peptide derivatives (Figure 3B) clearly demonstrated the equivalence of the clicked ligand 
system versus the established Nτ-derivatized His and Nα-acetylated His chelators. Radiolabeling 
yields and purities achieved with the conjugates bearing a regular click ligand were equal to that of the 
conjugates equipped with the reference chelators, as were their blood serum stabilities, cell 
internalization properties, receptor affinities, and receptor specificities. Most importantly, the nature of 
the ligand system did not influence the biodistribution of the radioconjugates as determined by 
experiments in vivo with the corresponding mouse models. 
Also, Ferro-Flores et al. have compared a bombesin derivative, [Lys3]BBS(1–14), radiolabeled 
with [99mTc(CO)3]+ via a regular click ligand with an analogous compound radiolabeled with 
technetium(III) using the EDDA/HYNIC (ethylenediamine N,N'-diacetic acid/hydrazinonicotinamide) 
chelating system [42]. As expected, the 99mTc-tricarbonyl radiopeptide exhibited an increased 
lipophilicity and thus, higher hepatobiliary excretion than the EDDA/HYNIC derivative. The authors 
conclude that the BBS conjugate radiolabeled with the 99mTc-tricarbonyl core via a regular click ligand 
is nevertheless the more promising candidate for clinical development because, unlike in the case of 
HYNIC chelates [43], it consists of a structurally defined metal complex on a tracer level, an important 
prerequisite for the approval of new radiopharmaceuticals by regulatory authorities.  
It is important to note that Click-to-Chelate not only offers an efficient and convenient way for the 
introduction of a ligand system into (bio)molecules of interest and their radiolabeling with 
[99mTc(CO)3]+ but also reduces significantly the synthetic effort to obtain the corresponding precursors, 
e.g., alkyne prochelators (or BFCAs with respect to other ligand systems). This benefit of Click-to-Chelate 
may not be obvious in the case of the modification of peptides to which different entities, including 
various ligand systems, can conveniently conjugated to on solid support. However, the advantages of 
Click-to-Chelate become more apparent when applied to the synthetically more challenging situation 
of the selective modification of polyfunctional molecules in solution. For example, the synthesis of 
1,2,3-triazole-modified folic acid (Figure 3A) was achieved by Click-to-Chelate in eight synthetic 
steps with an overall yield of approx. 80% [38]. In comparison, the analogous 99mTc-tricarbonyl 
labeled folic acid derivative equipped with an Nτ-derivatized His chelator required ten synthetic steps 
and provided the final radiotracer in < 1% yield [44]. This example, as well as others discussed below, 
demonstrates the synthetic efficiency of the Click-to-Chelate strategy for the assembly of 99mTc 
tricarbonyl radiotracers. 
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Figure 3. Comparison of regular click ligands with established chelators for the labeling 
of tumor-seeking vectors with the 99mTc tricarbonyl core. (A) Folic acid conjugated to a 
Nτ-derivatized His chelator or a regular click ligand. (B) Two peptides functionalized 
with a NαAc His chelator or a regular click ligand. The ßAla and the GSG motifs are 
spacer units that separate the receptor targeting peptide from the chelate. 
6. Multifunctional Radioconjugates by Extended Click-to-Chelate
So far, the synthesis of tridentate 1,4-disubstituted 1,2,3 triazole-containing ligand systems and 
their simultaneous conjugation to molecules of interest by means of the CuAAC have been discussed. 
The Click-to-Chelate approach can be readily extended to the preparation of multifunctional 
99mTc-tricarbonyl radioconjugates by structural modifications of the prochelators employed. Mindt et al. 
have demonstrated the feasibility of such applications by two different approaches [34,36]. In a first 
strategy, a lysine-derived prochelator is employed to which various molecules of interest (R1) can be 
selectively conjugated to via the Nε-amine functionality by amide bond formation (Scheme 5A). 
CuAAC with a second, azide-functionalized molecule (R2) covalently links the two molecules via the 
formed regular click ligand. Thus, the final product combines a nuclear reporter probe (99mTc) with 
two different chemical (or biological) entities in a trifunctional conjugate. The strategy was 
successfully applied to the preparation of a 99mTc-labeled conjugate comprising a tumor targeting 
peptide sequence ([Cha13, Nle14]bombesin(7–14)) and a low molecular weight albumin binder, a 
pharmacological modifier to elongate the blood circulation time of the conjugate. Evaluation of the 
trifunctional conjugate in vitro and in vivo provided promising results for its use as a SPECT imaging 
agent for the visualization of GRP-r-positive tumors [34]. Recently, Kluba et al. have reported yet 
another application of this strategy by combining the 99mTc-tricarbonyl core with two moieties, each 
specific for an extra- and intracellular target, respectively [45]. The trifunctional conjugate was 
designed to target cancer cells by interaction of a BBS fragment (R2) with GRP-r and, after 
ϰ
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internalization, with mitochondria via an organelle-specific triphenylphosphonium moiety (R1). 
Adding a moiety specific for an intracellular target to a tumor targeting peptide conjugate could 
improve the cellular retention of radioactivity after its successful delivery to tumors and metastases 
and thus, improve the efficacy of radiopeptide conjugates. 
The second approach to multifunctional conjugates involves chelators containing two 1,4-disubtituted 
1,2,3-triazoles derived from the CuAAC of azides with a bis-alkyne precursor (Scheme 5B) [36]. The 
latter can be readily obtained by the stepwise Nα-alkylation of, e.g., glycine with propargyl bromide or 
silyl protected derivatives thereof. One molecule (R1) can be selectively linked to the glycine precursor 
by amide bond formation. The other two molecules (R2 and R3) are conjugated by sequential CuAAC, 
first with the terminal alkyne and, after removal of the silyl protective group, with the second alkyne 
functionality. Thus, this strategy provides access to overall tetrafunctional conjugates by joining three 
different chemical or biochemical moieties with the 99mTc-tricarbonyl core. The utility of the approach 
was demonstrated by the conjugation of a GRP-r targeting bombesin derivative with a related 
bis-triazole ligand system to which two carboxylates were linked to by the CuAAC [36]. The observed 
low renal uptake and retention of the conjugate in vivo suggests that the two appending carboxylates 
act as pharmacological modulators, which successfully masked the otherwise unfavorable positive 
charge of the conjugate as the result of the cationic metal chelate. 
An almost infinite number of possible combinations of different chemical or biological moieties 
with the 99mTc-tricarbonyl core can be envisioned by the extended Click-to-Chelate approach and 
potential applications to radiopharmaceutical development are galore. For example, the combination of 
tumor avid vectors with pharmacological modifiers could lead to the development of radiotracers with 
improved pharmacological profiles, whereas the use of additional imaging probes or therapeutic agents 
may lead to the design of multimodal conjugates or theranostics. The exploitation of the strategies 
described has just begun and it is possible that ongoing research efforts directed towards the 
combination of different entities with the 99mTc-tricarbonyl core will lead to the development of novel 
radiopharmaceuticals with improved properties for application in molecular imaging and/or 
receptor-mediated radionuclide therapy. 
7. Applications of Click-to-Chelate to Radiotracer Development
In the following section, various reported applications of Click-to-Chelate to the development of 
radiotracers will be summarized, some examples of which have been mentioned already in the text 
above (including an example of a vitamin, namely folic acid, vitamin B9) [38]. Compounds reported 
without preclinical in vitro and/or in vivo data were not included (e.g., “clicked” phospholipids) [21]. 
Click-to-Chelate has been successfully applied to the 99mTc-tricarbonyl labeling of different tumor 
avid peptides including derivatives of bombesin and the ErbB-2-targeting peptides (see above). In 
these studies, the general utility of “clicked” triazolyl ligand systems for applications to 99mTc-tricarbonyl 
labeled peptides and multifunctional radioconjugates was demonstrated. A further example has been 
reported by Kim et al. (Figure 4) who have labeled an epitope-mimicking peptide of the hepatocyte 
growth factor (HGF)-mesenchymal-epithelial transition factor (Met) molecular pathway, which affects 
cancer development at different stages [46]. In their work, the length of a spacer unit that separates the 
c-met binding peptide from the 99mTc-tricarbonyl chelate was investigated. They have shown that the 
modification of the peptide was readily accomplished by Click-to-Chelate providing radiopeptides of 
good stability and excellent binding affinity to the c-met receptor. Based on the in vitro evaluation of 
the radiopeptides investigated, a spacer unit consisting of three glycine units (n = 3) provided the most 
promising results. 
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Figure 4. Investigations of the effect of the length of the spacer between a 
clicked-99mTc-tricarbonyl chelate and the tumor targeting c-met binding peptide. 
Glucose is considered as a key molecule in metabolic evaluation of tumors due to the up-regulation 
of glycolysis, which results in an increased consumption of the carbohydrate in tumor tissue [47]. In 
the past, different strategies have been reported for the identification of a 99mTc labeled glucose 
derivative as a more readily available SPECT surrogate of the established PET tracer [18F]-2-fluoro-2-
deoxy-D-glucose (FDG) [48]. Fernández et al. have prepared a glucose derivative functionalized at the 
C2 position by the one-pot, 2-step Click-to-Chelate protocol (Figure 5) and studied its biodistribution 
in comparison to FDG in a lung carcinoma mouse model [49]. Reported tumor uptake in vivo of the 
radiotracer was moderate in comparison to FDG and likely due to passive diffusion of the hydrophilic 
compound. As in the case of other reported 99mTc/natRe-labeled glucose derivatives, specific uptake via 
the GLUT-1 receptor pathway could not be confirmed. 
Figure 5. A glucose derivative functionalized at the C2 position with a regular click 
ligand by the one-pot, 2-step Click-to-Chelate procedure. 
Click-to-Chelate has also been employed to the development of hypoxia imaging agents, which are 
important radiotracers for the assessment of the oxygenation status of tumors critical for determining 
the effectiveness of radiation therapy [50]. Fernández et al. have investigated the utility of bi- and 
tridentate click chelators for the 99mTc-tricarbonyl labeling of 5-nitro-imidazole derivatives prepared 
by one-pot Click-to-Chelate protocols (Figure 6) [51]. Evaluation of the compounds in vitro and 
in vivo revealed that the compound equipped with a tridentate chelator was superior in terms of blood 
serum stability, plasma protein binding, and tumor uptake. In addition, the “clicked” 5-nitro-imidazole 
outperformed other 99mTc-labeled hypoxia imaging agents previously investigated by the same group 
(e.g., 5-nitroimidazol labeled with 99mTc(V) nitrido- or 99mTc(III) [4+1] chelates). The authors 
conclude that the compound with a tridentate regular click ligand is so far their most promising 
candidate for the development of a 99mTc radiopharmaceutical for hypoxia tumor diagnosis. 
Ϡ
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Figure 6. Comparison of tri- and bidentate click chelators applied to the development of 
novel hypoxia radiotracers based on 5-nitro-imidazoles. 
Analogs of the nucleoside thymidine have the potential to be recognized as substrates by the human 
cytosolic thymidine kinase (hTK1). Since hTK1 is overexpressed in a wide variety of cancer cells, 
radiolabeled thymidine derivatives represent potential markers for cancer cell proliferation. Struthers 
et al. have reported the synthesis and in vitro evaluation of 99mTc-tricarbonyl labeled thymidine analogs 
in an effort to develop a radiotracer for SPECT more readily available compared to the currently used 
PET tracer 3-deoxy-3'-[18F]fluorothymidine (FLT) [35,52]. They prepared a set of 99mTc-tricarbonyl 
labeled thymidine derivatives in a combinatorial fashion by parallel one-pot Click-to-Chelate synthesis 
(Scheme 7; see Table 1, entry 1–5 for examples of alkyne precursors employed). The products obtained 
differ not only in the position of functionalization (C3' versus N3) but also with regards to the size and 
overall charge of the radiometal chelate. Substrate activity studies carried out by phosphorylation 
assays showed that substrate recognition by hTK1 is dependent on both, the site of functionalization of 
thymidine as well as the charge of the 99mTccomplex. In general, C3'-functionalized compounds were 
the better substrates for hTK1 and a preference for neutral or anionic complexes was demonstrated. 
This elegant work has led to the identification of the first metal containing hTK1substrates. 
Scheme 7. Synthesis of thymidine analogs functionalized with regular click ligands at the 
C3' or N3 position developed as substrates for hTK1. dT = deoxythymidine; A and B 
represent functional groups for coordination of the 99mTc-ricarbonyl core. 
Seridi et al. [53] and Hassanzadeh et al. [54,55] have used CuAAC in the development of brain 
radiotracers. They describe the conjugation of bi- and tridentate regular click ligands to 
1-(2-methoxyphenyl)piperazine (MPP), a pharmacophore frequently found in imaging agents selective 
for 5-HT1A, a receptor subtype for the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT; Figure 7). 
The radiotracers exhibited favorable low protein binding, good blood serum stability, and a 
lipophilicity suitable to cross the blood-brain barrier (BBB). The compound functionalized with a 
tridentate click ligand was labeled with [99mTc(CO)3]+ and evaluated in vitro and in vivo. Receptor 
saturation experiments performed with homogenated hippocampus membranes of rats revealed a high 
receptor affinity (KD) of the compound in the single-digit nanomolar range. In vivo experiments with 
rats indicated a specific uptake of the radiotracer in the brain, being highest in the hippocampus. Both 
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groups conclude that the 99mTc-labeled MPP derivatives have suitable characteristics for use as central 
nervous system (CNS) receptor specific imaging agents. 
Figure 7. Bi- and tridentate clicked ligands conjugated to MPP for the development of 
CNS imaging agents. 
Finally, implementation of Click-to-Chelate to steroid-based radiotracers is discussed (Figure 8). 
Dhyani et al. have investigated 99mTc-tricarbonyl-labeled derivatives of 11ß-progesterone and 
17α-testosterone for targeting progesterone (PR) and androgen receptors (AR), which are overexpressed 
in breast and prostate cancer, respectively [56,57]. The compatibility of the site of functionalization of 
the steroids with regards to biological function as well as stereochemical considerations were taken 
into account for the design of the radiotracers. While the synthesis of the compounds was 
straightforward and the stability of the radiometal complexes in biological media was excellent, 
experiments in vivo using Swiss mice or Wistar rats did not reveal specificities towards the 
corresponding receptors. These findings may be the result of the bulkiness of the 99mTc chelate in 
comparison to the steroid vector, which could interfere with the interaction of the compound with its 
binding site. 
Burai et al. have reported the 99mTc-tricarbonyl labeling of tetrahydro-3H-cyclopenta[c]quinoline, 
the structural design of which was inspired by estrogen steroids (Figure 8) [58]. Derivatives of the 
parent compound are specific agonists/antagonists of the recently identified G protein-coupled 
estrogen receptor (GPER), but not the estrogen ERα/ß receptors. GPERs are involved in tumor 
signaling pathways and have shown promising properties as putatively important biomarkers or 
therapeutic targets in oncology. Again, receptor specificity of the vector was lost upon functionalization 
with the radiometal chelate as shown by in vitro assays measuring intracellular calcium 
immobilization or PI3K activation. In the same work, a series of other 99mTc-labeled derivatives of the 
parent compound was investigated of which some, particularly those with a spacer moiety between the 
radiometal chelate and the vector, showed retained activities as GPER agonists/antagonists. 
Surprisingly, in none of the “clicked” steroid examples discussed above, the effect of a spacer unit 
between the receptor specific vector and the radiometal chelate has been investigated. 
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Figure 8. Examples of steroids or analogs thereof radiolabeled with the 99mTc-tricarbonyl 
core by Click-to-Chelate. 
8. Summary and Perspectives
Since first reported in 2006, the Click-to-Chelate approach has found numerous applications for the 
development of radiopharmaceuticals based on the 99mTc-tricarbonyl core. Examples include 
organometallic radiotracers with potential for applications in nuclear medicine ranging from peptides, 
vitamins, carbohydrates, steroids to hypoxia imaging agents, substrates for tumor-associated enzymes 
(e.g., hTK1), and CNS imaging probes. Thus, Click-to-Chelate has had a demonstrated impact on the 
community involved in radiopharmaceutical sciences.  
The majority of applications discussed in this review employ propargyl glycine (Table 1, entry 1) 
as an alkyne prochelator. This is likely due to its commercial availability and demonstrated 
equivalency of the resulting tridentate triazolyl ligand system to Nτ-functionalized His. However, 
other alkyne derivatives (e.g., readily accessible Nα-propargylated amino acid derivatives; Table 1, 
entry 2) also hold great promise for future applications, especially in terms of the development of 
multifunctional radioconjugates. 
Meanwhile, new and innovative approaches have been described, which expand the portfolio of 
click chemistry applications in radiopharmaceutical sciences and eventually in nuclear medicine. With 
respect to radionuclides of technetium and rhenium, the CuAAC has been employed to BFCAs 
suitable for the complexation of oxo-technetium species [59], the development of a “click-to-cyclize 
and chelate” strategy for the cyclization of peptides and their radiolabeling [60], and pre-labeling strategies 
[61] for the labeling of molecules with pre-formed radiometal complexes. The CuAAC technique has 
also been applied to the preparation of multiple imaging probes derived from the same precursor for a 
direct comparison of different imaging probes as well imaging modalities [62]. In addition, copper-
free click reactions [63] have become increasingly popular for the development of radiotracers [64–69] 
including examples of pre-targeting approaches [70].  
Click chemistry, in particular the CuAAC reaction, has demonstrated its high potential for the 
development of radiotracers. However, there are ample opportunities left for new innovations to be 
reported in the future and first clinical applications of “clicked” probes are being awaited. Among the 
Ϡ ϟ
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many potential applications of click reactions in radiopharmaceutical sciences, Click-to-Chelate will 
continue to play an important role for the radiolabeling of molecules with the technetium- and 
rhenium-tricarbonyl cores. 
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metastases. However, after internalization of the radiopeptide into cancer cells and tumors, a 
rapid washout of a substantial fraction of the delivered radioactivity is often observed. This 
phenomenon may represent a limitation of radiopeptides for clinical applications. Here, we 
report the synthesis, radiolabeling, stability, and in vitro evaluation of a novel, dual-targeting 
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membrane receptor-specific peptide, and a second targeting entity directed towards 
mitochondria. While the specificity of the first generation of dual-targeting conjugates 
towards its extracellular target was demonstrated, intracellular targeting could not be 
confirmed probably due to non-specific binding or hindered passage through the membrane of 
the organelle. The work presented describes a novel approach with potential to improve the 
efficacy of radiopharmaceuticals by enhancing the intracellular retention of radioactivity. 
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Radiolabeled regulatory peptides are useful tools in nuclear medicine for the diagnosis (imaging) and
therapy of cancer. The specificity of the peptides towards GPC receptors, which are overexpressed by
cancer cells, and their favorable pharmacokinetic profile make them ideal vectors to transport conjugated
radionuclides to tumors and metastases. However, after internalization of the radiopeptide into cancer
cells and tumors, a rapid washout of a substantial fraction of the delivered radioactivity is often observed.
This phenomenon may represent a limitation of radiopeptides for clinical applications. Here, we report the
synthesis, radiolabeling, stability, and in vitro evaluation of a novel, dual-targeting peptide radioconjugate
designed to enhance the cellular retention of radioactivity. The described trifunctional conjugate is
comprised of a Tc-99m SPECT reporter probe, a cell membrane receptor-specific peptide, and a second
targeting entity directed towards mitochondria. While the specificity of the first generation of dual-
targeting conjugates towards its extracellular target was demonstrated, intracellular targeting could not be
confirmed probably due to non-specific binding or hindered passage through the membrane of the
organelle. The work presented describes a novel approach with potential to improve the efficacy of
radiopharmaceuticals by enhancing the intracellular retention of radioactivity.
Introduction
Conjugation of radionuclides to tumor-targeting peptides enables
their application for the diagnosis (using gamma- or positron-
emitting nuclides) and therapy (employing beta- or alpha-particle
emitters) of cancer. In particular, radiometal-labeled regulatory
peptides, which target G-protein-coupled receptors (GPCRs)
overexpressed in different cancers, have been a focus of radio-
pharmaceutical and nuclear medicinal research over the past
decade. As a result, some radiometal-labeled peptides have
found routine application in the clinic (e.g., somatostatin deriva-
tives for the management of neuroendocrine tumors), while
other promising candidates are currently the subject of preclini-
cal evaluation or have recently advanced to clinical trials.1–4
Radiolabeled regulatory peptides internalize into tumor cells
by GPCR-mediated endocytosis. A potential drawback of a
number of reported radiopeptides is represented by a rapid
washout of a substantial fraction of the intracellular radioactivity
from cancer cells (in vitro) and tumors (in vivo). In some
instances, the in vitro externalization of radioactivity from cancer
cells occurs at a rate comparable to the internalization.5–8 Also, a
significant washout of radioactivity from tumors over time is
often observed in vivo.6,9–11 This phenomenon can render the
initial efforts of delivering specifically radioactive nuclides to
cancer cells and tumors in part futile. The mechanism by which
the radioactivity is externalized from cancer cells and tumors is
yet not fully understood and can vary depending on, e.g., the
peptide carrier or the composition of the radioconjugate
employed. For example, cellular washout of radioactivity in the
form of metabolic degradation products has been reported for
radiometal-labeled derivatives of bombesin and minigastrins.12,13
On the other hand, the externalization of intact radiometal conju-
gates has been observed for somatostatin and exendin-4 deriva-
tives.7,9,11 Regardless of the metabolic fate of the tumor-
targeting peptide vector, it is generally accepted that the efficacy
of radioconjugates correlates with a high rate of internalization
into, and a low rate of externalization from targeted tissue.
We herein wish to report our efforts to combine tumor-
targeting radiolabeled peptides with a second moiety which
targets intracellular components. We hypothesized that such an
additional moiety (e.g., directed against intracellular proteins,
enzymes, or cell compartments) of the resulting dual-targeting
radioconjugates will decrease the externalization rate of radio-
activity from cancer cells and tumors independent of the vector
used. An increased retention time of the delivered radioactivity
within tumors holds the promise to improve the signal-to-back-
ground ratio important for diagnostic (imaging) applications and
†Electronic supplementary information (ESI) available. See DOI:
10.1039/c2ob26127h
University of Basel Hospital, Department of Radiology and Nuclear
Medicine, Division of Radiological Chemistry, Petersgraben 4,
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to enhance the efficacy of therapeutic radionuclides as a result of
the increased energy deposited in cancerous tissue.
In recent years, new approaches for the development of radio-
pharmaceuticals have emerged, which aim at the combination of
the tumor-targeting properties of radiolabeled peptides with
other entities of interest. Reported examples include the combi-
nation of radiopeptides with pharmacological modifiers to
improve their pharmacokinetic and/or –dynamic charac-
teristics14–16 or therapeutic efficacy,7,17–19 optical dyes for the
design of dual-modal imaging probes for high sensitivity and
high resolution imaging,20,21 and therapeutic agents22 for the
development of theranostics.23 The potential of multifunctional
radioconjugates, which exploit the individual properties of com-
ponents or synergistic effects thereof, respectively, for appli-
cations in nuclear medicine is intriguing, however, their
synthesis can be challenging.
We have previously reported a modular synthetic approach
which employs the Cu(I)-catalyzed alkyne–azide cycloaddition
(CuAAC; click chemistry)24,25 for the efficient preparation of
multifunctional radioconjugates.14,26 In this approach, an N(α)-
propargyl derivative of the amino acid lysine functions as the
center piece of the final conjugate by providing the means for
conjugation of two different chemical/biological moieties by
selective amide bond formation and CuAAC (Fig. 1). In
addition, the N(α)-propargyl lysine derivative is a prochelator
which forms, after formation of the 1,2,3-triazole by CuAAC, a
tridentate ligand system for the stable complexation of the
99mTc-tricarbonyl core suitable for imaging by single photon
emission computed tomography (SPECT).27,28 The diagnostic
isotope technetium-99m forms a “matched pair” with chemically
related therapeutic β−-particle emitters rhenium-186/188 and,
therefore, the chemistry developed has the potential to be used
for the development of radioconjugates for both diagnostic and
therapeutic applications in nuclear medicine.29
We set out to investigate the use of the “click chemistry” strat-
egy for the assembly of trifunctional conjugates made up of a
99mTc-tricarbonyl reporter probe for SPECT, a tumor-targeting
peptide, and an additional entity specific for an intracellular
target, e.g., a cellular compartment. For the first generation of the
proposed dual-targeting radioconjugates, we selected a reported,
stabilized variation of the minimal binding sequence of bombe-
sin (BBS), [Nle14]BBS(7–14),12 as an extracellular tumor-target-
ing component. BBS is a regulatory peptide that targets the
gastrin-releasing peptide (GRP) receptor, which is overexpressed
by various cancer cell types including prostate, breast, and
small-cell lung cancer.30 The potential of derivatives of [Nle14]-
BBS(7–14) radiolabeled with the 99mTc(CO)3 core for cancer
imaging has been demonstrated in vitro and in vivo.12,15,28 Based
on literature precedence, we introduced a spacer made of mul-
tiple β-alanine units to separate the tumor-targeting peptide from
other parts of the conjugate in order to minimize potentially
unfavorable interferences.10,12 As an intracellular target, we
chose the organelle mitochondria. It has been shown that lipo-
philic, cationic species such as triphenylphosphonium (TPP)
moieties can be driven electrophoretically through negatively
charged transmembranes, resulting in an accumulation of the
compounds inside the energized mitochondria of cells. TPPs
have been used as a drug delivery system for the transport of
therapeutic agents to the mitochondria.31 Also, radioactive
labeled TPP derivatives have been studied for myocardial
imaging and tumor imaging.32
The combination of receptor-targeting radiopeptides with moi-
eties specific for the cell nucleus (e.g., DNA intercalator or cell
penetrating peptides) has been reported to exploit potentially the
therapeutic effect of short-range Auger electron-emitting radio-
nuclides, however with varying degrees of success.7,19 The use
of mitochondria-specific entities (e.g., TPPs) for improving the
intracellular retention of radioactivity after selective delivery by
tumor-avid peptides has yet not been described in the context of
dual-targeting radioconjugates.
Results and discussion
Scheme 1 outlines the synthesis of building blocks required for
the assembly of trifunctional conjugates. The preparation of the
Fig. 1 Assembly of trifunctional conjugates by selective amide bond
formation, CuAAC (click chemistry), and (radio)metal complexation;
residues R1 and R2 represent two different moieties of biological func-
tion to be combined in the final (radio)metal conjugate.
Scheme 1 Synthesis of building blocks. (a) SPPS: (i) piperidine (20%)
in DMF; TBTU–HOBt (4 equiv.), (ii) Fmoc-amino acids or azidoacetic
acid (3 equiv.), HATU (3 equiv.); (b) see ref. 14; (c) toluene, reflux, 5 h.
This journal is © The Royal Society of Chemistry 2012
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tumor targeting peptide [Nle14]BBS(7–14), its N-terminal
elongation with three β-Ala units, and azidoacetic acid was
accomplished by standard solid phase peptide synthesis (SPPS)
yielding protected azide-functionalized peptide 1 on the resin
(Scheme 1A; see the Experimental section for details). The
central piece of the trifunctional conjugate, N(α)Boc-N(α)propar-
gyl lysine 3, was prepared from commercial BocLysOMe (2) in
five steps as previously described (Scheme 1B).14 An appropri-
ately functionalized mitochondria-targeting entity, 3-tris(p-
methoxyphenyl)-phosphonium propionic acid 6, was synthesized
by the reaction of tris(p-methoxyphenyl)phosphine (4) with
3-bromo-propionic acid (5; Scheme 1C).33
The assembly of the trifunctional conjugate started with the
coupling of TPP derivative 6 to the N(ε)-amine of the side chain
of Lys-derivative 3 followed by TFA-mediated removal of the
N(α)Boc protective group (Scheme 2). The resulting intermedi-
ate 7 was then reacted with protected, azide-functionalized
peptide 1 by CuAAC on a solid support. After cleavage from the
resin and deprotection, conjugate 9 was purified by preparative
HPLC and its structure was confirmed by mass spectrometric
analysis (Table 2). To study the effect of the mitochondria-target-
ing TPP moiety, we also synthesized reference compound 10
from intermediate 814 by the same synthetic pathway (see the
Experimental part for details). Compound 10 is identical to con-
jugate 9 in all respects but lacks the TPP moiety at the N(ε)-
amine of the Lys residue (replaced by an acetate group).
Both peptide conjugates 9 and 10 were readily radiolabeled
with [99mTc(CO)3(H2O)3]
+ within 30 min at 100 °C, providing
the desired radiopeptides [99mTc(CO)3(L)] (L = 9, 10) in >95%
radiochemical yield and purity. The radioconjugates were
obtained with a specific activity of up to 17.4 GBq μmol−1 (not
optimized). In the case of methyl ester 10, ester hydrolysis and
labeling with 99mTc-tricarbonyl occurred simultaneously under
the reaction conditions applied.14 For characterization purposes,
the corresponding non-radioactive rhenium tricarbonyl com-
plexes [Re(CO)3(L)] (L = 9, 10) were prepared by the reaction of
conjugates 9 and 10 with [Re(CO)3Br3][Et4N]2
34 for 60 min at
100 °C and analyzed by mass spectrometry. The identity of
[99mTc(CO)3(L)] (L = 9, 10) was confirmed in each case by com-
parison of the γ-HPLC trace with the UV trace of the corres-
ponding rhenium complexes [Re(CO)3(L)] (L = 9, 10), a
procedure which is common practice with 99mTc complexes on
an n.c.a. (no carrier added) level (Fig. 2).
The stability of the radiolabeled peptides was evaluated in
different media at 37 °C. Both [99mTc(CO)3(L)] (L = 9, 10) were
stable (>95% as determined by HPLC) in PBS (pH 7.4), NaCl
(0.9%), and in a cell culture medium (1% FBS) for >4 h, the
period of time required for the in vitro experiments described
below (see the Experimental part for details). We also verified
the stability of the Tc-99m complexes in a ligand challenge
experiment.35 Thus, [99mTc(CO)3(L)] (L = 9, 10) were incubated
at 37 °C in PBS containing a 4500-fold excess of histidine, an
excellent tridentate chelator for complexation of the Tc-99m
tricarbonyl core. No transmetallation was observed over a period
of 24 h, therefore demonstrating the suitability of the employed
Lys-based chelator unit of the conjugates.
Scheme 2 Assembly of dual targeting radiopeptide conjugates. (a) For
7: 6, SOCl2, CH2Cl2, rt overnight; then 3 and Et3N, −78 °C, 4 h; for 8:
see ref. 14; (b) CH2Cl2–TFA (3 : 1), rt overnight; (c) DIPEA, [Cu-
(CH3CN)4]PF6, TBTA, DMF, rt overnight; (d) trifluoroacetic acid,
phenol, water, triisopropylsilane (87.5/5/5/2.5%), 2 h, rt; (e) for M = Tc-
99m: 0.1 mM of 9 or 10 in water, [99mTc(CO)3(H2O)3]
+ (100–
250 MBq), 100 °C, 30 min; for Re complexes: 0.4 mM of 9 or 10 in
water, [Re(CO)3Br3][Et4N]2 (1.5 equiv.), 100 °C, 60 min.
Fig. 2 HPLC chromatographs of peptide precursor 9 (UV-trace A), the
corresponding metal conjugates [Re(CO)3(9)] (UV-trace B), and [
99mTc-
(CO)3(9)] (γ-trace C). The small difference of retention times between
[Re(CO)3(9)] and [
99mTc(CO)3(9)] (traces B and C) is due to the serial
arrangement of the UV- and γ-detectors.
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We next investigated in vitro the receptor affinity as well as
internalization and externalization characteristics of the conju-
gates [99mTc(CO)3(L)] (L = 9, 10) using PC-3 cells (n = 3–4 in
triplicate). The binding affinity of the bombesin derivatives
towards GRP-receptors was determined by receptor saturation
binding experiments employing increasing amounts of the radio-
conjugates (Fig. 3). Non-specific receptor binding was assessed
by using an excess of natural bombesin BBS(1–14). Reference
peptide [99mTc(CO)3(10)] displayed a dissociation constant (Kd)
of 5.6 ± 0.8 nM. In comparison, dual-targeting [99mTc(CO)3(9)]
exhibited a decreased receptor binding affinity with a Kd of
41.6 ± 5.8 nM. Values of dissociation constants in the single- to
lower double-digit nanomolar range are usually reported for
radiolabeled regulatory peptides.
Despite the differences in receptor binding affinities, we
observed that both radioconjugates internalized into PC-3 cells
to the same extent and at a comparable rate (approx. 25% of the
applied radioactivity within 30–90 min; Fig. 4). These results are
comparable with those reported for related BBS derivatives
labeled with the 99mTc-tricarbonyl core.15 In comparison to refer-
ence compound [99mTc(CO)3(10)], [
99mTc(CO)3(9)] exhibited
some degree of non-specific internalization as determined by
blocking experiments using a 1000-fold excess of natural
bombesin BBS(1–14). Albeit not ideal, low levels of non-
specific binding and internalization have been described for a
number of receptor-specific radiotracers, some of which have
advanced to the stage of preclinical or clinical investigations
nevertheless.11,36 In the case reported herein, however, the
lipophilicity introduced by the TPP moiety and/or the 99mTc-
(CO)3 core could also be in part responsible for the observed
non-specific binding and internalization of the trifunctional
conjugate.
Determination of the log D of peptide precursors 9 and 10,
and the corresponding metal conjugates by HPLC indeed
revealed increased lipophilicities for TPP-containing peptide 9
and, more pronounced, its metal-labeled analogues [M(CO)3(L)]
(M = 99mTc, Re; L = 9) (Table 1, n = 3). While some non-
specific binding and internalization of a peptidic radiotracer is
not necessarily a criterion for exclusion from further develop-
ments, one has to critically acknowledge that an increased lipo-
philicity can result in an unfavorable biodistribution. On the
other hand, it is known that the lipophilicity of a radiopeptide
can be adjusted by the attachment of polar groups (e.g., by pegy-
lation or glycosylation), or the use of charged and/or polar
linkers.16,37
Experiments performed with radiopeptides [99mTc(CO)3(L)]
(L = 9, 10) showed, undesirably, a very similar externalization
pattern for both conjugates, resulting in a washout of ca. 50% of
intracellular radioactivity after 90 min, approximately the same
time required for specific internalization of the radioconjugates
into GRP-receptor expressing PC-3 cells (Fig. 5).
Fig. 3 Receptor saturation binding experiments of radiometal conju-
gates using GRP-receptor expressing PC-3 cells; normalized to 106 cells
per well; specific binding of [99mTc(CO)3(10)] (●, dotted line) and
[99mTc(CO)3(9)] (▲, continuous line); Kd values were determined by
nonlinear regression.
Table 2 Yields and analytical data of synthesized peptides
Compound Molecular formula Yield (isolated) Calcd MW (g mol
−1) MALDI-MS m/z Purity (HPLC)
9 C88H123N21O19P 25.9% 1808.90 [M]
+: 1808.86 98.6%
10 C67H103N21O16 23.4% 1457.79 [M + H]
+: 1459.2, [M + 2H]2+: 730.2 97.6%
Fig. 4 Internalization of radiometal conjugates in GRP-receptor
expressing PC-3 cells; normalized to 106 cells per well; total binding of
[99mTc(CO)3(10)] (○, dotted line) and [
99mTc(CO)3(9)] (Δ, continuous
line); non-specific binding as determined by blocking experiments in the
presence of excess natural BBS: [99mTc(CO)3(10)] (●, dotted line) and
[99mTc(CO)3(9)] (▲, continuous line).
Table 1 Log D of peptides and (radio)metal-labeled analogues
determined by HPLC
Compound Log D
9 1.23 (±0.04)
[Re(CO)3(9)] 3.01 (±0.01)
[99mTc(CO)3(9)] 3.11 (±0.02)
10 0.51 (±0.06)
[Re(CO)3(10)] 0.80 (±0.07)
[99mTc(CO)3(10)] 0.78 (±0.01)
This journal is © The Royal Society of Chemistry 2012
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Puzzled by the results obtained from these experiments we
resorted to investigating in more detail the binding of the radio-
conjugates to mitochondria. Subcellular fractionation following
internalization experiments did not reveal a statistically signifi-
cant accumulation of the dual-targeting conjugate [99mTc-
(CO)3(9)] in the target organelle (data not shown). To simplify
the experimental set-up, additional tests were conducted with
mitochondria isolated from PC-3 cells (see the Experimental
part). In brief, [99mTc(CO)3(L)] (L = 9, 10; 11.5 kBq and
15.3 kBq, respectively; 5 pmol of peptide) were incubated with
mitochondria (1 μg protein per mL) for 30–120 min (Fig. 6;
n = 4 for all experiments described henceforth). In these experi-
ments, the multifunctional conjugate [99mTc(CO)3(9)] exhibited
a steady and statistically significantly enhanced binding to mito-
chondria (10.15 ± 1.41%) in comparison to reference compound
[99mTc(CO)3(10)] (1.98 ± 0.16%; unpaired t-test; p < 0.0001).
To the best of our knowledge these data represent the first report
of quantification of the binding of a radiotracer to isolated
mitochondria.
In a further effort to verify the specificity of [99mTc(CO)3(9)]
towards mitochondria, we performed experiments following pro-
cedures described by Murphy et al. and others,38–40 in which
isolated mitochondria are pretreated with established reagents
that either disrupt the transmembrane potential of the organelle
(sodium azide (NaN3) or carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP)) or enhance it (succinate), respectively.
In all cases, the binding of [99mTc(CO)3(9)] to mitochondria was
not influenced by the presence of the additive (Fig. 6). It is there-
fore possible that the binding of [99mTc(CO)3(9)] to mitochon-
dria described above is not driven by the transmembrane
potential of the organelle but may be the result of non-specific
binding. Alternatively, the ability of TPPs to shuttle conjugated
cargo into mitochondria can vary depending on the composition
of the conjugate. For instance, examples for successful and
unsuccessful mitochondria-targeting of TPP moieties conjugated
to (not receptor specific) peptides have both been reported.38,41
Thus, it is also feasible that the passage of [99mTc(CO)3(9)]
through the membrane of mitochondria is hindered and therefore
interfered with the intracellular targeting. Distinction of the two
possible processes, which could impede the specific accumu-
lation of the dual-targeting radioconjugate in mitochondria, may
be challenging and requires further investigations. In the mean-
time, we are examining a second generation of dual-targeting
radioconjugates, which target cytosolic proteins instead of orga-
nelles and therefore do not require trafficking through intracellu-
lar membranes. By simplifying the intracellular targeting system
we expect to gain more insights into the structural requirements
of a dual-targeting radioconjugate leading to an improved reten-
tion of radioactivity in cancer cells and tumors.
Experimental
CAUTION: 99mTc is a γ-emitter (140 keV) with a half-life of
6.01 h. All reactions involving 99mTc were performed in a labo-
ratory approved for the handling of radionuclides and appropriate
safety procedures were followed at all times to prevent
contamination.
General procedures
Fmoc-amino acids, Rink Amide MBHA LL resin
(100–200 mesh), HOBt, HATU, and TBTU were purchased
from Merck Biosciences (Nottingham, UK). Bombesin (1–14)
trifluoroacetate and BocLysOMe were purchased from Bachem
(Bubendorf, Switzerland). Solvents and all other chemicals
were purchased from Acros Organics (Geel, Belgium), Merck
(Darmstadt, Germany), or Sigma Aldrich (Buchs, Switzerland)
and used as supplied unless stated otherwise. Polypropylene
syringes for manual peptide couplings, fitted with polypropylene
frits and a polypropylene plunger, were obtained from MultiSyn-
tech (Witten, Germany) and Teflon taps from Biotage (Uppsala,
Sweden). Na[99mTcO4] was eluted from a Mallinckrodt
99Mo/99mTc generator (Tyco Healthcare, Petten, The Nether-
lands) using 0.9% saline. The precursor [99mTc(CO)3(H2O)3]
+
was prepared by using the IsoLinkTM kit (Mallinckrodt-Tyco,
Fig. 6 Accumulation of radiometal conjugates in mitochondria.
[99mTc(CO)3(9)] (white bars) and [
99mTc(CO)3(10)] (black bar) without
additives, and [99mTc(CO)3(9)] in the presence of succinate (10 mM),
FCCP (0.5 μM), or sodium azide (20 mM).
Fig. 5 Externalization of radioactivity from GRP-receptor expressing
PC-3 cells. Externalization of the total internalized fraction at t = 0
(100%) of radiotracers: [99mTc(CO)3(10)] (●, dotted line) and [
99mTc-
(CO)3(9)] (▲, continuous line).
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Petten, The Netherlands). Column chromatography was carried
out using silica gel C60 (particle size 0.04–0.063 mm) (Sigma)
and TLC was performed on precoated silica gel plates (0.25 mm,
60F254, Merck). 1H-, 13C- and 31P-NMR spectra were recorded
on a Bruker DPX 400 instrument. Chemical shifts are reported
in parts per million (ppm) relative to tetramethylsilane
(0.00 ppm) and coupling constants (J) in hertz (Hz). Standard
abbreviations indicating multiplicity are singlet (s), doublet (d),
doublet of doublets (dd), triplet (t), and multiplet (m). Analytical
and preparative HPLC were carried out with systems from Bis-
choff Chromatography, equipped with a λ-1010 UV/Vis and an
LB509 radioflow detector (Berthold Technologies), using C18
reversed-phase columns (Macherey Nagel Nucleodur C18 ISIS,
5 μm, 250 × 4.6 mm (column A) or Phenomenex Jupiter 4u
Proteo 90 Å, 4 μm, 250 × 4.6 mm (column B) for analysis and
Macherey Nagel Nucleodur C18 ISIS, 5 μm, 250 × 16 mm
(column C) or Nucleosil 100-5 C18, 5 μm, 250 × 21.0 mm
(column D) for purifications). HPLC solvents were 0.1% TFA in
H2O (A) and MeCN (B). Quality control of (radio)metal labeled
peptides was performed using column B and a linear gradient
from 80% to 30% A in 15 min (flow: 1.5 mL min−1); peptide
purification was performed using column C and a linear gradient
from 70% to 50% A in 15 min (flow: 8 mL min−1); purification
of compound 7 was done using column D and a linear gradient
from 55% to 35% A in 20 min (flow: 10 mL min−1). Log
D measurements were performed using column A and an
isocratic gradient 25% phosphate buffer (pH 7.4) and 75%
methanol (run time: 15–40 min; flow: 1 mL min−1). LRMS ana-
lyses were performed on a 4800 MALDI TOF/TOF™ analyzer
(Applied Biosystems) or on an ESI Bruker Esquire 3000 plus.
HRMS analyses were performed by LC-ESI on an LTQ Orbitrap
XL mass spectrometer (Thermo Scientific). Quantitative γ-count-
ing was performed on a COBRA II auto-gamma system (Model
5003; Packard Instruments).
Solid phase synthesis
Automated solid-phase peptide synthesis (SPPS; scale:
0.1–0.25 mmol) was run on a Pioneer synthesizer (Applied Bio-
systems) using standard Fmoc chemistry with TBTU–HOBt as
coupling reagents and 20% piperidine in DMF as the deprotec-
tion reagent. The elongation was carried out using a 4-fold
excess of protected amino acids and coupling reagents. For
manual solid phase peptide synthesis, Fmoc-protected amino
acids or azidoacetic acid (3 equiv.) were coupled onto the resin
(scale: 0.03–0.1 mmol) in a syringe fitted with a polypropylene
frit and a Teflon tap in the presence of HATU (3 equiv.) and
DIPEA (5 equiv.) in DMF for 2 h. The completion of the reac-
tion was verified by the Kaiser test and repeated if necessary.
Elongation yields were determined by the UV-absorption of the
fluorenylmethylpiperidine adduct after treatment of the resin
with 5 mL of a 20% piperidine–DMF solution (3 × 3 min).
CuAAC on a solid support was carried out under argon in
oxygen-free solvents by a modified procedure reported for
CuAAC in solution.42 In brief, the resin (loaded with 0.03 mmol
peptide) was swollen several times in degassed DMF (5 mL).
The solvent was drained off thoroughly and a solution of lysine
derivatives 7 or 8 (0.06 mmol) and DIPEA (0.03 mmol) in
degassed DMF (2–3 mL) were added to the resin. To the suspen-
sion was added tetrakis(acetonitrile)copper(I) hexafluorophos-
phate ([Cu(CH3CN)4]PF6) (0.015 mmol), tris[(1-benzyl-1H-
1,2,3-triazol-4-yl)methyl]amine (TBTA) (0.015 mmol) and the
mixture was vigorously shaken at rt overnight. The resin was
washed with DMF and a solution of diethyldithiocarbamate
(0.5% in DMF) to remove the remaining copper species. The
completion of the reaction was verified by a colorimetric test for
solid-supported azides.43 The peptides were cleaved from the
resin and deprotected using a solution of trifluoroacetic acid,
phenol, water and triisopropylsilane (0.5–1 mL; 87.5/5/5/2.5%)
as a cleavage cocktail at rt for 2 h. After precipitation in ice-cold
diethyl ether (approx. 40 mL), the crude mixture of peptides was
recovered by centrifugation and washed twice with cold diethyl
ether. The precipitate was dissolved in water (5–10 mg mL−1),
purified by preparative HPLC, and lyophilized (Table 2).
In solution synthesis of building blocks and intermediates
Compounds 3 and 8 were prepared as previously described.14
Compound 6. The synthesis was accomplished according to a
modified procedure reported by Leavens et al.33 In brief, tris-
(p-methoxy)phenylphosphine (501 mg, 1.42 mmol) and 3-bromo-
propionic acid (363 mg, 2.37 mmol) in toluene (15 mL) were
stirred at reflux for 5 h and then cooled to rt. The mixture
was centrifuged, the precipitate was washed with toluene
(4 × 10 mL), and dried under reduced pressure. The crude
product was dissolved in acetonitrile (2 mL) and precipitated at
4 °C by addition of diethyl ether (12 mL). After drying under
reduced pressure, product 6 was isolated as a white solid
(bromide salt, 702 mg, 98%); purity according to HPLC > 95%;
1H NMR (MeOH-d4): δ = 7.68 (dd, 6H, JH–H = 9.0 Hz, JH–P =
12.1 Hz), 7.27 (dd, 6H, JH–H = 9.0 Hz, JH–P = 2.6 Hz), 3.93 (s,
9H), 3.55–3.46 (m, 2H), 2.74–2.63 (m, 2H) ppm; 13C NMR
(MeOH-d4): δ = 173.7, 166.6 (d, JC–P = 3.0 Hz), 136.9 (d, JC–P
= 11.6 Hz), 117.3 (d, JC–P = 13.8), 110.3 (d, JC–P = 95.3 Hz),
56.6, 27.6 (d, JC–P = 52.5 Hz), 20.1 (d, JC–P = 57.8 Hz) ppm;
31P NMR (MeOH-d4): δ = 21.81 ppm (s); HRMS (ESI) m/z:
425.15119 [M]+ (calcd for C24H26O5P: 425.15124).
Compound 7. Compound 6 (bromide salt: 86.6 mg,
0.17 mmol) was dissolved under argon in CH2Cl2 (1.5 mL) and
SOCl2 (0.4 mL, 5.51 mmol) was added dropwise. The resulting
solution was stirred at rt overnight. The excess of SOCl2 was
removed with a nitrogen stream and then evaporated to dryness
under reduced pressure. The acid chloride of compound 6 was
dissolved under argon in CH2Cl2 (2 mL) at −78 °C, Et3N
(0.4 mL, 2.87 mmol) and compound 3 (34 mg, 0.12 mmol) were
added. The mixture was stirred for 4 h at −78 °C before quench-
ing the reaction by the addition of water (2 mL) followed by
warming to rt. The reaction mixture was washed with 0.1 M
citric acid and water. The aqueous phases were extracted twice
with CH2Cl2. The organic phases were combined, dried over
Na2SO4, and concentrated under reduced pressure. The Boc-pro-
tected intermediate was directly deprotected by stirring it in a
mixture of CH2Cl2–TFA (2 : 1; 6 mL) at rt for 5 h followed by
drying under reduced pressure. Purification by preparative HPLC
afforded compound 7 as a yellow oil (TFA salt; 50 mg; yield for
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3 steps: 59%); purity according to HPLC >95%; 1H-NMR
(400 MHz, MeOH-d4; recorded after completed H/D exchange):
δ = 7.62 (dd, 6H, JH–H = 9.0 Hz, JH–P = 12.1 Hz), 7.21 (dd, 6H,
JH–H = 9.0 Hz, JH–P = 2.5 Hz), 4.04 (dd, 1H, JH–H = 6.6 Hz,
JH–H = 5.1 Hz), 3.99 (dd, 1H, JH–H = 16.7 Hz, JH–H = 2.6 Hz),
3.93 (dd, 1H, JH–H = 16.7 Hz, JH–H = 2.6 Hz), 3.88 (s, 9H),
3.49–3.38 (m, 2H), 3.16 (t, 1H, JH–H = 2.6 Hz), 3.06 (t, 2H,
JH–H = 6.6 Hz), 2.60–2.50 (m, 2H), 2.00–1.83 (m, 2H),
1.50–1.23 (m, 4H) ppm; 13C NMR (MeOH-d4): δ = 171.7
(d, JC–P = 13.6 Hz), 171.0, 166.6 (d, JC–P = 3.0 Hz), 136.9 (d,
JC–P = 11.6 Hz), 117.3 (d, JC–P = 13.8 Hz), 110.3 (d, JC–P =
95.0 Hz), 79.7, 74.4, 60.1, 56.6, 55.0, 40.3, 36.5, 30.0 (d, JC–P =
7.2 Hz), 29.2 (d, JC–P = 2.8 Hz), 23.2, 20.2 (d, JC–P = 57.8 Hz)
ppm; 31P NMR (MeOH-d4): δ = 21.92 ppm (s); HRMS (ESI)
m/z: 591.26208 [M]+ (calcd for C33H40O6N2P: 591.26185).
(Radio)metal labeling of peptides
Na[99mTcO4] was eluted from a Mallinckrodt
99Mo/99mTc
generator (Tyco Healthcare, Petten, The Netherlands) using
0.9% NaCl. The precursor [99mTc(CO)3(H2O)3]
+ was prepared
according to published procedures.44 In brief, [99mTcO4]
− (1 mL,
1.5–2 GBq) in 0.9% NaCl was added to the IsoLinkTM kit
(Mallinckrodt-Tyco, Petten, The Netherlands) and heated for
20 min at 100 °C. After the solution was cooled to rt, the pH
was adjusted to pH 7 with a 1 : 2 mixture of 1 M phosphate
buffer (pH 7.2) and 1 M HCl (final pH 1.4). Aliquots of 1 mM
stock solutions of the peptides 9 or 10 in water (10–20 μL;
10–20 nmol) were added to a solution of [99mTc(CO)3(H2O)3]
+
(90–180 μL; 100–250 MBq) to reach a final peptide concen-
tration of 0.1 mM. The reaction mixture was heated at 100 °C
for 30 min and the radiochemical yield and purity of [99mTc-
(CO)3(L)] (L = 9, 10) was determined by HPLC.
Rhenium complexes were prepared by mixing aqueous stock
solutions of peptides 9 or 10 (100 μL, 1 mM) with [Re(CO)3Br3]-
[N(Et)4]2
34 (150 μL, 1 mM) and heating at 100 °C for 60 min.
The products were purified by HPLC and analyzed by MS.
[Re(CO)3(9)]: quantitative conversion of peptide 9 (HPLC);
purity >99%; MS (MALDI TOF) m/z: 2078.8 [M]+ (calcd for
C91H122N21O22PRe: 2078.84). [Re(CO)3(10)]: quantitative con-
version of peptide 10 (HPLC); purity >99%; MS (MALDI TOF)
m/z: 1714.7 [M + H]+ (calcd for C69H100N21O19Re: 1713.71).
Stability studies
The radiolabeled peptides [99mTc(CO)3(L)] (L = 9, 10) (100 μL;
100 pmol, 0.6 MBq) were incubated at 37 °C with 900 μL PBS
(pH 7.4), NaCl (0.9%), or a cell culture medium (1% FBS)
respectively. At different time points (1, 2, and 4 h), aliquots
were analyzed by HPLC (n = 3). In the case of the cell culture
medium, serum proteins were precipitated prior to HPLC analy-
sis by the addition of aliquots to ethanol followed by centrifu-
gation (2500g, 5 min).
Histidine challenge. Compounds [99mTc(CO)3(L)] (L = 9, 10)
(100 μL; 200 pmol, 1.1 MBq) were incubated at 37 °C with
900 μL of a solution of histidine (1 mM in PBS; 4500-fold
excess). Aliquots were analyzed by HPLC after 1, 4, and 24 h
(n = 3).
Log D determination
Determination of log D values of radiotracers is usually accom-
plished by partitioning between n-octanol and PBS (pH 7.4)
using the “shake flask method”. However, the OECD guidelines
for testing of chemicals (Nr. 117) recommend an HPLC method
for the determination of log D values in the range of log
D 0–6.45 Applying this method also allows the evaluation of
radioactive and non-radioactive species, e.g., peptide precursors,
and their radioactive and non-radioactive metal-labeled
analogues. In brief, log D values of analytes were determined by
correlating their retention time with those of standard com-
pounds of known log D values using a calibration curve with at
least six reference compounds. All measurements were done
with a Bischoff HPLC system, column A and an isocratic mobile
phase composed of methanol (75%) and phosphate buffer
(pH 7.4; 25%) at a flow rate of 1 mL min−1. Standard com-
pounds (L-sodium ascorbate (t0), aniline (log D = 0.9), benzal-
dehyde (log D = 1.5), anisole (log D = 2.1), bromobenzene (log D
= 3.0), naphthalene (log D = 3.6), and dibenzyl (log D = 4.8);
0.1% in methanol)45 and testing compounds were injected three
times and analyzed either by UVor gamma detection. The differ-
ences in retention times (approx. 0.3 min) of radioactive analytes
(99mTc-complexes) and the corresponding non-radioactive Re-
compounds as a result of the serial arrangement of the UV/Vis
and γ-detectors were corrected by analysis of co-injections. The
calibration curve was calculated by linear regression analysis
using GraphPad Prism 5.0 (see ESI†).
In vitro experiments
Cell culturing. Human Caucasian prostate adenocarcinoma
(PC-3) cells were obtained from HPA Culture Collections
(Salisbury, UK) and cultured at 37 °C and 5% CO2 in
Dulbecco’s modified Eagle’s medium (DMEM, high glucose)
containing 10% (v/v) heat-inactivated fetal bovine serum (FBS
superior, OXOID, Pratteln, Switzerland), L-glutamine (200 mM),
100 IU mL−1 penicillin and 100 μg mL−1 streptomycin. All
culture reagents, except FBS, were purchased from BioConcept
(Allschwil, Switzerland). The cells were subcultured weekly
after detaching them with a commercial solution of trypsin–
EDTA (1 : 250) in PBS.
Saturation binding assay. On the day prior to the experiment
PC-3 cells (106 cells per well) were plated in a six-well plate and
incubated at 37 °C and 5% CO2 overnight, allowing them to
attach. The next day, the cell-culture medium (1% FBS) was
changed (0.8 mL) and the cells were kept in the fridge for
30 min to stop cell activity prior to the start of the experiment. In
order to reach receptor saturation, the cells were incubated with
increasing concentrations (0.1, 0.5, 1, 5, 10, 20, 50, and 100 nM
per well; each 100 μL) of the radiolabeled peptides [99mTc-
(CO)3(L)] (L = 9, 10). Non-specific receptor binding was deter-
mined using an excess of natural bombesin (2.5 μM per well for
concentrations of the radiopeptide <10 nM, and 10 μM per well
for higher concentrations). After incubation at 4 °C for 2 h, the
supernatant was removed and the cells were washed twice with
1 mL of ice-cold PBS (pH 7.4). The combined supernatants rep-
resent the free, unbound radiopeptide fraction. To determine the
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receptor bound fraction, the cells were lysed with 1 M NaOH
(1 mL) for 10 min at 37 °C and the wells were washed twice
with 1 M NaOH (1 mL). The free and receptor bound fractions
were measured in a gamma counter for quantification. Dis-
sociation constants (Kd) were calculated from the data for
specific binding with nonlinear regression using GraphPad
Prism5, normalized to 106 cells (n = 3 in triplicate).
Internalization studies. On the day prior to the experiment,
PC-3 cells (106 cells per well) were placed in six-well plates
with a cell culture medium (1% FBS) and incubated at 37 °C,
5% CO2 overnight to let them attach. On the day of the experi-
ment, the medium was removed, and cells were incubated with
fresh medium (1.3 mL) for 1 h. Radiolabeled peptides [99mTc-
(CO)3(L)] (L = 9, 10; per well: 100 μL; 0.25 pmol; 1.5 kBq)
were added and the cells were incubated for different time points
(10, 20, 30, 60, 90, and 120 min) in triplicate to allow binding
and internalization. Non-specific receptor binding and internaliz-
ation was determined in the presence of a 1000-fold excess of
natural bombesin (250 pmol; 100 μL per well) as the receptor
blocking agent. After each time point, the supernatant was col-
lected, and the cells were washed twice with PBS (1 mL;
pH 7.4). The combined supernatants represent the free, unbound
radiopeptide fraction. Receptor-bound radioactivity was isolated
by incubating the cells twice for 5 min with an acidic glycine
solution (100 mM NaCl, 50 mM glycine, pH 2.8; 1 mL) on ice
followed by removal of the supernatant. The internalized fraction
was determined by cell lysis with 1 M NaOH (1 mL; 10 min;
37 °C, 5% CO2) and the wells containing the cell lysate were
washed twice with NaOH (1 M, 1 mL). All fractions were
measured radiometrically in a gamma counter and calculated as
percentage of applied dose normalized to 106 cells (n = 3 in
triplicate).
Externalization studies. PC-3 cells (106 cells per well) were
placed in six-well plates with a cell culture medium (1% FBS)
and incubated at 37 °C and 5% CO2 overnight to let them attach.
On the day of the experiment, the medium was removed and
cells were incubated with fresh medium (1.3 mL) for 1 h. Radio-
labeled peptides [99mTc(CO)3(L)] (L = 9, 10; per well: 100 μL;
0.25 pmol; 1.3 kBq or 2.5 pmol; 13.7 kBq) were added and the
cells incubated for 1 h in triplicate to allow internalization into
the cells. Non-specific receptor binding and internalization was
determined in the presence of a 1000-fold excess of natural bom-
besin (250 pmol or 2500 pmol; 100 μL per well) as the receptor
blocking agent. After 1 h, the supernatant was collected (free
fraction) and receptor-bound radiopeptides were removed by
washing the cells two times for 5 min with an acidic glycine
buffer on ice (bound fraction). A fresh cell culture medium
(1 mL) was added and the cells were incubated for 10, 20, 30,
60, 90, 120, 150, 180, 240, and 300 min. At each time-point, the
supernatant was collected and cells were washed twice (1 mL
PBS; pH 7.4). These fractions represent the externalized amount
of radioactivity. The remaining internalized amount of radio-
activity was recovered by cell lysis as described above. All frac-
tions were measured in a gamma counter for quantification
calculated as percentage of the total internalized fraction at
t = 0 min (n = 3 in triplicate).
Mitochondria-binding experiments. Mitochondria were iso-
lated from cultured PC-3 cells using the Thermo SCIENTIFIC
mitochondria isolation kit for cultured cells according to the pro-
cedure described in the operating manual. Isolated mitochondria
obtained by this procedure maintain their integrity.46,47 Protein
concentration was measured by the Bradford method using the
Bio-Rad protein assay and BSA as a standard. Mitochondria
binding experiments were performed following procedures pub-
lished by Murphy et al.38,39 In brief, isolated mitochondria were
resuspended in KCl medium (120 mM KCl, 10 mM Hepes
(pH 7.2), and 1 mM EGTA). The mitochondria (0.9 mL, 1 μg
protein per mL) were incubated with 100 μL of each radiolabeled
peptide [99mTc(CO)3(L)] (L = 9, 10; 5 pmol; 11.5 and 15.3 kBq,
respectively) at rt on a shaking plate for 30 min. To investigate
the specificity of [99mTc(CO)3(9)], mitochondria were preincu-
bated with sodium succinate (10 mM), FCCP (0.5 μM) or
sodium azide (20 mM)40 respectively for 10–30 min prior to the
addition of the radiolabeled conjugate. After the experiments,
the mitochondria were pelleted (centrifugation at 12 000g for
5 min) and the supernatant was removed. The pellet was washed
with KCl medium (1 mL), the supernatants combined and
measured in a gamma counter; this fraction represents unbound
radioactivity. The mitochondria precipitate was resuspended in
1 mL of triton X-100 (10% v/v) and measured in a gamma
counter to quantify the amount of the radioactive peptide associ-
ated with the mitochondria relative to total added activity (n = 4
for all experiments).
Conclusion
In summary, we report the synthesis and in vitro evaluation of
novel dual-targeting radiopeptide conjugates with the goal of
improving the cellular retention of radioactivity in cancer cells
after specific delivery. Starting from readily accessible building
blocks, a tumor-targeting peptide ([Nle14]BBS(7–14)), a 99mTc-
based SPECT reporter probe ([99mTc(CO)3]
+), and a mitochon-
dria-seeking triphenylphosphonium (TPP) moiety were selec-
tively and efficiently assembled into a trifunctional conjugate.
With the exception of the radiometal labeling step, the assembly
of the described multifunctional conjugates was accomplished
conveniently on a solid support. While the first generation conju-
gate bound and internalized specifically into GRP receptor
expressing PC-3 cells, it did not display specific accumulation in
its intracellular target, the mitochondria, resulting in an overall
unaltered externalization rate of radioactivity from PC-3 cells.
Nevertheless, the combination of two different entities specific
for an extra- and an intracellular target in the same radioconju-
gate is an attractive approach to improve the efficacy of radio-
tracers. We are currently employing the same modular synthetic
strategy for the development of a simplified, second generation
of dual-targeting radiopeptide conjugates in an effort to identify
the features required for improving the retention time of radio-
activity in cancer cells and tumors.
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Abstract: Radiolabeled peptides, which target tumor-specific membrane structures of cancer 
cells, represent a promising class of targeted radiopharmaceuticals for the diagnosis and 
therapy of cancer. A potential drawback of a number of radiopeptides reported is represented 
by a rapid washout of a substantial fraction of the initially delivered radioactivity from cancer 
cells and tumors. This renders the initial targeting effort in part futile and results in an 
imaging quality and efficacy of the radiotracer lower than achievable. We are investigating 
the combination of internalizing radiopeptides with molecular entities specific for an 
intracellular target. By enabling intracellular interactions of the radioconjugate, we aim at 
reducing/decelerating the externalization of radioactivity from cancer cells. Using the “Click-
to-Chelate” approach, the 99mTc-tricarbonyl core as a reporter probe for single-photon 
emission computed tomography (SPECT) was combined with the binding sequence of 
bombesin for extracellular targeting of the gastrin-releasing peptide receptor (GRP-r) and 
peptidic inhibitors of the cytosolic heat shock 90 protein (Hsp90) for intracellular targeting. 
Receptor-specific uptake of the multifunctional radioconjugate could be confirmed, however, 
the cellular washout of radioactivity was not improved. We assume that either endosomal 
trapping or lysosomal degradation of the radioconjugate is accountable for these observations. 
 
Keywords: multifunctional radioconjugates; intra- and extracellular targeting; tumor 
targeting; 99mTc-tricarbonyl; bombesin; shepherdin; gastrin-releasing peptide receptor; Hsp90; 
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Abstract: Radiolabeled peptides,  which target  tumor-specif ic  membrane s tructures  of  
cancer  cel ls ,  represent a promising class of targeted radiopharmaceuticals for the diagnosis and 
therapy of cancer. A potential drawback of a number of reported radiopeptides is the rapid washout 
of a substantial fraction of the initially delivered radioactivity from cancer cells and tumors. This 
renders the initial targeting effort in part futile and results in a lower imaging quality and efficacy 
of the radiotracer than achievable. We are investigating the combination of internalizing radiopeptides 
with molecular entities specific for an intracellular target. By enabling intracellular interactions of 
the radioconjugate, we aim at reducing/decelerating the externalization of radioactivity from 
cancer cells. Using the “click-to-chelate” approach, the 99mTc-tricarbonyl core as a reporter probe for 
single-photon emission computed tomography (SPECT) was combined with the binding sequence 
of bombesin for extracellular targeting of the gastrin-releasing peptide receptor (GRP-r) and 
peptidic inhibitors of the cytosolic heat shock 90 protein (Hsp90) for intracellular targeting. 
Receptor-specific uptake of the multifunctional radioconjugate could be confirmed, however, the 
cellular washout of radioactivity was not improved. We assume that either endosomal trapping 
or lysosomal degradation of the radioconjugate is accountable for these observations. 
!
Keywords: multifunctional radioconjugates; intra- and extracellular targeting; tumor targeting; 
99mTc-tricarbonyl; bombesin; shepherdin; gastrin releasing peptide receptor; Hsp90; SPECT 
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1. Introduction 
 
Regulatory peptides are known to display high specificity and affinity towards different G-protein coupled 
receptors (GPCRs) which are overexpressed on the cell membrane of various cancer cells [1]. On this account, 
a number of radiopharmaceuticals based on these peptides as tumor-targeting vectors are currently under 
preclinical and clinical evaluation or have already found application in nuclear medicine for the management of 
cancer [2–4]. However, after receptor-mediated uptake of radiolabeled regulatory peptides into tumors, a rapid 
washout of a significant fraction of radioactivity is often observed [5–9]. This not only renders the initial 
targeting efforts in part futile but may also impair imaging quality and the efficacy of radiopharmaceuticals 
where therapeutic radionuclides are employed. To overcome these limitations, new strategies are needed to 
enhance the cellular retention of radioactivity inside cancer cells and tumors. A possible approach to achieve 
this goal is represented by the application of radiolabeled conjugates which combine extra- and intracellular 
targeting. Such multifunctional radioconjugates have the promise to be recognized first by an extracellular target 
(e.g., a GPCR) that triggers cell internalization by endocytosis. Once inside the cell, the radioconjugate 
interacts with its intracellular target (e.g., an organelle or protein) by means of which the radioactive cargo is 
trapped [10]. Radioconjugates consisting of two molecular moieties, each of which specific for an extra- and 
intracellular target, respectively, have been reported; however, examples remain scarce. Ginj et al. have 
reported the combination of radiolabeled somatostatin derivatives with a nuclear localization sequence 
(NLS) to transport Auger electron emitting radionuclides to the cell nucleus. The reported conjugates target 
specifically the cell nucleus and display a decreased externalization rate in vitro; however, no in vivo data is 
available [6].With the same goal, the groups of Alberto and Santos have combined a 99mTc-labeled bombesin 
(BBS) derivative with the DNA intercalator acridine orange, which simultaneously serves as a fluorescent 
probe for optical imaging. The in vitro results reported on the ability of the conjugates to target the cell 
nucleus are not consistent and data on the externalization of radioactivity from cells is not reported 
[11,12]. The Garrison group investigated the combination of a radiolabeled BBS derivative with 2-
nitroimidazoles, a hypoxia-specific prodrug. Upon enzymatic reduction of the 2-nitroimidazole moiety, the 
radioconjugate gets covalently linked to intracellular proteins. While an enhancement of the retention of 
radioactivity in PC-3 cells as a result of 2-nitroimidazole moieties was demonstrated under hypoxic 
conditions in vitro, the effect was less pronounced in a mouse model [13]. Finally, we have recently reported 
a 9 9 m Tc-tricarbonyl-labeled, dual-targeting radiopeptide conjugate made of a modified amino acid sequence 
of BBS, [Nle14]BBS(7-14) (QWAVGHLNle), for extracellular targeting of the gastrin-releasing peptide 
receptor (GRP-r) and a triphenylphosphonium (TPP) entity specific for mitochondria by its ability to 
accumulate electrophoretically driven in the energized membrane of the organelle [10]. While receptor-
specific cell internalization of the conjugate could be confirmed, the cellular washout of radioactivity was 
not reduced. We tentatively ascribed our observations to the possibility of hindered passage of the TPP 
moiety through the membrane of mitochondria because of the peptide it is attached to; similar observations 
have been reported for cell penetrating peptide/TPP conjugates [14]. We therefore set out to investigate the 
utility of multifunctional radiopeptides,  which  target cytosolic proteins and thus, do not require multiple 
passages through intracellular membranes, a process considered as a major barrier for targeting intracellular 
epitopes [15]. With these considerations in mind, we chose the cytosolic chaperone, heat shock protein 90 
(Hsp90), as a potential intracellular target for our purpose. Hsp90 is a ubiquitous protein important for, e.g., cell 
proliferation and survival. As such, it is found overexpressed by nearly all cancer cells in high 
concentrations [16–18]. Hsp90 assists and controls the non-covalent folding/unfolding of many client 
proteins, including the peptide survivin [17,19,20]. The group of Altieri has identified the binding sequence 
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of survivin(K79-L87), termed “shepherdin” as an inhibitor of the survivin-Hsp90 interaction and Hsp90 
ATPase activity [21]. The high affinity and specificity towards Hsp90 and anticancer activities of 
shepherdin(79–87) (KHSSGCAFL) and its truncated form shepherdin(79–83) (KHSSG), respectively, have been 
demonstrated by different approaches [20–24]. However, applications of radiolabeled derivatives of shepherdin 
or its combination with tumor-targeting peptides for receptor-specific delivery have not yet been described. 
Herein, we wish to report the synthesis of BBS-shepherdin radioconjugates prepared by the previously reported 
modular “click-to-chelate” approach [25,26] (Figure 1) and their evaluation in vitro. 
Figure 1. Assembly of multifunctional, 99mTc-tricarbonyl-labeled peptide conjugates by amide bond 
formation, CuAAC, and (radio)metal complexation; residues R1 and R2 represent two different 
entities of biological function (e.g., derivatives of BBS and shepherdin) to be combined in the 
final radioconjugate. 
 
 
 
2. Experimental Section 
 
2.1. General Procedures 
 
General procedures, solvents, chemicals, synthesis equipment, analytic instruments (HPLC, MS, NMR, gamma 
counter) were previously described [10,27]. The “CRS Isolink kit” (Center for Radiopharmaceutical Science, Paul 
Scherrer Institute, Villigen, Switzerland) was used for the preparation of the precursor [99mTc(CO)3(H2O)3]
+. 
For analytical separation, a C12 reversed-phase column Phenomenex Jupiter 4u Proteo 90 Å, 4 µm, 250 × 
4.6 mm (column A) was used and preparative purification was performed on a Macherey Nagel Nucleodur 
C18 ISIS, 5 µm, 250 × 16 mm (column B). HPLC solvents were 0.1% trifluoroacetic acid (TFA) in water 
(A) and 0.1% TFA in acetonitrile (B). Quality control of (radio) metal-labeled peptides was performed 
using column A and a linear gradient from 80% A to 50% A in 20 min with a flow rate of 1.5 mL/min, 
or a linear gradient from 80% A to 60% A in 
20 min. Peptide purification was performed using column B and different linear gradients with a flow rate of 
up to 8 mL/min. The observed m/z correspond to the monoisotopic ions. Chemical shifts are reported in 
parts per million (ppm) and coupling constants (J) in Hertz (Hz) from high to low field. Standard
abbreviations indicating multiplicity are singlet (s), doublet (d), doublet of doublets (dd), triplet (t), and 
multiplet (m). 
 
2.2. Synthetic Procedures 
 
2.2.1. Organic Synthesis 
 
N(α)Boc-N(α)propargyl-Lys(OMe) 1 was synthesized in five steps from commercial BocLysOMe 
according to published procedures [28]. Subsequently, succinic anhydride (2 equiv. 2.22 mmol) was coupled 
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to N(α)Boc-N(α)propargyl-Lys(OMe)*HCl (1, 370 mg, 1.11 mmol) via amide bond formation in CH2Cl2 
under basic conditions (i-Pr2NEt; 6 equiv.) for two hours at rt (Scheme 1). The reaction mixture was 
concentrated under reduced pressure and the crude product was dissolved in ethyl acetate. The organic phase 
was extracted with citric acid (0.1 M) and saturated sodium hydrogen carbonate. The organic layer was
disposed. The hydrogen carbonate phase was acidified with hydrogen chloride (5%) under stirring and 
extracted twice with fresh ethyl acetate. The organic phases were combined, dried over magnesium sulfate, 
and concentrated under reduced pressure to yield compound 2a as a pale yellowish oil (435.3 mg, 91%; see 
Scheme 1). For characterization purposes, the Boc protecting group of 2a was removed (CH2Cl2/TFA, 2:1; 5 
h; rt) and the product was analyzed as its TFA salt 2b; 1H-NMR (400 MHz, MeOH-d4; recorded after completed 
H/D exchange): δ = 4.10 (dd, 1H, J = 7.0 Hz, J = 5.0 Hz), 3.96 (dd, 1H, J = 16.6 Hz, J = 2.5 Hz), 3.92 (dd, 1H, J 
= 16.6 Hz, J = 2.5 Hz), 3.79 (s, 3H), 3.18 (t, 1H, J = 2.5 Hz), 3.12 (m, 2H), 2.52 (t, 2H, J = 6.9 Hz), 2.38 (t, 2H, 
J = 6.9 Hz), 1.97–1.85 (m, 2H), 1.51–1.44 (m, 2H), 1.43–1.25 (m, 2H) ppm; 1 3C-NMR (MeOH-d4): δ =
176.42, 174.81, 170.19, 162.22 (TFA, q, JC-F: 35.7 Hz), 117.86 (TFA, q, JC-F: 290.7 Hz), 79.87, 74.28, 
60.07, 54.05, 39.65, 36.61, 31.65, 30.39, 29.99, 29.92, 22.99 ppm; ESI-HRMS (C14H23N2O5): [M+H]
+ m/z: 
299.16019 (calcd. 299.16013). 
 
Scheme 1. Synthesis of central lysine-based precursor. (a) see reference [28]; (b) succinic anhydride, i-
Pr2NEt, CH2Cl2, 2 h, rt. 
 
 
 
 
 
 
  
 
 
 
  
 
Solid-phase peptide synthesis (SPPS; scale: 0.03–0.25 mmol) was performed as described earlier [10,27]. Side-
chain protected Fmoc-amino acids were Cys(Trt), Gln(Trt), His(Trt), Lys(Boc), Ser(tBu), and Trp(Boc). 
Azide-functionalized bombesin derivative 3 was synthesized according to the literature [10]. The different 
protected shepherdin peptide sequences [21,24] obtained by SPPS (4–7; 0.03–0.06 mmol) were subsequently 
coupled manually via selective amide bond formation to the central lysine precursor 2a on solid support in the 
presence of HATU (2–3 equiv.) and i-Pr2NEt (5–6 equiv.) in DMF for 2 h at rt. After the coupling was 
completed, removal of protecting groups and cleavage of the peptides were done with a solution of 
trifluoroacetic acid, phenol, water, and triisopropylsilane (0.5–1 mL; 87.5/5/5/2.5%) at rt for 2–8 h. The 
precipitated crude peptides were dissolved in water, purified by preparative HPLC, and lyophilized. 
Afterwards, selective methyl ester hydrolysis of intermediates was achieved with LiOH (0.5 M; 1–3 h, rt) 
following a procedure described by Reddy et al. [29]. After reactions were completed and the solutions 
were neutralized with HCl (0.5 M), the crude peptides 8–11 were obtained (see Scheme 2). Finally, the 
alkyne functionalized shepherdin derivatives 8–11 were reacted with the purified azidoacetic acid-
functionalized bombesin sequence 3 according to published procedures [30] via the Cu(I)-catalyzed 
alkyne-azide cycloaddition (CuAAC) [31,32] in solution. In brief, stoichiometric amounts of alkyne-
shepherdin peptides 8–11 and azido-BBS peptide 3 (2 µmol) were dissolved in DMSO (400 µL) under an 
argon atmosphere and a freshly prepared Cu(I) solution was added (60 µL; 3 equiv.), prepared by mixing a
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CuSO4 pentahydrate solution (0.2 M, 30 µL) with an sodium ascorbate solution (0.4 M, 30 µL) on ice. The 
reaction was allowed to stir for 1 h at rt and completion of the reaction was checked by analytical HPLC. 
The click products were purified by preparative HPLC and lyophilized to obtain the final peptide conjugates 
12–15 (see Table 1 and Scheme 2). Reference compound 16 (see Scheme 2) was synthesized as described earlier 
[10]. 
 
 
 
Scheme 2. Synthesis of peptides and assembly of (radio)metal-labeled, multifunctional conjugates. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) SPPS: (i) piperidine in DMF; (ii) Fmoc-amino acids, TBTU-HOBt, (b) azidoacetic acid, HATU; (c) 
cleavage solution: trifluoroacetic acid, phenol, water, triisopropylsilane (87.5/5/5/2.5%), 2–5 h, 
rt; (d) SPPS: 2a, HATU, (e) cleavage solution, 2–8 h, rt; (f) LiOH (0.5 M), 1–3 h, rt; (g) 
CuAAC in solution; CuSO4 (0.2 M), Na-ascorbate (0.4 M), 1 h, rt; (h) (radio)metal labeling; for 
M=99mTc: 12–16 (0.1 mM, aq.), [99mTc(CO)3(H2O)3]
+, 100 °C, 30 min; for Re complexes: 12–
16 (0.4 mM, aq.), [Et4N]2[Re(CO)3(Br)3], 100 °C, 60 min; AA = amino acid. 
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Table 1. Analytical data and yields of synthesized peptides and natRe-complexes thereof. 
 
Compound MALDI-MS; m/z (observed) Yield [%] Purity [%]c 
12 [M+H]+: 2432.23 (calcd.: 2432.24) 31a 92.9 
13 [M+H]+: 2432.18 (calcd.: 2432.24) 10a 95.3 
14 [M+H]+: 1998.01 (calcd.: 1998.04) 17a 98.3 
15 [M+H]+: 1998.03 (calcd.: 1998.04) 18a 97.5 
16 [M+H]+: 1458.75 (calcd.: 1458.80) 23a 97.6 
[Re(CO)3(12)] [M+H]
+: 2700.10 (calcd.: 2700.17) quant.b >98 
[Re(CO)3(13)] [M+H]
+: 2700.16 (calcd.: 2700.17) quant.b >98 
[Re(CO)3(14)] [M+H]
+: 2265.95 (calcd.: 2265.97) quant.b >98 
[Re(CO)3(15)] [M+H]
+: 2265.93 (calcd.: 2265.97) quant.b >98 
[Re(CO)3(16)] [M+H]
+: 1712.7   (calcd.: 1712.71) quant.b >98 
a overall yield of isolated conjugates; b conversion of starting material (HPLC); c  determined by HPLC; 
for reference compound 16 see reference [10]. 
 
2.2.2. (Radio)Metal Labeling of Peptides 
 
Na[99mTcO4] was eluted from a Mallinckrodt 
9 9 Mo/99mTc generator, and the precursor 
[99mTc(CO)3(H2O)3]
+ was prepared by adding [99mTcO4]
- (1.5–2 GBq) to the “CRS Isolink kit for 
tricarbonyl” and heating for 30 min at 100 °C. Aliquots of 1 mM stock solutions of peptides 12–16 in water 
(10 µL, 10 nmol) were added to a solution of [99mTc(CO)3(H2O)3]
+ (~100 MBq; 0.1 mM final peptide 
concentration) and the reaction mixtures were heated at 100 °C for 30 min. Quality controls were performed 
by radio-HPLC to determine the radiochemical yield and purity of [99mTc(CO)3(L)] (L = 12–16). For 
characterization purposes, the peptides were labeled with cold natRe. In brief, aliquots of aqueous stock 
solutions of peptides 12–16 (30–100 µL, 1 mM) were added to a solution of [Et4N]2[Re(CO)3(Br)3] [33] (50–
150 µL, 1 mM) and heated for one hour at 100 °C [10]. The rhenium-complexes were purified by HPLC and 
analyzed by MS (see Table 1). 
 
2.3. LogD Determinations 
 
The hydrophilicity of the radiolabeled peptides 12–16 was evaluated by determination of their partition 
coefficient between n-octanol and phosphate buffered saline (PBS, pH 7.4) using the shake flask method 
[27]. In brief, 10 µL (1 µM) of radiolabeled peptides 12–16 were added to a pre-saturated solution of n-
octanol and PBS (1:1, 1 mL) and the tubes were vortexed (1 min) and centrifuged (3,000 rpm, 10 min). Aliquots of 
100 µL of each phase were radiometrically measured in a gamma counter and the logD values were calculated 
by the logarithm of the ratio between the radioactive counts in the octanol fraction and the radioactive counts in 
the PBS fraction. The experiment was performed 2–3 times, each in quintets, and results are reported by mean 
values ± standard deviation (SD). 
 
2.4. In Vitro Experiments 
 
Cell culturing of human Caucasian prostate adenocarcinoma (PC-3) cells and in vitro assays (internalization, 
receptor saturation binding, and externalization) were performed as previously described [10,27] and are 
thus described only in brief. 
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2.4.1. Internalization Assay 
 
For the determination of cellular uptake, PC-3 cells were incubated with the radiolabeled peptides 
[99mTc(CO)3(L)] (L = 14–16; 0.25 pmol; 1.5–2.0 kBq/well) for different time points to allow binding and 
internalization. Non-specific receptor binding and internalization was determined by incubating the cells 
with excess of natural bombesin(1–14) as a receptor blocking agent. At each time point, the supernatant was 
collected, representing the free radiopeptide fraction. The cell surface receptor bound fraction was obtained by 
treating the cells with an acidic saline glycine buffer (100 mM NaCl, 50 mM glycine, pH 2.8; 2 times for 5 
min, on ice). The internalized fraction was determined by cell lysis with 1 M NaOH (10 min). Fractions of free, 
receptor-bound, and internalized radiopeptide were radiometrically measured in the gamma counter and 
calculated as percentage of applied dose normalized to 106 cells for all time points (n = 2–3 in triplicates, 
reported by means ± SD) [10]. To verify whether specific uptake was influenced by the shepherdin 
sequence, internalization experiments were also conducted with excess shepherdin(79–87) (AnaSpec Inc., 
Fremont, CA, USA) as a blocking agent. 
 
2.4.2. Receptor Saturation Binding Assay 
 
PC-3 cells were incubated with increasing concentrations (0.1–100 nM/well) of the radiolabeled 
peptides [99mTc(CO)3(L)] (L = 14–16) at 4 °C for 2 h. Non-specific binding was determined in the 
presence of excess of natural bombesin(1–14) as described above. Fractions of free and receptor-bound 
radioconjugates were radiometrically measured in the gamma counter for quantification and apparent binding 
dissociation constants (Kd, app) were calculated (n = 2–4 in triplicates, reported by means ± SD) [10]. 
 
2.4.3. Externalization Assay 
 
PC-3 cells were incubated with the radiolabeled peptides [99mTc(CO)3(L)] (L = 14–16; 2.5 pmol; 14–21 
kBq/well) for one hour to allow cell internalization. The free and receptor-bound radiopeptide fractions were 
removed as described above, fresh cell culture medium was added, and the cells were incubated for different 
time points (10–300 min). At each time-point, the externalized fractions were collected and the medium 
replaced. The remaining internalized amount of radioactivity was recovered by cell lysis. All fractions were 
radiometrically measured and calculated as percentage of the total internalized fraction (n = 4–7 in 
triplicates, reported by means ± SD) [10]. 
 
3. Results and Discussion 
 
The syntheses of building blocks and multifunctional conjugates are depicted in Schemes 1 and 2. 
N(α)Boc-N(α)propargyl-Lys(OMe) (1) was synthesized from commercial BocLysOMe in five steps 
according to previously published procedures [28]. Reaction of compound 1 with succinic anhydride 
provided intermediate 2a appropriately functionalized with a carboxylic acid functionality for conjugation reactions 
via amide bond formation. Shepherdin derivatives 4–7 [21,24] were synthesized by automated solid-phase 
peptide synthesis (SPPS) using Fmoc-chemistry. Compounds 5 and 7 with a scrambled amino acid 
sequences were prepared for control experiments. Peptides 4–7 were coupled to the Lys precursor 2a on 
solid support, cleaved from the resin, and fully deprotected under standard conditions. 
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Subsequent hydrolyses of the methyl ester of intermediates with LiOH provided alkyne-derivatized peptides 
8–11. The corresponding CuAAC reaction partner, N-terminally functionalized azido-(βAla)3[Nle
14]BBS(7–14) 
3, was obtained by similar SPPS procedures [10]. A (β-Ala)3 spacer was introduced at the N-terminus of 
peptide 3 in order to prevent potential interference between the different moieties of the final multifunctional 
conjugate [9,10]. Reaction of alkyne-bearing shepherdin derivatives 8–11 and azido-BBS 3 by CuAAC in 
solution afforded final peptide conjugates 12–15. For a side-by-side comparison, reference conjugate 16, 
identical in all respects but lacking a shepherdin moiety (replaced by a methyl group; Scheme 2) was used, 
the synthesis and characterization of which has been previously described [10]. For analytical data of products 
see Table 1. 
Radiolabeling of the triazole-containing peptide conjugates with 99mTc-tricarbonyl was achieved 
following established procedures reported by us and others [10,28,34]. In brief, heating of aqueous 
solutions of 1,2,3-triazole containing peptide conjugates 12–16 with [99mTc(CO)3(H2O)3]
+ yielded the 
corresponding radiolabeled compounds [99mTc(CO)3(L)] (L = 12–16) in >95% radiochemical yield and purity 
and with a specific activity of up to 100 GBq/µmol. As common practice for the identification and 
characterization of n.c.a. (no carrier added) 99mTc-labeled compounds, the corresponding non-radioactive analogous 
compounds [natRe(CO)3(L)] (L = 12–16) were also prepared by reaction of conjugates 12–16 with 
[Et4N]2[Re(CO)3(Br)3] [33] (for MS data see Table 1). Direct comparison of the UV-HPLC traces of the 
rhenium tricarbonyl complexes with the corresponding γ-HPLC traces of 99mTc-tricarbonyl complexes confirmed 
in each case their identity (see Supplementary Information). 
Already at this stage we recognized a high and persistent unspecific binding of conjugate 
[99mTc(CO)3(12)] containing the full length shepherdin(79–87) sequence to material used as well as cell 
surfaces. In particular, the unspecific binding of [99mTc(CO)3(12)] impeded with in vitro assays regardless 
of precautions taken (e.g., using prelubricated disposables, the addition of solvents (e.g., DMSO or EtOH), or 
varying the composition and ionic strength of the media; data not shown). We therefore focused henceforth 
on radioconjugates containing the truncated shepherdin(79–83) sequence for which unspecific binding was 
not an issue. Thus, the physico-chemical properties of compounds [99mTc(CO)3(L)] (L = 14,15) were 
evaluated in comparison to reference compound [99mTc(CO)3(16)]. 
The lipophilicity of the conjugates was determined by the shake flask method. LogD values obtained ranged 
from −1.70 ± 0.13 and −1.68 ± 0.08 for compounds [99mTc(CO)3(14)] and [
99mTc(CO)3(15)], respectively, 
which indicates an improved hydrophilicity in comparison to the reference compound [99mTc(CO)3(16)] (logD 
= −0.44 ± 0.07). 
BBS-shepherdin conjugate [99mTc(CO)3(14)], its analog with the scrambled amino acid sequence 
[99mTc(CO)3(15)], and reference compound [
99mTc(CO)3(16)] exhibited similar cell internalization profiles into 
GRP-r overexpressing PC-3 cells in terms of extent and rate of uptake (Figure 2). Approximately 25%–
30% of the applied radioactivity was internalized within 30–60 min, which is comparable to related 
bombesin derivatives labeled with the 99mTc-tricarbonyl core described by us and others [10,35]. Cell 
internalization was not influenced by the addition of shepherdin(79–87) and receptor-specific uptake was 
verified for all compounds by blocking experiments in the presence of excess natural bombesin(1-14) (data 
not shown). 
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Figure 2. Receptor specific internalization of radiometal conjugates in PC-3 cells, 
overexpressing GRP-receptor; [99mTc(CO)3(14)] (□, continuous line), [
99mTc(CO)3(15)] (∆, dotted 
line), [99mTc(CO)3(16)] (○, continuous line); normalized to 10
6 cells per well; n = 2–3 (in 
triplicates, reported by means ± SD, calculated by non-linear regression using GraphPad Prism 
5.0). 
 
 
 
Binding affinities of radiolabeled conjugates [99mTc(CO)3(L)] (L = 14–16) towards the GRP-r were 
investigated by receptor binding saturation assays (Figure 3). All three derivatives showed high affinities 
towards GRP-r. Compared to reference compound [99mTc(CO)3(16)] with an apparent dissociation constant 
(Kd, app) of 5.6 ± 0.8 nM, dual-targeting BBS-shepherdin conjugate [99mTc(CO)3(14)] revealed a slightly 
decreased receptor binding affinity (Kd, app = 10.9 ± 0.7 nM) as did its scrambled version [99mTc(CO)3(15)] 
(Kd, app = 11.3 ± 2.2 nM). Kd values of receptor-specific radiopeptides in the low two-digit nanomolar range 
are still considered appropriate for applications in vivo [36,37]. 
 
Figure 3. Specific receptor saturation binding to PC-3 cells; [99mTc(CO)3(14)] (□, continuous line), 
[99mTc(CO)3(15)] (∆, dotted line), [
99mTc(CO)3(16)] (○, continuous line); normalized to 10
6
 
cells 
per well; n = 2–3 (in triplicates, reported by means ± SD, and calculated by non-linear 
regression using GraphPad Prism 5.0). 
 
 
 
After having verified the specificity and affinity of the radioconjugates for their tumor-specific, 
extracellular target (GRP-r), we next set out to study the effect of the conjugated shepherdin moiety with 
regards to the cellular retention of radioactivity. Unexpectedly, the externalization profiles of the three 
radioconjugates [99mTc(CO)3(L)] (L = 14–16) were comparable (Figure 4). A washout of 50% of
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the initially internalized radioactivity was observed within approximately 90 min for all conjugates. Thus, 
the additional shepherdin moiety of [99mTc(CO)3(14)] did not lead to an improved cellular retention of 
radioactivity in comparison to compounds [99mTc(CO)3(L)] (L = 15–16). These results were puzzling 
because of the reported high affinity (80 nM) and specificity of shepherdin(79–83) and peptide conjugates 
thereof towards Hsp90 [20,21], the expression of which in PC-3 cells was verified by western blot 
experiments (data not shown). A potential explanation for our findings might include the possibility of 
endosomal entrapment of the conjugate as a consequence of endocytotic cell internalization, which in turn 
would prevent interactions of [99mTc(CO)3(14)] with its cytosolic target Hsp90 [12,15,38]. Alternatively, 
enzymatic degradation of the peptidic radioconjugate within the intracellular endosome-lysosome cascade 
could result in the destruction of the shepherdin moiety and thus, loss of its specificity towards Hsp90 
[15,38,39]. In either case, the intracellular fate of receptor-specific (radio)conjugates after cell internalization 
by endocytosis is generally not well understood in detail. There are recent reports suggesting solutions to 
overcome issues of endosomal entrapment including examples of the application of biomimetic peptides [40], 
cleavable linkers [41,42], and synthetic polymers [15]. In addition, reported non-peptidic inhibitors of 
Hsp90 [43] could be employed in order to address potential issues of the stability of the Hsp90-specific 
peptide moieties described herein. To address the challenging goal of improving the cellular retention of 
radioactivity after receptor-specific delivery to cancer cells by peptidic radiotracers, future research efforts 
will be directed towards the combination of our conjugates with the strategies outlined above. 
Figure 4. Externalization of radiolabeled compounds [99mTc(CO)3(L)] (L = 14–16) from PC-3 
cells; [99mTc(CO)3(14)] (□, continuous line), [
99mTc(CO)3(15)] (∆, dotted line), [
99mTc(CO)3(16)] 
(○, continuous line); n = 4–7 (in triplicates, reported by means ± SD; calculated by non-linear 
regression using GraphPad Prism 5.0). 
 
 
 
4. Conclusions 
 
We herein report the synthesis and in vitro evaluation of bombesin-shepherdin conjugates radiolabeled with the 
99mTc-tricarbonyl core by the “click-to-chelate” strategy. The multifunctional radioconjugates were designed 
for a combined extra- and intracellular targeting in order to improve the cellular retention of radioactivity after 
its receptor-specific delivery to cancerous cells. While the specificity of the radioconjugates towards the 
extracellular target (GRP-r) could be confirmed, the cellular externalization of radioactivity was not improved. 
The combination of extra- and intracellular targeting entities in a multifunctional radioconjugate represents a 
novel and innovative approach with potential to improve the efficacy of radiotracers provided that issues such 
as endosomal entrapment and lysosomal degradation can be addressed. 
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The targeted delivery of diagnostic and therapeutic agents to
tumors and metastases has emerged as a promising strategy
for the management of cancer.[1] The functionalization of
cytotoxic agents and imaging probes with targeting moieties
(vectors) enables their specific delivery to tumors with an
efficiency higher than in nonconjugated form and may thus
reduce side effects and improve imaging, respectively.[2]
Ideally, a vector should be readily synthesized, offer the
possibility for conjugations, exhibit an appropriate stability,
have a well-defined structure, and display nanomolar affinity
towards a cell surface recognition element (e.g., receptors),
which is overexpressed by tumors but not in nontargeted
tissue.[3] Some naturally occurring, synthetically accessible
small molecules fulfill these criteria and have found applica-
tion in the clinic. For example, cyclic peptides (octreotide,[4]
RGD[5]) labeled with diagnostic or therapeutic radionuclides
are currently used in nuclear medicine. On the other hand, the
employment of linear peptides (e.g., bombesin, neurotensin)
in this context has been hampered despite their high potential
in part due to their low stability in vivo.[6] Considerable
research efforts have been made in the past in order to
stabilize such peptides while not impacting their favorable
biological properties, however, with varying degree of suc-
cess.[6a] Therefore, new approaches for the metabolic stabili-
zation of tumor-targeting peptides are needed.
It has previously been shown that 1,4-disubstituted 1,2,3-
triazoles can effectively mimic trans-amide bonds because of
their similar size, planarity, H-bonding capabilities, and dipole
moment.[7] It has also been suggested that the replacement of
an amide bond by a 1,2,3-triazole isostere could afford
protease-resistant peptidomimetics.[7a,h,8] However, to the best
of our knowledge, no study has yet reported the influence of
such backbone modifications on the stability of the peptide.
With the goal to develop a tumor-targeting peptidic vector
with retained high receptor affinity but improved stability, we
set out to replace systematically amide bonds of linear
peptides with 1,4-disubstituted 1,2,3-triazoles by the CuI-
catalyzed azide–alkyne cycloaddition (CuAAC)[7a,9] and study
the effect of the structural changes. For proof of concept of
the new methodology (termed a triazole scan), we chose the
minimal binding sequence of the peptide bombesin (BBN(7-
14)). This short octapeptide (H-QWAVGHLM-NH2) is
a high-affinity agonist of the gastrin-releasing peptide recep-
tor (GRPr), which is overexpressed in a variety of clinically
relevant tumors including, prostate and breast cancer.[10]
BBN(7-14) undergoes cell internalization by endocytosis
upon activation of the GRPr and thus is widely studied for
applications in drug delivery and nuclear oncology.[11] BBN(7-
14) represents not only a good model peptide to illustrate the
potential of this novel stabilization technique but also
a challenge as other backbone-modification strategies (e.g.,
cyclization, carbonyl reduction, N-methylation) have had
only moderate success in providing bombesin analogues with
maintained affinity towards GRPr.[12]
We are particularly interested in BBN(7-14) as a tumor-
targeting vector for the development of novel radiopharma-
ceuticals using radioactive metals (radiometals) in a theranos-
tic approach.[13] For this purpose, the peptide can be
functionalized N-terminally through a spacer unit with an
appropriate chelator for complexation of a radiometal.In this
work, we used the universal macrocyclic chelator 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA),
a short hydrophilic tetraethylene glycol (PEG4) spacer, and
lutetium-177 (177Lu) as a clinically established therapeutic
radionuclide with a concomitant g-emission for imaging.[14] In
addition, the methionine residue in position 14 of the amino
acid sequence was replaced by norleucine to avoid the
formation of oxidation side products during radiolabeling.[15]
These modifications have all been reported to be tolerated by
the peptide.[16]
The peptide analogues described herein were synthesized
by a solid-phase approach, which includes the CuAAC
reaction. Amino alkyne and azido acid building blocks were
prepared following reported procedures (Scheme 1). In brief,
chiral Fmoc-protected amino alkynes were obtained by
reduction of amino acid derived Weinreb amides followed
by a Seyferth–Gilbert homologation of the in situ generated
a-amino aldehydes using the Bestmann–Ohira reagent.[17]
The enantiomeric purity of the alkyne building blocks was
verified in each case.[18] Azido acids were synthesized from
amino acids with retention of chirality by diazo-transfer
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reactions employing the reagent imidazole-1-sulfonyl azide[19]
either in solution or on the solid support.[20] The introduction
of the 1,2,3-triazole amide bond surrogate into the amino acid
sequence was achieved by CuAAC with
the azide on the solid support and the
corresponding amino alkynes using Cu-
[CH3CN]4PF6.
[21] After completion of
the amino acid sequence, the peptides
were elongated N-terminally with
a PEG4 spacer and conjugated to the
chelator DOTA. Cleavage from the
support, subsequent deprotection, and
purification by HPLC afforded the
desired conjugates. Labeling of the
bombesin analogues with 177LuCl3
using standard reaction conditions
yielded radiolabeled compounds 1–10
in radiochemical yields and purities of
> 95%.[16] The synthesis of compound 5
is shown as an example in Scheme 1.[18]
With radiotracers 1–10 in hand, we
first studied their proteolytic stability
by incubation in blood serum (Table 1).
With the exception of compounds 2 and
10, serum half-lives of backbone-modi-
fied compounds were significantly
improved (by up to 20-fold) in compar-
ison to the reference conjugate 1. In
general, we observed that the introduc-
tion of a 1,2,3-triazole in the C-terminal
region of the peptide had the most
pronounced effect on serum stability.
Next, we investigated the influence of
the backbone modifications on the
biological properties of the targeting
vector [Nle14]BBN(7-14) in vitro using
GRPr-overexpressing PC3 cells. Recep-
tor-binding and cell-internalization
characteristics of radiolabeled peptido-
mimetics 2–10 were assessed and com-
pared with those of unmodified conju-
gate 1.[18] In the case of compounds 3, 4, and 8–10, receptor-
specific cell binding and internalization was abolished,
whereas conjugates 2, 5, and 7 displayed properties similar
Scheme 1. Synthesis of radiolabeled peptidomimetics illustrated by the synthesis of 5. Fmoc-
SPPS: 1) 20% piperidine/DMF; 2) Fmoc-amino acid or azido acid, HATU, iPr2NEt; DMF, a) (9H-
fluoren-9-yl)methyl prop-2-yn-1-ylcarbamate, [Cu(CH3CN)4]PF6, iPr2NEt, DMF; b) DOTA(tris-tBu),
HATU, iPr2NEt; DMF, c) trifluoroacetic acid/H2O/PhOH/iPr3SiH; d)
177LuCl3, 95 8C, ammonium
acetate buffer (pH 5.0). Fmoc-SPPS: Fmoc-based solid-phase peptide synthesis, Fmoc: 9-
fluorenylmethoxycarbonyl, tBu: tert-butyl, Trt: trityl, DMF: N,N-dimethylformamide, HATU: N-
[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium-3-
oxide.
Table 1: Structures and biological properties of radiolabeled compounds 1–10.
Compound Structure[a] Half-life
[h][b]
Uptake
after 4 h[c,e]
KD
[nm][e,f ]
1 (reference) [177Lu]DOTA-PEG4-Gln-Trp-Ala-Val-Gly-His-Leu-Nle-NH2 5 27.7 2.0!0.6
2 [177Lu]DOTA-PEG4-Gln-Trp-Ala-Val-Gly-His-Leu-Nley[Tz]-H 6 29.1 3.0!0.5
3 [177Lu]DOTA-PEG4-Gln-Trp-Ala-Val-Gly-His-Leuy[Tz]Nle-NH2 60 0.2 n.d.
4 [177Lu]DOTA-PEG4-Gln-Trp-Ala-Val-Gly-Hisy[Tz]Leu-Nle-NH2 >100 n.o.
[d] n.d.
5 [177Lu]DOTA-PEG4-Gln-Trp-Ala-Val-Glyy[Tz]His-Leu-Nle-NH2 17 28.3 3.1!1.0
6 [177Lu]DOTA-PEG4-Gln-Trp-Ala-Valy[Tz]Gly-His-Leu-Nle-NH2 25 8.4 48.6!11.5
7 [177Lu]DOTA-PEG4-Gln-Trp-Alay[Tz]Val-Gly-His-Leu-Nle-NH2 16 24.5 5.9!1.8
8 [177Lu]DOTA-PEG4-Gln-Trpy[Tz]Ala-Val-Gly-His-Leu-Nle-NH2 8 n.o.
[d] n.d.
9 [177Lu]DOTA-PEG4-Glny[Tz]Trp-Ala-Val-Gly-His-Leu-Nle-NH2 14 n.o.
[d] n.d.
10 [177Lu]DOTA-PEG4y[Tz]Gln-Trp-Ala-Val-Gly-His-Leu-Nle-NH2 5 0.5 n.d.
[a] y[Tz] represents the replacement of an amide bond by a 1,4-disubstituted [1,2,3]-triazole. [b] Determined in blood serum at 37 8C. [c]Ratio of
specific receptor-bound and cell-internalized compound expressed in % of administered dose normalized to 106 cells. [d] n.o.: not observed; no
specific binding or internalization was detected at a peptide concentration of 2.5 pmol/well. [e] All the values are means of at least two experiments
performed in triplicate. [f ] Determined by receptor saturation binding assay; n.d.: not determined.
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to those of the reference compound 1. Finally, compound 6
exhibited slower binding and internalization kinetics, indicat-
ing a decreased affinity for the GRPr. Receptor affinities
(KD) towards GRPr of conjugates 1, 2, and 5–7 were
determined by receptor saturation binding assays. As
expected, the compounds selected based on the receptor-
binding and cell-internalization experiments all showed
excellent affinities. Compounds 2, 5, and 7 exhibited single-
digit nanomolarKD values and a receptor affinity comparable
to that of reference 1 and other reported bombesin-based
radiotracers.[15–16,22] Notably, the triazole scan of [Nle14]BBN-
(7-14) provided four novel peptidomimetic analogues with
conserved biological activity, a screening result which is
superior to that of other reported peptide bond substitution
strategies.[12a]
Compound 5with the most promising properties (retained
GRPr affinity and 3.5-fold improved serum stability) was
selected for evaluation in vivo and a side-by-side comparison
with the parent compound 1 (Figure 1). Biodistribution
studies were performed in athymic nude mice bearing PC3
xenografts 4 h after injection of the radiotracers.[18] In general,
both conjugates showed a similar biodistribution pattern.
Accumulation in nontargeted tissue (e.g., muscle) was
negligible for both compounds. Low levels of radioactivity
were found in blood and in the liver, indicating fast blood
clearance and the absence of hepatobiliary elimination,
respectively. Unspecific uptake was observed in the kidneys
as the result of renal excretion, a common feature of
radiolabeled peptides. Strikingly, receptor-specific accumula-
tion of radioactivity in receptor-positive organs (e.g., pan-
creas) was significantly enhanced for compound 5 and tumor
uptake was doubled. Blocking experiments carried out by co-
injection of natural bombesin suppressed GRPr-specific
uptake, demonstrating that the triazole-modified peptide 5
retained its full in vivo specificity.[18] Thus, the introduction of
a single 1,2,3-triazole heterocycle between Gly11 and His12 of
[Nle14]BBN(7-14) increased the peptide!s proteolytic stability
and led to an improved tumor uptake in vivo.[23]
In summary, we report for the first time a triazole scan of
a biologically relevant peptide and its utility for the identifi-
cation of novel peptidomimetics with improved properties.
Application of the new strategy to the bombesin fragment
[Nle14]BBN(7-14) led to the identification of a series of
peptide-based radiotracers with retained nanomolar receptor
affinity and an up-to-fivefold improved serum stability. In
vivo evaluation of a backbone-modified peptide analogue
demonstrated the enhanced stability of the vector and its
improved tumor-targeting capability. Further optimization of
our lead compounds and application of triazole scans to other
peptides of medicinal interest are currently in progress. We
expect that this new methodology for the stabilization of
peptides will find broad application in the field of tumor
targeting with small peptides for drug delivery, imaging, and
peptide receptor radiotherapy.
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Abstract: In clinical trials, overexpression of neurokinin-1 receptors (NK1R) in gliomas has 
been exploited by intratumoral injection of its radiolabeled ligand, substance P (SP). 
However, despite proven NK1R expression, patients’ response to the therapy was 
inhomogeneous. This study aims to identify the factors predicting response to NK1R-targeted 
glioma therapy, thereby allowing the discrimination between potential “responders” and 
“nonresponders” and thus a personalized therapeutic approach. Four widely used glioblastoma 
cell lines were examined concerning their RNA levels of full-length and truncated NK1R 
subtypes. Binding of SP to NK1R and internalization into glioma cells was studied by three 
different approaches using radiolabeled SP (177Lu-[DOTA,Thi8,Met(O2)11]–SP), a 
fluorescence-labeled SP derivative (SP-FAM), and a toxin–SP conjugate (saporin-SP). While 
NK1R RNA was detected in all cases, receptor subtype analysis revealed impressive 
differences between the cell lines; LN319 exhibited the highest level of full-length NK1R 
RNA. Significant binding of SP conjugates to NK1R, cell internalization, and specific cell 
killing were only observed with the cell line LN319. Thus, different NK1R subtype profiles of 
glomerular basement membrane (GBM) cell lines appear to influence the binding of SP 
conjugates and their cell internalization properties. Both processes are crucial steps for NK1R-
based targeted therapy. Pre-therapeutic testing for NK1R subtype expression may therefore be 
advisable before initiation of this generally promising therapeutic modality. 
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Abstract
In clinical trials, overexpression of neurokinin-1 receptors (NK1R) in gliomas has been exploited by in-
tratumoral injection of its radiolabeled ligand, substance P (SP). However, despite proven NK1R expression,
patients’ response to the therapy was inhomogeneous. This study aims to identify the factors predicting
response to NK1R-targeted glioma therapy, thereby allowing the discrimination between potential ‘‘respond-
ers’’ and ‘‘nonresponders’’ and thus a personalized therapeutic approach. Four widely used glioblastoma cell
lines were examined concerning their RNA levels of full-length and truncated NK1R subtypes. Binding of SP to
NK1R and internalization into glioma cells was studied by three different approaches using radiolabeled SP
(177Lu-[DOTA, Thi8, Met(O2)
11]–SP), a fluorescence-labeled SP derivative (SP-FAM), and a toxin–SP conjugate
(saporin-SP). While NK1R RNA was detected in all cases, receptor subtype analysis revealed impressive
differences between the cell lines; LN319 exhibited the highest level of full-length NK1R RNA. Significant
binding of SP conjugates to NK1R, cell internalization, and specific cell killing were only observed with the cell
line LN319. Thus, different NK1R subtype profiles of glomerular basement membrane (GBM) cell lines appear
to influence the binding of SP conjugates and their cell internalization properties. Both processes are crucial
steps for NK1R-based targeted therapy. Pretherapeutic testing for NK1R subtype expression may therefore be
advisable before initiation of this generally promising therapeutic modality.
Key words: substance P, neurokinin-1 receptor (NK1R), glioblastoma multiforme, targeted glioma therapy
Introduction
Brain-intrinsic neoplasms represent the second most fre-quent cancer-related cause of death in the age group of
15 to 35 years after leukemias.1 The prognosis of malignant
gliomas has only slightly improved during recent decades.2,3
Median survival for patients with glioblastoma multiforme
(glomerular basement membrane [GBM], WHO IV) ranges
from 10 to 18 months in patients 70 years old or younger4–6
and is worse in older patients.7 The currently accepted stan-
dard of care for high grade gliomas is surgical resection
followed by combined radiotherapy and chemotherapy.4,8,9
Several experimental therapeutic strategies are in develop-
ment, of which the exploitation of glioma-specific antigens as
target structures is one of the most promising approaches.10–13
The neurokinin-1 receptor (NK1R) is a surface structure
molecule that has been described as consistently over-
expressed in gliomas.14,15 The physiological ligand of NK1R
is substance P (SP).16–18 In nude mice with U373 human
glioma xenograft, an inhibitory effect on tumor growth by
using SP antagonists was demonstrated, as was the reversal of
this inhibitory effect by using SP agonists.19 Another group
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demonstrated glioma growth inhibition and apoptotic cell
death by using the SP antagonist aprepitant in a concentration-
dependent manner.20 Aprepitant (Emend, Merck Pharma-
ceuticals) is FDA approved to treat chemotherapy-induced
nausea. A clinical study to evaluate aprepitant as an adjunct to
multimodal glioma therapy has been suggested.21
In clinical studies evaluating 90Y- and 213Bi-labeled SP
radioconjugates in glioma therapy, the overexpression of
NK1R was confirmed pretherapeutically in every patient
without significant NK1R expression in surrounding brain
tissue by local injection of 111In-labeled SP derivative.22–24
In the majority of study patients, a significant radiological
and clinical response was observed. Despite confirmed
NK1R expression, the response was not as pronounced as
expected in several patients. Taking into account the suffi-
cient intratumoral distribution as shown by the pre-
therapeutic test injection, we postulated that there might be
specific features of these gliomas responsible for the vari-
able response of patients to NK1R-targeted therapy.
Characterization of NK1R revealed that there are at least
two distinct NK1R isoforms, differing in the length of the
carboxyl terminus: (1) a full-length form with 407 amino
acids (AAs), NK1R-Fl, and (2) a truncated variant with 311
AAs, NK1R-Tr. Both receptors have identical ligand-
binding domains but differ in their cytoplasmic tails. Spe-
cifically, the cytoplasmic tail of NK1R-Tr lacks 96 amino
acid residues, a region that functions as a substrate for
phosphorylation by G protein–coupled receptor kinases in
NK1R-Fl. Consequently, NK1R-Tr shows a reduced ca-
pacity to undergo SP-induced internalization and desensiti-
zation.25,26 In contrast to NK1R-Fl, NK1R-Tr may play a
role in tumor progression, as shown in breast cells trans-
fected with NK1R-Tr.27 Besides a potential role in tumori-
genesis, NK1R-Tr has physiological functions (e.g., during
monocyte/macrophage differentiation).28
In summary, NK1R overexpression in gliomas is a
promising target structure for specific glioma therapy (e.g.,
peptide receptor radionuclide therapy [PRRT]). Ther-
apeutics targeting NK1R are usually bifunctional molecules,
consisting of a targeting domain (e.g., interleukins or anti-
bodies)29,30 and an effector domain (e.g., therapeutic radio-
nuclides or toxins).31,32
Besides radionuclides, a promising candidate for conju-
gation with SP may be presented by saporin, an herbal toxin
isolated from Saponaria officinalis.33–35 The toxin is a po-
tent member of the group of ribosome inactivating proteins
(RIPs)36 due to its N-glycosidase activity and has high in-
trinsic stability against denaturation and proteolysis. RIPs
often contain a second protein strand that inserts the toxin
into cells. Saporin does not exhibit such a structure; thus, it
needs to be conjugated to a targeting molecule.37–39
In this work, we set out to study the mechanism of NK1R-
based targeting of gliomas beyond the well documented
overexpression of NK1R, in an effort to identify factors that
may render some gliomas more responsive to NK1R-tageted
therapy than others. The knowledge gained might help to
evaluate whether or not NK1R is a worthwhile target for
glioma therapy. Toward this goal, we analyzed four glioma
cell lines routinely used preclinically in glioma research
(LN71, LN229, LN319, LN405) for their RNA levels of the
truncated isoform (NK1R-Tr) and the full-length isoform
(NK1R-Fl). NK1R-specific binding of SP conjugates as well
as their internalization into these glioma cells was examined
by using a radiolabeled SP and a fluorescence-labeled SP.
The effect of saporin-labeled SP as a toxin-based targeted
therapeutic was studied to evaluate the cell internalization in
more detail.
Materials and Methods
In vitro experiments described henceforth were per-
formed with n = 2-3 (in triplicates). The date shown in
Figures 1, 3, and 5 are represented as mean values – standard
deviations (indicated by error bars) calculated using estab-
lished software (e.g., GraphPad Prism 5.0).
Cell lines
Glioblastoma cell lines LN71, LN229, LN319, LN405
and chicken fibroblast DF1 cells were cultured at 37!C in
5% CO2 atmosphere in DMEM medium (Sigma, St. Louis,
MO) with 5% fetal bovine serum (FBS) and penicillin-
streptomycin (Invitrogen Gibco, Paisley, UK, 100 units/
mL). Cell lines were obtained from Monika Hegi, Uni-
versity Hospital of Lausanne, Lausanne, Switzerland.
RNA extraction
Total RNA was extracted from glioblastoma cell lines by
using Tri-Reagent (Sigma). Phase separation was performed
using chloroform. After centrifugation (12’000 ·G, 15
minutes), RNA-containing aqueous phase was mixed with
70% ethanol and transferred to spin columns of RNeasy
Mini Kit (Qiagen, Hilden, Germany). Extractions were
performed following the instructions of the supplier. Ex-
tracted RNA was subjected to genomic DNA digestion by
TURBO DNase Kit (Ambion, Austin, TX).
Reverse transcription
Complementary DNA (cDNA) was synthesized from 1lg
of total RNA with QuantiTect Reverse Transcription
Kit (Qiagen). Reverse transcription was maintained at 42!C
for 15 minutes, and termination at 95!C for 3 minutes.
Obtained cDNA was used as a template for real-time PCR
amplification.
Real-time PCR primers
PCR primers for quantitative measurement of long and
short isoforms of NK1R messenger RNA (mRNA) were
previously published.28,40 Sequences of primer pair for spe-
cific amplification of the full-length isoform were 5¢-TCTTC
TTCCTCCTGCCCTACATC-3¢ (sense) and 5¢-AGCACCG
GA-AGGCATGCTTGAAGCCCA-3¢ (antisense). Sequences
of primer pair for truncated NK1R were 5¢-TCTTCTTCCT
CCTGCCCTACATC-3¢ (sense) and 5¢-TGGAGAGCTCAT
GGGGTTGGGATCCT-3¢ (antisense). Primer pair for glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) was pur-
chased from Qiagen. Primers were resuspended in Tris-EDTA
buffer and stored at –20!C.
Real-time PCR assay
The CFX96 real-time cycler system (Bio-Rad, Hercules,
CA) was used. For each PCR, 1 ll of cDNA template or 1ll
of corresponding non–reverse transcription (NRT) control
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was mixed with 12.5 ll of QuantiFast SYBR Green PCR
Master Mix (Qiagen) and a primer pair for either full-length
or truncated NK1R (300 nM) or for GAPDH was added.
Reaction efficiencies were monitored by standard curve on
each plate. All amplifications were performed as duplicates.
Threshold cycle (Ct) numbers of the duplicates were aver-
aged and normalized to Ct values of endogenous GAPDH
control. Standard comparative Ct method 2-DCt was used to
calculate relative mRNA expression levels of full-length and
truncated NK1R.
The applied thermal cycling conditions were an initial
denaturation (95!C, 5 minutes), followed by 40 cycles of
95!C for 10 seconds and 60!C for 30 seconds, finished by
melting curve starting at 65!C, and increased for 0.5!C each
5 seconds until reaching 95!C. Fluorescent measurements
were recorded during each annealing step and after each
temperature increment during the melting process.
Radiolabeling of SP
177Lu-[DOTA, Thi8, Met(O2)
11]–SP was prepared by re-
acting 20 lg per 20 lL (0.56mM) [DOTA, Thi8, Met(O2)
11]–
SP (Mw = 1772.06 g/mol) with*37MBq 177LuCl3 in 300lL
0.4MNH4OAc (pH 5.0) in prelubricated Eppendorf tubes for
30 minutes at 95!C. After adding 9 nmol of 0.1mM natLuCl3
solution, the mixture was heated for additional 30 minutes
(95!C). Quality control was performed by reversed phase
high-phase liquid chromatography (HPLC) on Bischof sys-
tem with HPLC pumps 2250, a k-1010 UV detector, Berthold
LB509 radioflow detector, and EC250/4.6 Nucleodur C18 Isis
5-lm column (Macherey-Nagel, Du¨ren, Germany). The
column was eluted with mixtures of acetonitrile (solvent A)
and water with 0.1% trifluoroacetic acid (TFA) (solvent B) at
a flow rate of 0.75mL per minute and a linear gradient
(0 minutes 80% B, 20 minutes 60% B, 22 minutes 5% B, 25
minutes 5% B, 27 minutes 80% B, 30 minutes 80% B).
Binding and internalization studies
with radiolabeled SP
LN71, LN229, LN319, and LN405 cells were seeded at a
density of 0.8 to 1 million cells per well in a six-well plate
and incubated (37!C, 5% CO2) overnight in medium (1%
FBS in DMEM medium, high glucose). On the day of the
experiment, the medium was removed and cells were wa-
shed once with PBS (1mL). Then 1.3mL culture medium
(1% FBS in DMEM medium) was added, plates were incu-
bated at 37!C, 5% CO2. Next, 0.25 pmol (100lL, final
concentration: 0.17 nM) of 177Lu-[DOTA, Thi8, Met(O2)
11]–
SP were added and incubated (37!C, 5% CO2). For deter-
mination of nonspecific binding the cells were incubated
in the presence of additional 250 pmol (1000-fold excess,
final concentration 0.17lM) of unlabeled [DOTA, Thi8,
Met(O2)
11] –SP. Internalization was stopped by removal of
medium and washing cells two times with ice cold PBS at
four time points (0.5, 1, 2, and 4 hours). Cells were treated
with glycine buffer (0.05M, pH 2.8) twice for 5 minutes at
4!C to determine the cell surface–bound fraction. Inter-
nalized fraction was determined by cell lysis with 1M
NaOH. Fractions of free radioligand, receptor-bound frac-
tions, and internalized fractions were measured radiometri-
cally (c-counter) and calculated as percentage of applied
dose per 106 cells. Peptide concentration–dependent inter-
nalization was studied using two different concentrations of
177Lu-[DOTA, Thi8, Met(O2)
11] –SP (0.17 nM and 1.7 nM).
SP-FAM internalization and immunohistochemistry
LN319, LN71, LN229, and LN405 cells were plated on
35-mm culture dishes (4 inner rings, Greiner Bio-One,
Frickenhausen, Germany) and allowed to attach overnight.
Cells were treated with 1 nM of either FAM-labeled SP, 5-
FAM (AnaSpec, Fremont, CA), SP ([Sar9, Met(O2)
11]–
substance P, Sigma) or left untreated. After 8 and 24 hours,
cells were washed and stained with 5lg/ml of CellMask
Deep Red plasma membrane stain (Invitrogen) at 37!C for 5
minutes. Cells were washed two times with PBS and fixed
with 4% formaldehyde (Thermo Scientific, Rockford, IL)
for 10 minutes. After blocking with 10% donkey serum
(Jackson Immuno Research Laboratories, Suffolk, UK) in
PBS for 1 hour, rabbit anti-NK1R (Abcam, ab13133, 1:500)
was incubated overnight in 5% donkey serum in PBS at 4!C.
Cells were washed three times with PBS and incubated for 1
hour at room temperature with DAPI and the secondary
antibody, DyLight 549-conjugated donkey anti-rabbit IgG
(H+L, 1:300; Jackson Immuno Research Laboratories,
West Grove, PA). Cells were washed again three times with
PBS and mounted with Dako Fluorescent Mounting Med-
ium (Dako, Glostrup, Denmark). Internalization of FAM
and localization of NK1R was examined with confocal
microscopy (Zeiss LSM 710, spectral type, laser lines at
405, 458, 488, 514, 543, 633 nm). Image analysis was per-
formed with ZEN 2010 (Zeiss, Jena, Germany).
Cytotoxicity assay
SP–saporin (SP-SAP, conjugate of peptidase-resistant
[Sar9, Met(O2)
11] SP–analogue and ribosome-inactivating
protein saporin) was purchased from Advanced Targeting
Systems (San Diego, CA).
LN71, LN229, LN319, LN405, and DF1 cells were plated
at 2500 cells per 100 ll in triplicates on a 96-well plate.
Cells were allowed to attach overnight and treated with SP-
SAP at a concentration of 1 nM. After incubation for 72
hours, MTS and PMS (colorimetric CellTiter 96" AQueous
Non-Radioactive Cell Proliferation Assay, Promega, Madi-
son, WI) were added and the incubation was continued for 2
hours. Optical density was measured at 490 nm and mean
values per standard deviations were calculated. The aver-
aged data (in triplicates) were compared to those obtained
from controls (PBS). Standard deviations of measured val-
ues were less than 10%.
Results
NK1R isoforms in glioma cell lines
With LN319, we detected a high level of NK1R mRNA,
whereas the other three cell lines showed only moderate to
low mRNA levels. Differentiating between the full-length
and the truncated isoform of NK1R mRNA, LN319 showed
a very high level of full-length NK1R mRNA, whereas the
level of the truncated isoform was reduced by a factor of
about 40 in comparison to the level of the full-length iso-
form. The level of full-length NKR1 mRNA of LN71 was
less than 2% in comparison to that of LN319, while the level
of the truncated isoform was found to be approximately 40%
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of the full-length isoform. In contrast, LN405 and LN229
showed only very low levels of the full-length NK1R
mRNA. Interestingly, the levels of truncated NK1R mRNA
in LN405 and LN229 were higher than full-length NK1R
mRNA in these cell lines (Fig. 1).
Radiolabeling of [DOTA, Thi8, Met(O2)
11]–SP
(DOTA-SP) with 177LuCl3
Radiolabeling of DOTA-SP with Lu-177 was achieved in
high radiochemical yield and purity ( > 99.5%) at a specific
activity of 3.3 GBq/lmol (Fig. 2).
Internalization of radiolabeled SP
Internalization of 177Lu-[DOTA, Thi8, Met(O2)
11]-SP was
detected only in glioma cell line LN319 but not in LN71,
LN229, and LN405. For a peptide concentration of 0.17 nM,
the specific internalization for LN319 cells was 16.3%– 0.2%
of totally administered activity after 30 minutes, increasing to
31.4%– 0.5% after 4 hours (Fig. 3). Applying the ten-fold
peptide concentration (1.7 nM) resulted in 15.2%– 0.6% after
30 minutes and 30.1%– 0.9% after 4 hours. Nonspecific
binding as determined by blocking experiments in the pres-
ence of 1000-fold excess of unlabelled DOTA-SP was less
than 1% in all assays.
Internalization of FAM-labeled SP
Examinations with SP-FAM confirmed the results of ex-
periments with radiolabeled SP. Only LN319 cells exhibited
significant internalization of FAM–labeled SP. The highest
amount of internalized SP-FAM was observed after 24 hours
(Fig. 4).
Effect of saporin-labeled SP on glioma cell lines
LN319 cells were selectively killed by saporin–SP with a
reduction of cell viability of approximately 40%. The viability of
the other cell lines, LN71, LN229, and LN405, was not signif-
icantly affected. The viability of the control cell line, DF1, was
also not affected. Saporin and SP alone did not show a significant
effect on cell viability in all examined cell lines (Fig. 5).
Discussion
The results of this work confirm previous findings of con-
sistent overexpression of NK1R in gliomas,15 as we could
detect NK1R by quantitative reverse transcriptase (qRT) PCR
in all cell lines. In previous clinical trials with radiolabeled
SP,22–24 the therapeutic response was difficult to predict
FIG. 1. Different endogenous mRNA expression levels of
NK1R in glioma cell lines. qRT-PCR analysis of the full-
length and the truncated variant of NK1R was used, and
GAPDH was used as endogenous control.
FIG. 2. Radio-HPLC chromatograph of 177Lu-[DOTA,
Thi8, Met(O2)
11]–SP.
FIG. 3. Internalization of 177Lu-[DOTA, Thi8,
Met(O2)
11]–SP (0.25 pmol) in LN319 glioma cells, nor-
malized to 106 cells per well. Data points include the fol-
lowing: Total internalized (B, continuous line); nonspecific
binding (,, continuous line) as determined by blocking
experiments in the presence of excess (1000 · ) [DOTA,
Thi8, Met(O2)
11]–SP; and specific internalized (D, dotted
line) as difference thereof.
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despite confirmed NK1R expression and sufficient in-
tratumoral distribution of radiolabeled SP. This observation
raised the question whether or not there are other factors
downstream in the NK1R pathway that may account for the
variable response to therapies employing SP radioconjugates.
Hall et al. and Fong et al.25,41 have reported two different
variants of NK1R, a full-length (NK1R-Fl) and a truncated
variant (NK1R-Tr), the latter of which also exhibits differ-
ent functionalities. Our study using qRT-PCR confirms
different levels of expression of the two receptor subtypes
and suggests that the sole fact of NK1R expression may
not be an adequate overall parameter to reliably predict the
therapeutic response to NK1R–targeted therapy.14,15
We have investigated the correlation of NK1R-Fl ex-
pression for internalization of SP conjugates by three inde-
pendent techniques, including the in vitro evaluation of a
radiolabeled SP, a fluorescence-labeled SP derivative, and a
toxin-SP conjugate. Of the cell lines tested, only the NK1R-
Fl expressing LN319 was able to internalize the radiolabeled
and fluorescence-labeled SP and, thus, showed a response to
the toxin-SP conjugate. Our observations correlate well with
previous reports depicting an NK1R-Tr association with
a reduced capacity to undergo SP-induced internalization
and desensitization.25,26
Consequently, NK1R-Fl expression could be considered a
prerequisite for SP binding and internalization and, thus, the
positive outcome of SP-based therapies. The findings of this
work provide a possible explanation for the inconsistent
therapeutic response observed in previous clinical studies using
90Y- and 213Bi-labeled SP conjugates for glioma therapy.22–24
The observation of good responders and poor responders in
these studies suggests that an examination of NK1R subtype
expression of individual glioma patients may be advisable
before initiation of NK1R-based targeted radiotherapy.
Conclusion
NK1R is a G protein–coupled membrane receptor consis-
tently expressed by glioma cells and can therefore be consid-
ered a valuable target for peptide receptor–specific therapy.
However, subclassification of the receptor into the two iso-
forms, the full-length and truncated variants, could be essential
to predicting the functionality concerning cell internalization of
its ligand and, hence, the efficacy of SP-based therapies. On the
basis of our preclinical in vitro investigations reported herein,
sufficient expression of the full-length NK1R appears to be
required so that SP conjugates are internalized into glioma cells
and the therapeutic effect of their cargo can be deployed. Thus,
pretherapeutic screening for NK1R subtype expression may be
advisable when considering this NK1R-specific therapeutic
modality for the treatment of GBM.
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VII. Conclusions and Perspectives 
 
Over the last two decades, the knowledge of molecular targets and their ligands, molecular and cell 
biology of malignancies, and structure-activity relationship of potential new radioligands has 
increased.5,15a,37,55,58d,77 Also, advancements in combinatorial peptide chemistry, bioconjugation 
strategies, coordination chemistry of radiometals, radiolabeling protocols, and the availability of 
imaging instruments for small animals have expedited research in the fields of metal-based 
radiopharmaceutical chemistry and nuclear medicine.2,8,15a,19a,59d,68 Nowadays, targeting peptides 
represent an integral part of research aimed at the development of novel radiotracers for molecular 
imaging and radionuclide therapy of cancer.2,8,10,15a,c,19a,37,41,52-53,58d,83 Different approaches towards the 
optimization of radiolabeled, tumor targeting peptides to improve the quality of molecular imaging 
and to enhance the efficacy of radionuclide therapy of cancer were evaluated in this Ph.D. thesis. 
Conclusions and perspectives thereof will be discussed in the following sections.  
 
 
Dual-targeting radioconjugates 
 
Both, efficient internalization of radioactivity into tumor cells and prolonged retention are crucial 
features for the successful application of agonistic, radiolabeled peptides for targeted molecular 
imaging and therapy of cancer.5,10,19a,37,41,52 We investigated dual-targeting bombesin radioconjugates 
to reduce rapid efflux of radioactivity from cancer cells after successful delivery. In a first step, we 
focused on developing new bifunctional, radiolabeled bombesin analogs for additional intracellular 
targeting of mitochondria, using TPP-derivatives. Starting from readily accessible building blocks, a 
dual-targeting BBS-TPP analog was assembled on solid support selectively and efficiently via an 
extended Click-to-Chelate31c strategy. Radiolabeling with the 99mTc-tricarbonyl core afforded stable 
complexation of the radionuclide. Dual-targeting BBS-TPP analog and a reference compound lacking 
the TPP moiety were evaluated in vitro using PC-3 cells. Attaching 3-tris(p-methoxyphenyl)-
phosphonium propionic acid for mitochondria targeting did not alter the high affinity of the bombesin 
analog towards the GRP-r and specific receptor-mediated internalization into PC-3 cells was observed. 
Compared to the reference conjugate, the additional TPP moiety proved significant higher binding to 
isolated mitochondria in vitro. However, in intact PC-3 cells, dual-targeting TPP-BBS displayed an 
overall unaltered externalization rate of radioactivity from PC-3 cells. We speculate that hindered 
passage through the mitochondria membrane could have interfered with the intracellular targeting of 
the conjugate.51c,139 Since the combination of two different entities specific for an extra- and 
intracellular target in the same radioconjugate is an attractive approach to reduce cellular washout of 
radioactivity, we decided to evaluate further this strategy with intracellular targets that do not require 
multiple trafficking through membranes.  
In the next step, we simplified the system and developed bifunctional bombesin analogs for 
intracellular targeting of the ubiquitous, cytosolic chaperon protein Hsp90, which is found 
overexpressed in high concentrations by nearly all cancer cells.129-130 For interaction with Hsp90, we 
covalently attached the peptidic Hsp90 inhibitor shepherdin132-133 to a bombesin analog by the same 
synthetic approach. The attachment of the hydrophilic shepherdin[79-83] sequence did not interfere 
with specific receptor-mediated internalization into PC-3 cells, but reduced slightly the binding 
affinity towards the GRP-r. Compared to the reference conjugate lacking the shepherdin sequence, the 
dual-targeting BBS-shepherdin[79-83] conjugate did not result into a reduced efflux of radioactivity 
from PC-3 cells.  
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The fate of the radioligand after endocytosis and intracellular processes leading to externalization of 
the radiotracers is not fully understood in detail. Reasons for the observed lack of intracellular 
targeting of the conjugates described might include the enzymatic degradation of the shepherdin 
sequence or, alternatively, endosomal entrapment of the radioconjugate. Both scenarios would prevent 
the interaction with the cytosolic target.49,51a,c,140 Potential issues of the stability of peptidic shepherdin 
sequences could be overcome by applying non-peptidic inhibitors of Hsp90.141 Strategies to achieve 
endosomal release for intracellular delivery might include the combination of the radiopeptide 
conjugate described with cleavable linkers,142 biomimetic peptides,51a,140 or synthetic polymers.51c,140,143 
Different cleavable linkers including enzymatically degradable units, nucleophile/base- or 
electrophile/acid-sensitive, pH- or redox-sensitive entities, but also photo-cleavable linkers, and metal-
assisted linker systems have been reported in the literature for various applications.142 Amongst them, 
reduction-sensitive, disulfide-containing linkers have been most widely used in biochemistry.142b 
Disulfide bonds are known to be cleaved by glutathione via thiol/disulfide exchange and thus, are 
frequently used in the design of prodrugs for release of the pharmaceutical upon enzymatic 
reduction.142a,144 Endosomal escape is also a crucial requirement for other drug delivery systems used, 
e.g., for the delivery of nucleic acids as potential therapeutic macromolecules for the prevention or 
treatment of several diseases, including cancer, cardiovascular diseases, infections, and genetic 
disorders.51a,c,140 Reported strategies to enhance endosomal release of non-viral vectors for delivery of 
nucleic acids include, for example, the use of weak bases (e.g., chloroquine) that cause osmotic 
swelling and rupture of the endosomes.51a,140 The possibility of endosomal membrane fusion, 
destabilization mechanisms, or the formation of pores in the membrane of endosomes have also been 
studied with e.g., cell penetrating peptides.51a,140 Future research is directed towards the combination of 
the dual-targeting radiopeptides with the strategies outlined above. 
In conclusion, endocytosis is a major route for cellular uptake of drugs and drug delivery 
systems.51a,c,140 Further research towards the elucidation of the mechanism of the escape of drugs from 
the endosomes is needed in order to design efficient systems that ensure the release of the drug to the 
cytosol. Such novel drug delivery systems may also be used to increase the performance of 
radiolabeled, tumor targeting peptides.  
 
 
1,2,3-Triazoles as protease-resistant peptidomimetics for tumor targeting 
 
The metabolic stability of tumor targeting, radiolabeled peptides in vivo is crucial to extend their blood 
circulation time, which can increase tumor uptake.15c,19a,26,42 We reported the systematic replacement of 
amide bonds of the bombesin derivative [Nle14]BBS(7-14) by isosteric 1,2,3-triazoles with the goal to 
improve the metabolic stability of the peptide while maintaining its high affinity towards the        
GRP-r.30c,137-138 The triazole scan provided a series of novel peptidomimetics with an up to 3.5-fold 
improved serum stability and retained high binding affinity to the GRP-r in the low nanomolar range. 
Peptidomimetics with amide bonds substituted at the C-terminus and between positions Gly11-His12, 
Val10-Gly11, and Ala9-Val10 exhibited internalization properties and specific affinity towards the GRP-r 
comparable to that of the unmodified reference peptide sequence. In addition, radioconjugates bearing 
the 1,2,3-triazole in positions Gly11-His12, Val10-Gly11, and Ala9-Val10 showed significantly improved 
serum half-lives in vitro. The most promising 177Lu-radiolabeled peptidomimetic bearing a triazole 
between Gly11 and His12 was compared side-by-side with the reference compound in vivo by 
biodistribution experiments in tumor-bearing mice. Metabolic stabilization of this peptide analog by 
the 1,2,3-triazole enhanced the uptake in GRP-receptor-positive organs (e.g., pancreas) and doubled 
the tumor uptake in vivo. Encouraged by these results, triazole scans of other peptides of medical 
interest are currently ongoing.145 Further optimization of the lead compound(s) identified and the 
introduction of multiple 1,2,3-triazoles are also under evaluation. This new methodology for the 
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stabilization of peptides may allow broad applications for the development of novel, tumor targeting, 
radiolabeled peptides for molecular imaging and PRRT.  
A pharmaceutical approach to increase the metabolic stability of radiopeptides administered in vivo is 
the utilization of enzyme inhibitors.55,134,146 Nock et al. recently reported an efficient and promising 
strategy to increase metabolic stability of radiopeptides by co-administration of the neutral 
endopeptidase inhibitor phosphoramidon (PA).146 They evaluated the co-administration of PA with 
radiolabeled derivatives of somatostatin, bombesin, and gastrin to tumor-bearing mice and observed 
significantly improved tumor uptake in all cases.146 Thus, future research could also include the 
combination of co-administration of enzyme inhibitors and chemical stabilization of radiolabeled 
peptidomimetics.  
 
 
Different NK1R-isoforms overexpressed in glioblastoma multiforme 
 
Several human cancers overexpress the NK1-receptor that can be targeted with radiolabeled SP-
derivatives for PRRT.53,111b,114a,115 Intratumoral administration of radiolabeled SP analogs has 
previously been evaluated clinically in glioma patients.118a-c However, differences in the response of 
the patients that received local radionuclide therapy were observed.118a,c Reasons might be different 
concentrations of the NK1R-Fl and NK1R-Tr isoforms of the receptor in heterogeneous tumor tissues. 
Our preclinical in vitro evaluations suggested that confirmation of NK1R expression alone might not 
be an adequate parameter to predict the therapeutic response to NK1R-targeted therapy. Sufficient 
expression of the full-length NK1R isoform appears to be essential for efficient binding and 
internalization of (radiolabeled) SP derivatives into glioma cells. The receptor expression of 
glioblastoma tissue may be different for multi-passaged glioma cell lines. Thus, future research should 
be directed towards the examination of NK1R-subtypes in glioblastoma tissue samples. The expression 
of the different NK1R isoforms should also be confirmed on the protein level by, e.g., western blot 
techniques. In conclusion, pre-therapeutic screening for the actual expression of the NK1R-Fl isoform 
could improve the selection of glioma patients to benefit from NK1R-specific radionuclide therapy and 
pave the way towards patient-individualized medicine in the future.  
 
 
!
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